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2ABSTRACT
Epstein-Barr virus, EBV, is a human herpes virus that establishes a life long,
persistent, latent infection in B lymphocytes. In vitro, EBV readily transforms and
immortalizes primary B cells. EBV exists in two types, named EBV type 1 and type
2. These are defined on the basis of polymorphism in the EBNA2 locus. The EBNA2
gene encodes a viral transcription factor that controls viral and cell genes and is
absolutely required for B cell transformation.  EBV type 1 strains are much more
efficient than EBV type 2 at transforming B cells and the enhanced transformation
efficiency was previously mapped to the EBNA2 gene.
A transfection assay was devised to compare the ability of type 1 and type 2
EBNA2 to sustain cell proliferation in EREB2.5 lymphoblastoid cells, which contain
a ∆EBNA2-Epstein-Barr virus and express a conditional EBNA2. The reduced
proliferation in cells expressing type 2 EBNA2 correlated with loss of expression of
some cell genes that are known to be targets of type 1 EBNA2. Microarray analysis of
EBNA2 target genes in stably transfected Burkitt lymphoma cells identified a small
number of genes that are more strongly induced by type 1 than type 2 EBNA2 and
one of these genes (CXCR7) was shown to be required for proliferation of
lymphoblastoid cell lines.
The Epstein-Barr virus LMP1 gene is directly induced by EBNA2 and is
critically involved in B cell transformation. In Daudi Burkitt lymphoma cells, EBNA2
type 1 induced LMP1 much more strongly than EBNA2 type 2, although both reached
comparable levels after 48 hours. The results show that differential gene regulation by
Epstein-Barr virus type 1 and type 2 EBNA2 is likely to be the basis for the much
weaker B cell transformation activity of type 2 Epstein-Barr virus strains compared to
type 1 strains.
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1. INTRODUCTION
1.1 Overview
1.1.1 The Epstein-Barr Virus
Half a century ago, the English physician Dennis Burkitt was serving in
equatorial Africa as a government surgeon when he reported to the scientific
community the identification of an endemic cancer affecting the jaw of indigenous
children (Burkitt, 1958). He later developed the idea that a vector born virus was the
culprit for the disease (Burkitt, 1962). The Epstein Barr Virus, EBV, was soon
identified in 1964 (Epstein et al., 1964) in the EB1 lymphoblastoid cell line, derived
from a Burkitt’s lymphoma biopsy. EBV is today known to be a ubiquitous human
herpesvirus that infects up to 95% of the population worldwide.
Like all herpesviruses, EBV persists latently in a cell reservoir that is separate
from the cell type it first infects. Primary infection is thought to occur in the resting B
cells under the crypts of the tonsils and progresses to a life long persistence in the
memory B cell compartment. The transmission happens by contact with oral
secretions that contain the virus (Niederman et al., 1976). Most infections occur in
early childhood and are normally sub-clinical but in western countries adolescents and
adults may undergo a benign self-limiting lymphoproliferative disorder known as
infectious mononucleosis (IM) (Escobar et al., 1970). The infected cell population in
normal latent persistence ranges from 1 to 50 cells per million lymphocytes (Kahn et
al., 1996). Despite this low level, the EBV genome and its encoded gene products
have been found in cells isolated from an increasing number of human malignancies,
suggesting a role for the virus in the aetiology of the diseases. These pathologies
include Burkitt Lymphoma (BL) (Epstein et al., 1964), immunoblastic lymphomas of
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immune compromised patients (Carbone, 2003), X-linked lymphoproliferative disease
(Coffey et al., 1998) and Hodgkin’s disease (Weiss et al., 1989). As a result of
atypical infection of T cells, some rare T lymphomas (Jones et al., 1988) are also
linked to EBV. The most frequent EBV associated cancer is undifferentiated
nasopharyngeal carcinoma (Hu et al., 1995), reflecting the ability of the virus also to
infect epithelial cells.
1.1.2 Herpesviridae
The family of the Herpesviridae is composed of about 130 herpesviruses that
can infect most vertebrates. The parasitic relationship between virus and host has been
forged during evolution so that each herpesvirus does not normally infect more than
one species, being sometimes asymptomatic for the natural host (Ackermann, 2004).
The members of this virus family have been grouped into three subfamilies called
Alpha, Beta and Gamma, on the basis of their biological properties and DNA
sequences (Figure 1.1). The Alpha subfamily includes viruses that present a variable
host range, short reproductive cycle and rapid spread in culture. Members infectious
for humans are Herpes Simplex 1 and 2 (HSV 1/2) and Varicella Zoster virus (VZV).
The Beta subfamily presents a restricted host range, long reproductive cycle and slow
progression in culture. Cytomegalovirus (CMV) is a member of this family. EBV
belongs to the Gamma subfamily that is characterised by a host range that is limited to
the family or order to which the natural host belongs; the gamma viruses replicate
mainly in lymphoblastoid cells. This subfamily contains two genera:
Lymphocryptovirus, to which EBV belongs and Rhadinovirus, to which KSHV
belongs (Kieff & Rickinson, 2001).
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1.1.3 EBV viral particle and genome
The architecture of the virion, from inside out, typically consists of a protein
core wrapped by a linear double stranded DNA, and an icosadeltahedral capsid of
approximately 100-110 nm in diameter, containing 162 capsomers. Outside this there
is an asymmetric material surrounding the capsid, known as tegument and an
envelope containing viral glycoprotein spikes on the surface (Roizman & Pellet,
2001). The tegument contains specific viral proteins together with cell protein
including actin, tubulin and heat shock proteins. The envelope contains several viral
glycoproteins including gp350, 78 and 42 (Johannsen et al., 2004).
Herpesviridae
Alphaherpesvirinae
Betaherpesvirinae
Gammaherpesvirinae
Simplexvirus:             HHV-1/2  (HSV1/2)
Varicellovirus:            HHV-3 (VZV)
Cytomegalovirus:       HHV-5 (HCMV)
Roseolovirus:             HHV-6/7
Lymphocryptovirus: HHV-4 (EBV)
Rhadinovirus:             HHV-8 (KSHV)
Family                                    Sub-family                              Genus                    Species
Figure 1.1 Herspesviridae taxonomy
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EBV has a large and complex genome of approximately 172 kb
containing at least 84 genes, (as reported by Paul Farrell at GenBank: AJ507799),
whose mRNAs may contain introns and undergo splicing. It is present in a linear form
in the viral capsid and it rapidly circularises after infection of B cells via the terminal
repeat (TR) sequences, which are typical of gamma herpesviruses and located at the
ends of the linear genome (Bankier et al., 1983). Like the genome of other
lymphocryptoviruses, EBV is divided into four distinct regions that include a long and
a short unique sequence (US and UL), which are terminated by a variable number of
0.5-kb TRs and separated by repetitions of 3-kb internal sequences (IRs) with
functional relevance because they contain the Wp latency promoter (Rickinson &
Kieff, 2001). The sequence of the B95-8 genome of EBV was published first in 1984,
and the region deleted in the B95-8 strain was later sequenced in the Raji strain
(Parker et al., 1990). Further minor corrections were made by De Jesus et al (De Jesus
et al., 2003). Position 1 of the genome is numbered from 1 nucleotide before the
EcoRI site separating EcoDhet from EcoI, the first A of the sequence AGAATTC.
The map was built by sequencing DNA fragments derived from digestion of the
genome with EcoRI and BamHI restriction enzymes. The restriction fragments were
named alphabetically by their size (A being the largest). Open reading frames (ORFs)
were identified using criteria of length, codon usage, relationship to AAUAAA-polyA
addition sites and direction of the reading frame. For example, the BARF1 gene is the
first rightward reading frame starting in BamHI A. Several EBV genes have been
found to have similarities to cellular genes, like BHRFI to BCL-2 (Pearson et al.,
1987) BZLF1 to c-FOS (Farrell et al., 1989) and BCRF1 to IL-10 (Moore et al.,
1990). Many genes involved in the lytic cycle show a high degree of conservation
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across the herpesviruses (Ryon et al., 1993), whereas little or no conservation is
shown amongst latent genes (Davison & Taylor, 1987).
1.2 The Life Cycle
1.2.1 EBV primary infection and natural reservoir
The virus infects naïve B cells in the tonsils but the role of the epithelium in
the lytic cycle is still debated. In favour of an active role there are the findings that
EBV is associated with pathologies of epithelial origin such as oral hairy leukoplakia
(Loning et al., 1987), nasopharyngeal carcinomas (Anderson-Anvret et al., 1979) and
gastric carcinomas (Burke et al., 1990).  However, in vitro addition of EBV to
squamous epithelial cells yields a low rate of infection unless co-cultured with B cells
(Shannon-Lowe et al., 2006).  One possibility is that EBV gains access to B cells by
entering the Waldeyer’s ring structures of the tonsils, where crypt formations
penetrate the lymph nodes through the epithelium (Faulkner et al., 2000).  Deep into
the crypts, the epithelium is composed of a single cell layer, and the crypts represent a
vast area able to sample antigens contained in the saliva (Perry & Whyte, 1998). In
this dual tropism model, epithelial cells would serve as a site of virus amplification
upon exit from the carrier or a location for continuous infection of closely positioned
naïve B cells. Involvement of epithelial cells in natural infection has been advanced
by Borza and Hutt-Fletcher, who have shown that EBV particles produced from
epithelial cells have a higher efficiency for infecting B cells and vice versa. (Borza &
Hutt-Fletcher, 2002).  Studies by Tugizov et al seem to show instead that these cells
are resistant to EBV infection from the mucosal site (Tugizov et al., 2003).
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1.2.2 Cell entry
Attachment and entry are two separate events in herpesviruses (Spear et al.,
2000). EBV attachment to B cells is mediated by the Cluster of Differentiation (CD)
antigen 21 (CD21), also known as Complement Receptor (CR) 2, (CR2) (Nemrow et
al., 1987, Tanner et al., 1987). The physiological ligand is the C3d component of the
complement (Barel et al., 1988). CD21 binds to gp350, the outer envelope
glycoprotein of EBV and mediates the endocytosis (Fingeroth et al., 1984).
Penetration into B cells involves the cooperation of a complex composed of three
viral glycoproteins, gp42, gH and gL that mediate the binding of gp42 to the Human
Leukocyte Antigen (HLA) class II on the surface of the cells (Li et al., 1997).
Antibodies against gp42 selectively block the fusion but not the adsorption. Once
inside the cell, the viral capsid disperses and the genome is translocated to the
nucleus, where it is maintained as an episome. Infection of HLA class II negative
cells, like epithelial cells, is mediated by gH and gL in the absence of g42 (Wang et
al., 1998). The experiments of Borza and Hutt-Fletcher involving infection of
epithelial cells, can be explained on the basis of this mechanism. The virus envelope
contains three part complexes and two part complexes, composed respectively of gH,
gL and gp42, or gH and gL. Alternate replication in HLA class II-positive B cells and
HLA-negative epithelial cells modifies the ratio of three-part gH-gL-g42 complexes
to gH-gL complexes, changing the tropism of the virus. The binding of gp350 to
CD21 ligands has additional important functions involving the preactivation of B
cells. Upon binding, the CD21 receptors cluster and form a multimeric signal
transduction complex that activate tyrosine and PI3 kinases, the NF-kB pathway and
the E2F-4 protein, facilitating cell cycle entry (Sinclair & Farrell, 1995, Spender et
al., 1999).
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1.2.3 The Lytic cycle
EBV persistent infection consists of a subtle interplay between the virus
attempting to maintain its infectious load and the immune system trying to clear the
cell population from the infected pool. The lytic phase represents the strategy for the
virus to continuously re-infect novel populations of naïve B cells and also to shed the
virus to other hosts. Crawford and Ando have shown that EBV induction is associated
with B cell maturation (Crawford & Ando, 1986) and Laichalk and Thorley-Lawson
have confirmed in vivo that, in the tonsils of healthy carriers, the lytic cycle is
observed exclusively in terminally differentiated plasma cells (Laichalk & Thorley-
Lawson, 2005). These cells are essentially antibody secreting factories, so they may
be well suited to the efficient production of virions. Also, they are located in the tonsil
epithelium, which would allow them to shed virus into the saliva.
The genes that are expressed are divided in three groups: immediate early
genes, early genes and late genes (Amon et al., 2004). Viral immediate early genes are
induced directly by signal transduction from the B cell receptor, BCR (Bryant &
Farrell, 2002). BZLF1 and BRLF1 are the major genes involved in the immediate
early response (Biggin et al., 1987), but BZLF1 is first in the BCR response. BZLF1
alone can trigger the entire lytic cascade (Countryman et al., 1987) and BZLF1 is the
only gene that responds directly to BCR signal transduction (Amon et al., 2004).
BZLF1 is a transcription factor with sequence similarity to c-FOS and has binding
sites in several viral and cell gene promoters, activating the expression of BRLF1 as
well (Sinclair et al., 1991). The promoter for BZLF1, Zp, contains sequence motifs
that have been characterized into four groups called, ZI, ZII, ZIII and ZIV and in
vitro, the lytic cycle can be induced in Akata cells by cross-linking of the B cell
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receptor, BCR (Amon et al., 2004). ZI is composed of four elements with negative
modulation effects in the absence of lytic stimuli, mediated by MEF2D that recruits
histone deacetylase complexes and reduces Zp activity (Gruffat et al., 2002). The
engagement of the BCR causes a rapid dephosphorylation of MEF2D altering its
effects on Zp (Bryant & Farrell, 2002). This response would envisage antigen binding
to the BCR to be a trigger of lytic cycle reactivation. It has also been proposed that
signals that promote EBV induction should come from the cell as it differentiates,
since infected memory cells do not undergo lytic phase. Recent studies have identified
an XBP-1 binding site in the ZID/ZII region of Zp (Bhende et al., 2007, Sun &
Thorley-Lawson, 2007). Mutation of this sequence in the Zp promoter led to
abrogation of XBP-1 binding and reduced promoter activity. Direct binding of XBP-
1s to endogenous Zp was observed in an EBV-infected plasma cell line and over-
expression of XBP-1 resulted in increased expression of BZLF1, whereas knockdown
of XBP-1 with short hairpin RNA reduced BZLF1 expression. XBP-1 promotes
protein synthesis in plasma cells (Shaffer et al., 2004) and activates chaperone genes
and major histocompatibility complex class II genes (Iwakoshi et al., 2003).  XBP-1
could represent a physiological signal to reactivate and begin viral replication
although recent reports indicate it is not sufficient to activate the lytic cycle in
lymphoma cell lines. Globally, immediate early genes and early genes are involved in
the replication of viral genome whereas the late genes express structural genes, which
will lead to the packaging of the virus (Amon et al., 2004). Lytic replication requires
the lytic origins of replication (oriLyt), which are present in two copies in the viral
genome (Laux et al., 1985). Forced activation of the lytic cycle is being studied as a
method to selectively kill cancer cells in EBV related pathologies, since the lytic cycle
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eventually kills the cell, and induces an immune response against lytic phase antigens
(Amon et al., 2004).
1.2.4 The Latent phase of infection
1.2.4.1 Genes involved in latent infection
1.2.4.1a EBNA 1
The Epstein Barr virus Nuclear Antigen 1, EBNA1, is a 76 kd protein
involved in the maintenance of the EBV episome during cell division (Rawlins et al.,
1985). In LCLs EBNA1 mRNA is expressed from a long primary transcript whose
spliced products will produce mRNAs for all EBNAs from the Cp promoter
(Bodescott & Perricaudet, 1986). EBNA1 binds as a dimer to the viral latent origin of
replication (oriP) (Rawlins et al., 1985), which contains tandem repeats of the EBNA1
binding sites and causes viral replication. The oriP is composed of two main elements
called FR (a 20 member family of 30 bp repeats) and the dyad symmetry domain, DS
(Wang & Sugden, 2005, Yates et al., 1984). Each FR repeats contains a high-affinity
binding site for EBNA1 whereas the DS contains four domains that bind EBNA1 at
lower affinity but are essential for bidirectional genome replication. The FR element
acts as an enhancer, revealing an additional role of EBNA1 as a transcription factor.
EBNA1 in fact influences, through this element, the expression of the Cp promoter in
one direction and the expression of the LMP1 viral oncogene in the other (Sugden &
Warren, 1989, Gahn & Sugden, 1995). EBNA1 also binds to non-histone
chromosomal proteins, tethering the EBV genome to mitotic chromosomes, allowing
the episome to be distributed to daughter cells at chromosome segregation (Ohno et
al., 1977). This process mediated by oriP is independent from the replication 
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and is essential for stable infection (Lee et al., 1999). EBNA1 is expressed throughout
EBV latent infection and remains during the lytic phase (Heller et al., 1982). In
latency I BL and in NPC cells, EBNA1 is expressed from the Qp promoter, allowing
it to be made in the absence of other EBNAs (Tsai et al., 1995). It has been proposed
that memory B cells only express EBNA1 during cell division, from the Qp promoter
induced during S phase (Hochberg et al., 2004). EBNA1 is expressed also in all
malignancies associated with EBV infection and in vitro in all cell lines. The
interaction of EBNA1 with the oriP allows stable episome maintenance and this type
of vector system was used in this thesis.
1.2.4.1b EBNA2
The Epstein Barr virus Nuclear Antigen 2, EBNA2, is a transcription factor
and is one of the first proteins to be expressed during latent infection. Lack of the
EBNA2 gene renders EBV unable to establish proliferation and immortalization of
infected B cells (Rabson et al., 1982).  EBNA2 is expressed from the Wp promoter
upon viral infection of B cells under the control of the RNA pol II of the cell.
Another nuclear antigen, EBNA-LP is expressed and translated from a partially
overlapping mRNA (Woisetschlaeger et al., 1990). The Wp promoter is located inside
the major internal repeat of the virus (IR1) and thus is present in multiple copies
(Sample et al., 1986, Speck et al., 1986b). The presence of multiple copies of the Wp
may facilitate the initial EBNA2 gene transcription in resting B cells and the detection
of a ladder of EBNA-LP polypeptides during the initial stages of infection is
consistent with transcription initiation from multiple copies of Wp (Rooney et al.,
1992). It is important to mention that the expression of the Wp promoter depends on
PAX5 that is expressed during B cell development and in germinal centres but is
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absent in terminally differentiated plasma cells (Tierney et al., 2007). Subsequently,
EBNA2, enhanced by EBNA-LP, is thought to regulate the second latency promoter,
Cp (Woisetschlaeger et al., 1991, Yoo & Speck, 2000), inducing the expression of an
alternative spliced transcript that gives rise to mRNAs for the whole family of latency
nuclear antigens (EBNA1, 2, 3s, LP). However, construction of recombinant EBV
strains containing specific mutations in the RBP-Jk binding site in the Cp promoter
did not significantly affect induction of Cp suggesting that other factors are also
involved in the regulation of Cp (Evans et al., 1996) and recent data suggests that
EBNA1 activation of Cp is important in the promoter switching (Zettergberg et al.,
2004). Cp is located in the unique region just upstream of the IR1 repeats
(Woisetschlaeger et al., 1989) and the use of the Wp and Cp promoters tends to be
mutually exclusive (Woisetschlaeger et al., 1989).
EBNA2 directly induces the expression of the viral latent membrane proteins, LMPs
(Fahraeus et al., 1990b, Wang et al., 1990a) and several cell genes involved in B cell
activation and proliferation, and this transcription activity is augmented by EBNA-LP
(Ling et al., 2005, Peng et al., 2007). EBNA2 does not bind to target DNA directly
but through mediation of DNA binding proteins. The most studied is RBP-Jk that
interacts in very similar fashion with NOTCH-IC (Henkel et al., 1994b). NOTCH-IC
and EBNA2 share structural and functional characteristics that will be discussed
further in this introduction.
1.2.4.1c EBNA-LP
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The Epstein Barr virus Nuclear Antigen Leader Protein, EBNA-LP, co-
operates with EBNA2 in the activation of viral and cell targets such as LMP1 or
Cyclin D2 (Harada & Kieff, 1997, Sinclair et al., 1994). Structurally, the protein is
composed of a unique carboxyterminal sequence and a repetitive N terminal portion
(Speck et al., 1986a). EBNA-LP is encoded by W1 and W2 exons contained in the
major internal repeat region of EBV and by the more downstream Y1 and Y2 unique
exons (Sample et al., 1986, Speck et al., 1986a). An alternative splice between the
non coding W0 exon and the 5’ end of the first W1 exon will determine whether
EBNA2 mRNA or EBNA-LP mRNA will be produced (Figure 1.2).
W1 and W2 encode the N terminus of EBNA-LP and the product of these two exons
retains the ability to co-operate with EBNA2 in the transformation of B cells
(Kempkes et al., 1995b, Tierney at al., 2007).  EBNA-LP co-localizes in the nucleus
W0
Wp
  W1
W1’ W2
W2 [          ]nW1W1 W2W2
W0: ….CACACAAU                CUAGGGGAGACCG
W1         W1’
Figure 1.2. Alternative splicing at the Wp promoter produces mRNA coding for EBNA-LP or
EBNA2
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of LCLs with pRB and has been shown to interact in vitro with pRB and p53 (Szekely
et al., 1993).  The function of EBNA-LP independent from EBNA2 is still matter of
study but Garibal et al, have recently reported that Burkitt lymphoma strains
harbouring a deleted version of EBNA-LP show increased resistance to caspase
dependent apoptosis induced by staurosporine, linking this phenotype to an
interaction of the truncated EBNA-LP with protein phosphatase A2 (PPA2) (Garibal
et al., 2007).
1.2.4.1d The EBNA3 family
The EBNA3A, 3B and 3C genes are adjacent on the viral genome and show
similar exon structure, a modest sequence similarity in the amino-terminal portion and
different tandem repeats towards their carboxyl terminal (Farrell, 1995). The
similarity suggests a similar function but so far only EBNA3A and EBNA3C have
been shown to be essential, in the transformation of B cells by EBV (Kempkes et al.,
1995a, Tomkinson et al., 1993). All three proteins interact with RBP-Jk (Robertson et
al., 1996) and interfere with the induction of the genes regulated by EBNA2, as well
as viral targets like the Cp promoter, functioning as direct antagonists for RBP-Jk
binding (Radkov et al., 1997, Waltzer et al., 1996). However there are data showing
co-operation as well, since EBNA2 and EBNA3C, in concert, can regulate the
expression of LMP1 (Allday et al., 1993, Zaho & Sample, 2000) whereas EBNA3C
can regulate the expression of CD21 in EBV negative Burkitt lymphoma cells,
similarly to EBNA2 (Wang et al., 1990a).  In contrast, EBNA3B appears to regulate
the expression of CD40 in EBV negative Burkitt lymphoma cells (Silins & Sculley,
1994). It seems that a complex network involving EBNA2 and EBNA3s controls the
expression and regulation of viral and cell genes. EBNA3C has been shown to
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interfere with the cell cycle by controlling a G2/M check point since transfection in
EBV negative cells, in the absence of serum, promotes nuclear division as a result of
the abrogation of the mitotic spindle check point (Leao et al., 2007, Parker et al.,
2000).
1.2.4.1e The Latent Membrane Protein 1
The Latent Membrane Protein 1, LMP1, is a transmembrane protein composed
of 386 aminoacids that mimics a constitutively active CD40, a receptor that is
involved in B cell activation and survival (Gires et al., 1997). EBV cannot sustain
stable proliferation in the absence of EBNA2 (Kempkes et al., 1995) but LMP1
expression is sufficient to establish a signalling cascade that activates the NF-KB
pathway and promotes cell survival (Zimber-Strobl et al., 1996). Inhibition of this
pathway causes apoptosis in LCLs (Cahir-McFarland et al., 2000). LMP1 has been
described as an oncogene because it can transform rodent fibroblasts (Wang et al.,
1985) and can sensitize transgenic mice to lymphomas (Kulwichit et al., 1998).
Several anti-apoptotic genes are induced by LMP1, for example BCL2, A20, MCL-1
and BFL-1 (Henderson et al., 1991, Laherty et al., 1992, Wang et al., 1996).
Structurally, LMP1 is an integral membrane protein consisting of a short cytoplasmic
hydrophilic N-terminus, a hydrophobic transmembrane domain consisting of six alpha
helices and a longer acidic C-terminus (Eliopoulos & Young, 2001, Lam & Sugden,
2003). The transmembrane helices mediate the spontaneous formation of LMP1
oligomers in the membrane, which induce signal transduction at the C-terminal
cytoplasmic signalling domain (Mosialos et al., 1995). Two C-terminal domains
named C-terminal activating region 1 and 2 (CTAR1, CTAR2) are required for B cell
transformation (Huen et al., 1995). CTAR1 binds to Tumor Necrosis Factor Receptor
29
(TNFR) associated factors (TRAFs), inducing the non canonical NF-kB pathway.
CTAR2 mediates the activation of the canonical NF-kB pathway via IKKB and
phosphorylation and degradation of I-kB.
Regulation of LMP1 expression by EBNA2 is complex. Several transcription
factors are involved in the modulation of the promoter including RBP-Jk, p300/CBP,
ATF/CREB and PU Box binding factors and SWI-SNF (Fahraeus et al 1990a,
Sjoblom et al, 1998., Wang et al., 2000). Histone acetylation has been shown to be
important in the regulation of the LMP1 promoter since EBNA2 recruits p300/CBP
histone acetylase on to AP-2 regulatory sequences of the LMP1 promoter (Jannson et
al., 2007) and Trichostatin A, an inhibitor of HDAC activity, induces LMP1
expression in EBV positive and EBNA2 negative Burkitt lines (Sjoblom-Hallen et al.,
1999).
In vivo, LMP1 is expressed in the germinal centres, which represent a critical
compartment for EBV to gain access to memory cells (Thorley-Lawson, 2001). LMP1
endows germinal centre cells with survival signals that block apoptotic death. Adler et
al have shown that LMP1 suppresses virus reactivation, inhibiting anti-IgM or
phorbolester-induced transcription of the viral immediate early protein BZLF1, which
controls entry into the viral lytic cycle (Adler et al., 2002). In germinal centres and
other latency II infections, EBNA2 is absent but LMP1 is expressed, contrary to
latency III, where LMP1 expression depends on EBNA2. The viral and cell signals
that could sustain LMP1 in the absence of EBNA2 are not yet understood.  Possible
mechanisms could involve IL4, IL10 and IL21 that can affect LMP1 expression. IL10
was shown to induce LMP1 in the absence of EBNA2 in Daudi cells and in LCLs
containing a conditional EBNA2 (Kis et al., 2006). The same authors showed that IL4
and CD40 selectively induce LMP1 without induction of EBNA2 (Kis et al., 2005).
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Furthermore, IL10 induced the expression of LMP1 in normal B cells infected with
the EBNA2-defective EBV strain P3HR1 and IL10 up-regulated LMP-1 in two NK
lymphoma cell lines. All these data suggest that IL10 may be responsible for the
establishment of type II latency in EBV-infected cells in vivo, since it is provided by
the cells of the GC microenvironment. These data could be even more relevant when
considering that EBV, like some other herpesviruses, expresses viral homolgues of
human interleukins. BCRF1, is the viral homologue of IL-10 (Moore et al, 1990).
Classically, BCRF1 is considered a lytic gene and its expression has been proposed to
modulate the immune-response to EBV infected cells, thus regulating and limiting the
viral load during reactivation (Stewart and Rooney, 1992). Nevertheless, Myiazaki et
al, have reported that BCRF1 is expressed 6 hour post EBV infection (Myiazaki et al,
1992). If this data holds for in vivo infection, BCRF1 could recapitulate the effects of
the host IL-10 on EBV positive B cells, promoting the expression of LMP1 in an
EBNA2 negative context, and consequently facilitating the onset of the latency II
pattern.  In experiments measuring B cell outgrowth in response to EBV infection,
vIL-10 enhanced the transformation efficiency by inhibiting IL-2 release from T cells
(Bejarano and Masucci, 1998). These data combined with the observation that BCRF1
expression is associated with a percentage of EBV positive lymphomas (Benjamin et
al, 1994, Stewart et al, 1992) suggest that vIL-10 could function in vivo to establish B
cell latent infection but could also in some circumstances enhance cell transformation
leading to EBV linked proliferative pathologies.
 Konforte et al, have shown that IL21 has a reciprocal effect on induction of EBNA2
and LMP1, perhaps shedding some light on how the latent infection might switch
from latency III to latency I (Konforte et al., 2008). These authors have established a
type III latency EBV positive human B cell line that resembles post germinal centre,
31
antigen-activated IgG+ B cell blasts (Konforte & Paige, 2006). In these cells,
administration of IL21 reduced EBNA2 expression and its target genes and in parallel
increased expression of LMP1 and induction of EBNA1 from the Qp promoter. In
contrast, Rastelli et al have studied the effect of LMP1 in development of B cells in
mice independently from cytokine signals (Rastelli et al., 2008) by generating a
fusion product of CD40 to LMP1 that retained the LMP1 cytoplasmic domain but
needed the CD40 clustering ability to initiate signaling. In this model, LMP1 was able
to induce B cell differentiation, somatic hypermutation and class switching
independently from cytokine signals, suggesting that LMP1 has evolved to imitate T-
helper cell induced functions, such as B cell activation, proliferation, and
differentiation (Rastelli et al., 2008).
LMP1 presents several epitopes that elicit a strong T cell response, and since
Hodgkin lymphomas and nasopharyngeal carcinomas are HLA class I and class II-
positive, the LMPs could serve as both CD8+ and CD4+ T cell targets (Haigh et al.,
2008).
1.2.4.1f The LMP2 family
The LMP2 family comprises the LMP2A and LMP2B proteins. LMP2A and
LMP2B are expressed from a common gene, LMP2, that encodes two messages of 2.0
and 1.7 kb in length, and are produced by alternative promoter usage (Laux et al.,
1988, Sample et al., 1989). The longer message encodes LMP2A, while the shorter
message is initiated from a bidirectional promoter, 5kb downstream, that is
responsible for the expression of LMP1 as well, in the other direction (Laux et al.,
1988, Rowe et al., 1999). The mRNAs share eight exons at the 3’ end that code for
twelve membrane spanning segments connected by short loops and end with a
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cytoplasmic C-terminal domain (Longnecker, 2000). The major difference between
the two isoforms is that LMP2A has an N-terminal cytoplasmic signalling domain
that is absent in LMP2B. The expression of these genes during the initial steps of
infection is coordinated by EBNA2 (Bornkamm & Hammerschmidt, 2001).
Neither protein is essential for the establishment of EBV transformation of
peripheral B cells (Longnecker et al., 1992, Speck et al., 1999) and mutations in
LMP2 do not affect the development of LCLs in mice (Rochford et al., 1997).
However, Brielmeier et al, have shown that LMP2A greatly influences the efficiency
of the process (Brielmeier et al., 1996). In this experiment, an EBV mini plasmid,
expressing EBNA2, EBNA-LP, LMP1, LMP2s and EBERs was found to initiate and
maintain B cell proliferation. The corresponding minimal EBV plasmid lacking
LMP2A, showed a greatly reduced ability to immortalize B cells.  LMP2A acts as a
constitutively active B cell receptor, BCR, and provides survival signals to the B cells
(Caldwell et al., 2000, Merchant et al., 2000). The BCR produces two types of signal
(MacLennan et al., 1994). One is simply required to maintain survival of the resting B
cells and the second leads to B cell activation, proliferation and ultimately
differentiation into secreting plasma cells (Maclennan, 1994). LMP2A is able to
selectively provide the first by inhibiting the activity of the endogenous BCR. This
effect is achieved through interaction to specific cell kinases. These include the Src
family tyrosine kinase, Lyn, which is expressed in B cells (Fruehling et al., 1998). In
addition, the amino-terminal domain of LMP2A includes eight tyrosine residues, two
of which form an immunoreceptor tyrosine-based activation motif (ITAM). This
amino-terminal domain has been shown to be necessary for LMP2A association with
the Src family PTKs (Miller et al., 1995). Since the main switch of the EBV lytic
cycle, BZLF1 responds to BCR signalling, LMP2A blocks EBV reactivation (Miller
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et al., 1994). This could be relevant to infection in vivo, when LMP2A is expressed in
memory B cells when re-circulating through lymph nodes (Miyashita et al., 1995,
Thorley-Lawson, 2001).  Recent work by Mancao and Hammerschmidt has shown
that LMP2A protein allows survival of EBV infected germinal centre B cells carrying
potential deleterious somatic hypermutations of their immunoglobulin genes (Mancao
& Hammerschmidt, 2007). Considering the fact that EBV positive Hodgkin
lymphoma cells often carry similar defective rearrengments of immunoglobulin genes
(Brauninger et al., 2006), this work lays down the basis for a mechanism by which
EBV could contribute to Hodgkin lymphoma development.
LMP2B as mentioned above shares consistent structural features with LMP2A
but its role is still quite unclear. One suggestion is that the lack of the N-terminal
region could make it resemble a decoy LMP2A receptor (Bornkamm &
Hammerschmidt, 2001). Rechsteiner et al, supported this by showing that upon BCR
cross-linking, transfection of LMP2B in EBV positive Akata BL cells increased the
rate of latent to lytic switch (as indicated by a stronger upregulation and expression of
EBV lytic genes and an increased production of transforming EBV) compared to
LMP2A-over-expressing cells (Rechsteiner et al., 2008).
1.2.4.1g EBERs
The Epstein-Barr virus (EBV) small non polyadenylated RNAs EBER-1 and
EBER-2 (167 and 172 nucleotides, respectively) are highly structured non-coding
RNA polymerase III transcripts expressed at high levels within the nuclei of cells
latently infected by EBV (Glickman et al., 1988) and are easily detected by RNA in
situ hybridization. The EBERs can contribute to the tumorigenic potential of Burkitt
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lymphoma (BL) and other B-lymphoma cell lines, as well as the growth of cells
derived from gastric and nasopharyngeal carcinomas (Komano et al., 1999, Iwakiri et
al., 2003, Iwakiri et al., 2005). Recently Wu et al, have created recombinant EBVs
with deletion of either EBER1 or EBER2 (Wu et al., 2007). The transforming ability
of the recombinant EBV lacking EBER2 was impaired. A role for the EBERs has
been proposed in Burkitt lymphoma, in the induction of IL10, which can act as an
autocrine factor of BLs, opening new possibilities for their role in cancer (Kitagawa et
al., 2000).
1.2.4.2 Latency III and B cell immortalization
During immortalization of peripheral B cells in vitro, EBV expresses 9 genes
comprising 6 EBNAs (EBNA1, 2, 3A, 3B, 3C, LP) and three LMPs (LMP1, 2A, 2B),
together with the two small non coding RNAs (EBER1 and EBER2)
(Anagnostopoulos et al., 1995, Rowe et al., 1992).  Recently this picture has been
extended to possibly include the BCL2 homologue BHRF1 (Rickinson, 2008, SGM
meeting, Edinburgh). LCLs have an irregular shape and a tendency to aggregate
because of an increased expression of surface adhesion molecules (Gregory et al.,
1988, Rowe et al., 1987). At first this characteristic to growth transform B cells, lead
to this phenotype being thought to represent the pattern of expression assumed by
EBV in the associated malignancies, supported by the fact that some Burkitt
lymphoma tumors showed a phenotype which resembled that of B blasts (reviewed in
Gregory et al., 1990). However, it has been shown that these tumors have a poorly
differentiated resting B cell phenotype and express only the EBNA1 protein (Rowe et
al., 1986, Rowe et al., 1987). The nomenclature Latency I, II and III refers to three
recurrent patterns of gene expression, in latently infected B cells (Rowe et al., 1987,
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Rowe et al., 1992). Latency III refers to the pattern of expression observed in B cell
transformation and LCLs. Burkitt lymphomas display commonly a Latency I
phenotype, which is characterized by the expression of the EBNA1 protein alone. The
latency III pattern, which is typical of in vitro immortalized B cells, is detected in
vivo in EBV infected naïve cells in the tonsil of patients (Thorley-Lawson, 2001) but
it is also found in connection to some EBV associated pathologies like infectious
mononucleosis and lymphoma arising in immune compromised patients like post
transplanted patients and AIDS patients (Bower, 2002). The determination of these
patterns of expression is still not clear. Kelly et al, found that about 10% of endemic
Burkitt lymphoma cell lines of African origin have an altered pattern of expression,
with an active Wp promoter lacking EBNA2 expression (Kelly et al., 2002). The
striking finding is that a relatively consistent deletion prevented the expression of
EBNA2 and consequently LMP1, but retained expression of EBNA1, EBNA3s and a
deleted EBNA-LP. All these cells lines were co-infected with a wild type strain of
EBV, but the Wp promoter was in this case silent. The deletion could represent a
strategy to bring the Wp promoter close to the BHRF1 locus, favoring its expression
in a BL context.
As already anticipated, EBV infection in vivo follows the route of
differentiation of B cells with which is closely entwined, therefore it is useful to
briefly describe the events that characterize B cell development.
1.2.4.3 B cell development
The development of B cells in the adult starts in the bone marrow from a
hemopoietic stem cell (HSC), which differentiates into a common lymphoid precursor
(CLP) that is still pluripotent, as it can differentiate into B cell, T cell and dendritic
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cells precursors (Rothenberg, 2000). Recently, a new model has suggested that thymic
maturation arises from a progenitor that retains myeloid and T lymphoid potential,
ETP, but has lost B lymphoid potential (Bell & Bhandoola, 2008). Genes involved in
differentiation include NOTCH1 and PAX5, respectively critical for T cell lineage
differentiation (Radtke et al., 1999) and for B cell development (Nutt et al., 1997).
Once cells have committed to the B lineage, they undergo maturation through control
of the BCR (Figure 1.3). In pre B cells the BCR is composed of two immunoglobulin
µ heavy chains and two surrogate light chains (SLC) unable to recognize the antigen
(Martensson et al., 2007). Only after substitution of SLC on the IgM with a bona fide
light chain can the B cell become mature for antigen recognition. At this stage it
migrates from the bone marrow to peripheral lymphoid organs like the tonsils, which
are the site of EBV infection. The lymph nodes in the tonsils are rich in mature resting
B cells ready to react with antigens. Naïve mature B cells continuously re-circulate in
the peripheral circulation, through lymphoid organs. They reside for few days in the
follicles and they re-enter the circulation, unless they encounter an antigen presented
by dendritic cells or T helper cells, in which case they become activated and produce
proliferating blasts (Brantzaeg et al., 1999). The proliferating B cells in the lymph
nodes can form germinal centres (GCs) (Klein & Dalla-Favera, 2008).
Morphologically germinal centres are divided into dark and light zone. The dark zone
is the site of clonal expansion of centroblasts and somatic hypermutation (SHM), a
process that increases antigen affinity, also known as the germinal centre reaction.
During this phase, B cells cease expression of surface immunoglobulins, mainly
because they undergo a process of Ig class switching and, as a result, a population of
centrocytes arises expressing bona fide IgM, IgG, IgA or IgE (Rajewsky, 1996,
Weller et al., 2003). After randomly mutating their immunoglobulins, the cells re-
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express the immunoglobulin on the surface and rest. In the light zone, centrocytes
derived from this reaction undergo selection based on the affinity of the BCR for the
antigen. If the mutation has increased the affinity of the Ig it will compete for antigen
and survive, otherwise it will die by apoptosis (Liu et al., 1989).  The survivors will
differentiate into memory B cells or plasma cells, the first representing the pool of
cells ready to react quickly to further invasion from the antigen and the second
representing a pool of antibody secreting cells that will patrol almost every part of the
body. Both cell types are released into the blood stream and the memory B cells can
terminally differentiate into plasma cells under specific cytokine signals (like TGF-β)
when recirculating into lymph nodes.
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1.2.4.4 Genes relevant to EBV involved in B cell
development: the NOTCH family, IRF4 and BCL6
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Figure 1.3 Stages of B cell differentiation
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The NOTCH pathway controls cell fate choices in many tissues during
development, including the hematopoietic system (reviewed in Dallman et al., 2005).
NOTCH is involved in many developmental steps that require a binary fate choice,
for example development and differentiation of lymphocytes. NOTCH acts as a
receptor when located in the membrane and as a transcription factor when it migrates
into the nucleus (reviewed in Dallman et al., 2005). Structurally, it is a large single-
pass trans membrane protein derived from the non-covalent binding of two fragments.
It contains an N-terminal PEST domain that modulates protein stability, a
transactivation domain, and two nuclear localization signals surrounding an Ankyrin
repeat domain. There is also an RBP-Jk associated module, RAM; The trans
membrane domain separates it from the C-terminal extracellular domain, which is
composed of EGF-like repeats.  The ligands for the NOTCH receptor are members of
the Delta and Jagged families; a third form of ligand, Fringe, causes modulation of the
NOTCH receptor (reviewed in Dallman et al., 2005). Binding of the ligand to the
receptor causes a proteolytic cleavage by γ secretase and ADAM metalloprotease that
releases the N-terminal part of the protein, which then migrates to the nucleus as a
intracellular fragment (NOTCH-IC). Four members of the NOTCH family are
expressed in mammals, called NOTCH1, 2, 3, and 4. NOTCH1 and 2 share the same
modularity, whereas NOTCH3 and 4 do not possess a clear transactivation domain.
Activation of the NOTCH pathway causes hematopoietic stem cells to differentiate
into T cells rather than B cells (Sambandam et al., 2005). In contrast, enhanced
expression of NOTCH in HSCs resulted in massive accumulation of stem cells (Pui et
al., 1999). However, the basic explanation is more complex. NOTCH is also
expressed in mature B cells and it has been shown that NOTCH2 is indispensable in
the spleen for development of the marginal zone B lineage from recirculating memory
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B cells (Saito et al., 2003). At this stage, the Deltex homologue 1, DTX1, that is
normally a modulator of the NOTCH pathway, interferes with NOTCH2 signalling.
NOTCH2 expression induces CD21, HES1 and DTX1 and downregulates the Ig-µ
chain promoter, leading to a strengthening of BCR signalling and eventually to
differentiation (Dallman et al., 2005). NOTCH1 function reappears in late stage B
cells and is critical for differentiation of marginal zone cells into antibody secreting
cells in response to Delta ligands (Santos et al., 2007). Therefore it appears that
NOTCH function in B cells has to be addressed in the context of B cell
differentiation.
The interferon regulatory factor 4, IRF4, and B cell lymphoma 6, BCL6,
proteins are reciprocally involved in regulation of B cell differentiation (Saito et al.,
2007). BCL6 is expressed during the transition of B cells into germinal centres by
centroblasts whereas IRF4 is downregulated during the same period. IRF4 is
expressed in centrocytes, memory B cells and plasma cells (Cattoretti et al., 1995,
Klein et al., 2006). In mice, mutants that do not express BCL6 lack germinal centres,
whereas enforced expression of BCL6 represses p53, which may prevent cell-cycle
arrest and apoptosis, facilitating the rapid expansion of the germinal centre. This may
also favor somatic hypermutation, which is thought to be mediated by DNA breaks
without inducing a p53-mediated apoptotic response (Phan & Dalla-Favera, 2004).
IRF4 is expressed at several stages of B cell differentiation and IRF4 knock out mice
have a block in B cell development at the stage of immature B cells since the
deficiency impairs the rearrangement of the pre-BCR, the switch from a surrogate
light chain to a bona fide light chain and consequent migration from the bone marrow
to the lymph nodes (Lu et al., 2003, Mittrucker et al., 1997). At later stages, IRF4 is
essential for the onset of the class switch recombination, which will lead to
41
differentiation into memory B cells and antibody secreting plasma cells. It is also
critical for the maintenance of memory B cells (Klein et al., 2006). IRF4 acts
upstream to XBP1, also involved in B cell terminal differentiation and reactivation of
EBV from latency. The roles of these genes, NOTCH, IRF4 and BCL6 are important
in the context of B cell development of EBV infected cells, since they control critical
steps of germinal centre differentiation, relevant to the onset of latency in vivo.
1.2.4.5 EBV in the germinal centres
A model developed by Thorley-Lawson describes the progression of EBV
through latency (Thorley-Lawson, 2001) (Figure 1.4). The general idea is that EBV
infection of B cells in the tonsils, progressing in a fashion that recapitulates the
developmental sequence of a mature B cell after antigen activation.  EBV exploits this
route, from activation in naïve B cells to differentiation in germinal centres and
maintenance in memory cells, to reactivate in plasma cells, using different
transcription programs in different cellular backgrounds. EBV infects resting B cell
and activates them inducing proliferation, expanding at the same time the fraction of
EBV infected cells. During this period the latency III program is expressed. Some of
these antigens are processed by the B cell and exposed on the MHC I to be presented
to T cells (Taylor & Rickinson, 2007). Consequently, this expansion elicits a
consistent response from the T cells, so the aim of the virus is to reach the quiescent
memory B cell compartment by gradually switching off gene expression while
passing through the germinal centres. To test this, Babcock et al, used flow cytometry,
to isolate subsets of B cells from the tonsils of patients who underwent tonsillectomy
(Babcock et al., 2000). Naïve cells, centroblasts and centrocytes were separated on the
basis of their clusters of differentiation and analyzed for the expression of EBV
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markers. The pool of activated B cells infected by EBV was found to express the full
array of EBNAs and LMPs, a condition known as Latency III. The formation of
germinal centres and the passage from centroblasts of the dark zone to the centrocytes
of the light zone corresponds to the down regulation of some latent genes. EBV
adopts a Latency II pattern of expression in germinal centres, where only LMP1 and
2A are expressed, together with EBNA1. EBV has a Latency 1/Latency 0 phenotype
in memory B cells, characterized by the expression of only EBNA1 to ensure
replication of the viral genome when the cells rarely divide (Thorley-Lawson, 2001).
The memory cell is a suitable location for EBV to persist because it can hide from the
immune system but still replicate in these cells. More over, according to this theory,
memory cells can re-circulate through follicles to acquire survival signals by
expressing two LMPs, LMP1 and LMP2A, which usurp the CD40 and BCR signal
cascades (Eliopoulos et al., 1996, Caldwell et al., 1998). In this way the virus can
persist for a long time but in order to maintain a constant level of infection, new naïve
B cells have to be re-infected at times. Terminal differentiation of memory B cells
into plasma cells causes the activation of the lytic cycle (Laichalk & Thorley-Lawson,
2005). When this happens in the follicles, the viral load produced will be in contact
with naïve cells, which can be infected. This model envisages a dynamic equilibrium
between the immune system of the host that is trying to clear the infection and the
virus that is trying to evade it and at the same time use some signals to its advantage.
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1.2.4.6 Extra-follicular maturation
Several pieces of evidence suggests that EBV can directly infect memory B
cells as well as naïve B cells and that infected naïve B cells can also proliferate in
extrafollicular formations (Kurth et al., 2003, Kurth et al., 2000, Niedobitek et al.,
1992). In tonsils of IM patients, many of these extrafollicular proliferating cells did
not show any rearrangement of the V-region of the Ig and expressed EBNA2, and
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Figure 1.4 Thorely-Lawson model for EBV latent infection
44
moreover sometimes did not express LMP1, leading to the hypothesis that EBNA2
expression can produce a pool of infected cells that will not undergo somatic
hypermutation.
1.2.5 The Epstein Barr Nuclear Antigen 2
1.2.5.1 Role in B cell transformation
The EBNA2 protein is essential for immortalization of B cells in vitro. Viral
strains with a deletion in the EBNA2 locus, like P3HR1 (Hinuma et al., 1967), are
unable to immortalize B cells, unless the deletion is complemented by recombination
with a wild type strain (Cohen et al., 1989, Skare et al., 1985). Greatly improved
understanding of the role of EBNA2 has come from the development by Kempkes et
al, of an EBV system expressing a conditional EBNA2 fused with the estrogen
receptor (Kempkes et al., 1995b). The system is based on a B lymphoblastoid cell line
infected with P3HR1 EBV strain together with a second large plasmid carrying the
region deleted in P3HR1 but expressing a conditional EBNA2 from the Wp promoter.
The maintenance of the vector in the cell is supported by the presence of an OriP
sequence. The presence of two BamHI-W repeats of the Wp promoter allows the
expression of a functional EBNA-LP, which is also defective in P3HR1. EBNA2 is
critical for the maintenance of the growth of transformed cells; if the estrogen is
withdrawn, about half of the EREB2.5 cell population die by apoptosis and the
remainder enter a proliferation block at G1 and G2 stages.  Only the cells blocked in
G1/G0 can be rescued back into the cell cycle. In summary, EBNA2 acts as a
transcription factor to induce EBV latency III gene expression and to modify cellular
gene expression with a resultant stimulation of G1 cell cycle progression. This
EREB2.5 cell line was used as a basic system in this thesis.
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Recently Lee et al have assigned to EBNA2 an additional role, other than a
transcription factor, showing that it can bind to Nur77 (Lee et al., 2004). The intrinsic
function of Nur77 is not yet fully understood; its regulation of apoptosis has been
characterized as cell type-dependent and agent context-dependent, but it can migrate
to mitochondria causing release of cytochrome C (Wu et al., 2002). Whereas LMP1 is
ineffective, EBNA2 protected B cells from Nur77 mediated apoptosis (Lee et., 2004).
1.2.5.2 EBNA2 target genes
Being such a powerful transcription factor, EBNA2 is involved in the gene
regulation of many cell and viral genes (Figure 1.5). Several cell genes are induced
directly by EBNA2 binding to factors associated with regulatory sequences on their
promoters, whereas other genes are secondarily induced. In order to understand the
mechanism of EBNA2, researchers have focused on its direct targets. The following
list is a compendium of EBNA2 direct targets identified prior to this thesis.
B cell activation markers, CD21 and CD23 were amongst the first genes to be
directly linked to EBNA2 (Cordier et al., 1990, Larcher et al., 1995, Wang et al.,
1987). Cordier et al, used Burkitt lymphoma cells infected with the defective strain
P3HR1, which does not possess an EBNA2 locus. By stably transfecting EBNA2,
they noticed that EBNA2 expression was associated with activation of CD21 and
CD23. Larcher et al, confirmed the direct induction of CD21, extending this function
to T cells as well.
c-MYC is directly regulated by EBNA2 (Kaiser et al., 1999). The proto-
oncogene c-MYC plays critical roles in regulating cell proliferation, differentiation
and apoptosis in a cell type and context-dependent manner (Eisenmann, 2001).  Its
role is strictly related to a dose effect, since basal levels potently drive S phase
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progression in most somatic cells, whereas overexpression triggers the induction of
p53, resulting in apoptosis in the same cells (Packham & Cleveland, 1995).  In the
EREB2.5 LCL, which expresses a conditional EBNA2, the induction of c-MYC
enhances cell proliferation (Polack et al., 1996). By stably expressing c-MYC in the
absence of estrogen, rendering EBNA2 inactive, proliferation was uncoupled from the
function of EBNA2 and completely dependent on c-MYC. However, the effects on
the expression of phenotypic markers were different, since c-MYC downregulates
activation markers typical of LCLs as well as adhesion molecules, whereas it induces
CD10 and CD38 that are not present on LCLs (Pajic et al., 2001). These changes
happen only in the absence of EBNA2 and LMP1. EBNA2 and c-MYC interaction is
important in the context of Burkitt lymphoma. The Burkitt lymphoma is frequently
characterized by the translocation of the c-MYC gene under the control of the
promoter of the µ immunoglobulin heavy chain (Brady et al., 2007). The promoter of
the µ immunoglobulin heavy chain happens to be a direct negative target of EBNA2
in B cells (Jochner et al., 1996). The consequence is suppression of the translocated
allele of c-MYC in Burkitt lymphoma cells, causing reduced proliferation.
c-FGR is a direct target of EBNA2 in B cells and codes for a tyrosine kinase
of the src family (Knutson., 1990). It is a proto-oncogene involved in regulation of
cell growth, with a viral form expressed by the Feline Gardner-Rasheed sarcoma
oncogenic retrovirus (Rasheed et al., 1982).
Johansen et al, identified BATF as a direct target of EBNA2 (Johansen et al.,
2003). In contrast to other target genes activated by EBNA2, the BATF gene encodes
a member of the AP-1 family of transcription factors that functions as an antagonist of
cell growth. The same study indicates that BATF could favor EBV latency by
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negatively regulating BZLF1 so as to reduce the frequency of lytic replication in
latently infected cells.
CCR7 is direct target of EBNA2 (Maier et al., 2005) expressed in mature B
cells and involved in controlling migration of B cells to secondary lymphoid organs,
and also in chemoattraction in response to its ligand CK-beta-11 (Kim et al., 1998).
One of the most recent and interesting targets of EBNA2 is the RUNX3 gene
(Spender et al., 2002). RUNX3 is a member of the “Runt domain” family of
transcription factors, which are important regulators of hematopoiesis and
osteogenesis (Spender et al., 2002). Aberrant expression of RUNX proteins can
contribute to leukemia (Whiteman & Farrell, 2004).
EBNA2 is involved as well in down regulation of TCL1 and BCL6
(Boccellato et al., 2007), and the activation-induced cytidine deaminase, AID, all
germinal centre associated proteins (Boccellato et al., 2007). This suggests that
EBNA2 could interfere with the germinal centre.
Figure 1.5 EBNA2 induces viral and cell genes
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1.2.5.3 EBNA2 structure
EBNA2 is associated with nucleoplasmic, chromatin and nuclear matrix
fractions and localizes to large nuclear granules. EBNA2 self associates in dimers or
tetramers and some of the EBNA2 complexes in lymphoblasts can be greater then
1MDa (Tsui & Schubach, 1994).
EBNA2 protein structure comprises several modules, which have been
conserved through the evolution of the human and non human lymphocryptoviruses
(Ling et al., 1993). The protein can be considered to have 9 conserved regions, CR 1-
9, plus other two relevant regions (Figure 1.6). Knowledge of the function of EBNA2
and its role in B cell transformation has been acquired through a long series of studies
involving deletion and site directed mutants of conserved regions (Gordadze et al.,
2004, Grabusic et al., 2006, Ling et al., 1993, Yalamanchili et al., 1996).  The CRs are
not evenly distributed but rather grouped in two main clusters, one at the amino
terminus, comprising CR1-4 and one at the carboxy terminus, comprising CR5-9
(Kieff & Rickinson, 2001). The portion between CR4 and CR5 is commonly referred
to as the divergent region; it varies in length and sequence amongst different EBNA2
isoforms and homologues (Ling et al., 1993). Two variable regions of interest are a
long stretch of prolines between CR2 and CR3 and an R-G repeat between CR6 and
CR7.
Various different systems have been used to study EBNA2 function
comprising in vitro activation of promoters (Peng et al, 2004), recombinant viruses
(Yalamanchili et al., 1996) and transcomplementation assays (Gordadze et al., 2002).
These systems do not always give similar results; for example, the polyproline region
was found to be completely dispensable for B cell transformation in studies by
Gordadze et al, whereas seven prolines from position 98 to 105 seem to be required in
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experiments by Yalamanchili et al. To summarize the results so far, the portion
containing CR1-CR4 is involved in formation of homotypic and self interactions and
transformation ability whereas the portion CR5-9 is more involved in binding to co-
factors, complex formation, transactivation ability and the nuclear localization signals
(Kieff & Rickinson, 2001). CR1, CR2 and CR3 have been all shown to be involved in
self-association by co-immunoprecipitation assays (Harada et al., 2001). Several
mutants of the N-terminus surrounding the polyproline region lead to impaired
transformation ability in different systems. Gordadze et al, have shown that aa 3-30
are essential for LMP1 induction, explaining why mutants with this deletion have
greatly reduced ability to immortalize B cells (Gordadze et al., 2004). Deletion of
CR4 greatly reduced B cell immortalization (Grabusic et al., 2006) and this effect was
independent of the CBF1/RBP-Jk co-factor. CR4 could be involved according to the
same authors in the only non transcriptional function identified so far for EBNA2, the
binding to the apoptotic protein Nur77.
The organization of the C-terminus is strikingly similar to the structure of
NOTCH-IC, which is also known to interact with RBP-Jk. In complementation assays
NOTCH-IC and EBNA2 have been shown to substitute for each other (Strobl et al.,
2000, Gordadze et al., 2001). Binding to CBF1/RBP-Jk is mediated by CR6 (Henkel
et al., 1994a, Hsieh & Hayward, 1995). CR5 is also involved in maintaining the
interaction between EBNA2, CBF1 and its co-factor SKIP. CR6, CR7, CR8 and the
R-G domain, comprise the transactivator domains and are involved in the binding to
several important co-transcription factors of EBNA2 like PU.1, p100, p300, PCAF,
SMN and hSWI/SNF (Barth et al., 2003, Johannsen et al., 1995, Wang et al., 2000,
Wu et al., 1996b). EBNA2 transcription activity is mediated by binding to p100
(Tong et al., 1995, Yang et al., 2002) and RNA pol II and to TFIIB and TAF40, both
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members of the transcription activation complex (Tong et al., 1995).  The nuclear
localization signal (NLS) function is dependent on two acidic domains, CR7 and CR9
(Ling et al., 1993). The R-G domain is involved in chromatin interaction, as it
specifically binds H1 histones, raising the possibility of a role in chromatin
remodeling, particularly when considered together with the ability to bind the HATs
(Yalamanchili et al., 1996, Kieff & Rickinson, 2001). Phosphorylation of the R-G
stretch has been shown to be involved in an interaction with the survival motor
neuron protein, SMN, that is part of the RNA splicing complex (Barth et al., 2003).
Finally, as already mentioned, EBNA2 and EBNA-LP co-operate in the induction of
several genes, and studies by Peng et al, have identified four domains on the EBNA2
protein which enhance this interaction, spread along the whole sequence (Peng et al.,
2004). Hyperphosphorylation on serine and threonine residues during mitosis inhibits
EBNA2 function and suppresses transactivation activity (Yue et al., 2005, Yue et al.,
2006).
Untitled2    1 MPTYYLALHGGQSYNLIVDTDMSGNPSLSVIPTNPYQEQLSNNPLIQLQI  49
Untitled1    1 MPTFYLALHGGQTYHLIVDTDSLGNPSLSVIPSNPYQEQLSDTPLIPLTI  50
                **.********.*.******  *********.******** .*** * *
Untitled2   50 VVGENTGAP--------------------------APPQPPPPPPPPPPP  73
Untitled1   51 FVGENTGVPPPLPPPPPPPPPPPPPPPPPPPPPPPPPPSPPPPPPPPPPP 100
                ****** *                           ** ***********
Untitled2   74 ERRDAWTQEPLPLDMNPLGSDASQGPLASSIRMLCMAQYLLRNARGQQGL 123
Untitled1  101 QRRDAWTQEPSPLDRDPLGYDVGHGPLASAMRMLWMANYIVRQSRGDRGL 150
               .********* ***  *** *  .*****..*** **.*..*..** .**
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               . * ****  *  * .  *   *  ** **     *    * *..   . 
Untitled2  174 LQPTP--------PPRPTLPQ--PRIPLIIPPRHTNQPATTPPTAPQRLT 213
Untitled1  201 TPPTPLPPATLTVPPRPTRPTTLPPTPLLTVLQRPTELQPTPSPPRMHLP 250
                 ***        ***** *   *  **.   .. ..   **     .* 
Untitled2  214 LGHQLSLPPHPPPHQSTPHCSSDSTGLPPPPTSYSIPSMTLSPEPLPPPA 263
Untitled1  251 VLHVPDQSMHPLTHQSTPNDP-DSPEPRSPTVFYNIPPMPLPPSQLPPPA 299
               . *      **  *****.   **     *   * ** * * *  *****
Untitled2  264 APAHPLPGVIYDQQALPPTPGPPWWPPVRDPTPTTQTPPTNTKQGPDQGQ 313
Untitled1  300 APAQPPPGVINDQQLHHLPSGPPWWPPICDPPQPSKTQGQSRGQS--RGR 347
               ***.* **** ***      *******. **   ..*      *   .*.
Untitled2  314 GRGRWRGRGRSKGRGRMHKLPEPRRPGPDTSSPSMPQLSPVVSLHQGQGP 363
Untitled1  348 GRGRGRGRGKGKSRDKQRKPGGPWRPEPNTSSPSMPELSPVLGLHQGQGA 397
               **** ****. * * . .*   * ** * *******.****. ****** 
Untitled2  364 ENSPTPGPSTAGPVCRVTPSATPDISPIHEPESSDSEEPPFLFPSDWYPP 413
Untitled1  398 GDSPTPGPSNAAPVCRNSHTATPNVSPIHEPESHNSPEAPILFPDDWYPP 447
                 *******.* **** . .*** .********  * * * *** *****
Untitled2  414 TLEPAELDESWEGIFETTESHSSDEENVGGPSKRPRTSTQ 453
Untitled1  448 SIDPADLDESWDYIFETTESPSSDEDYVEGPSKRPRPSIQ 487
               ...**.*****. ******* ****. * ******* * *
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Figure 1.6. Conserved regions in EBNA2 type 1 and type 2
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1.2.5.4 Interaction with the NOTCH pathway
EBNA2 induction of viral and cell genes does not happen through direct
binding to the target promoters but is mediated by several co-transcription factors, of
which the most characterized is RBP-Jk or CBF1 (Henkel et al., 1994). RBP-Jk is a
transcription factor, expressed ubiquitously and highly conserved during evolution,
which plays an essential role in mediating NOTCH regulation of transcription (Hsieh
et al., 1995). The importance of its binding to transcription factors is illustrated by the
fact that, of two regions of the EBNA2 protein that were absolutely necessary for B
cell immortalization, one is required for binding to RBP-Jk and the other is the
transactivation domain (Cohen & Kieff, 1991). Virus strains carrying mutations of
these regions of EBNA2 were non-immortalizing for B cells (Yalamanchili et al.,
1994). RBP-Jk links the molecular biology of EBNA2 to NOTCH and in some
respects EBNA2 is a viral functional homologue of activated NOTCH.
RBP-Jk is normally a repressor; after binding to target promoters it tethers
histone deacetylation factors (HDACs) that block the activity of controlled regions
(Hsieh et al., 1999). RBP-Jk can also bind factors of the transcription machinery,
TFIIA and TAFII110, both required for initiation of transcription (Olave et al., 1998).
The mechanism of EBNA2 and NOTCH-IC function is based on the ability of RBP-
Jk binding to access the promoters of target genes and at the same time to recruit
histone acetyltransferases (HATs), like PCAF and p100, transforming the repression
complex into an activation one (Wang et al., 2000). EBNA2 interacts also with the
chromatin remodeling complex hSWI-SNF, which renders the chromatin structure
more accessible for transcription (Wu et al., 1996a). RBP-Jk represses target genes by
chromatin remodeling (Figure 1.8). There are two repressor complexes studied so far.
One includes SMRT, NcoR and HDAC1 (Kao et al., 1998) and a second comprises
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SAP30, CIR and HDAC2 (Zhou & Hayward, 2001). These complexes bind the
transcription activators TFIID and TFIIA to prevent activation of transcription (Olave
et al., 1998). CIR functions as a link to HDACs. A central role in the organization of
the complexes is exerted by the Ski interaction protein (SKIP), which was identified
as a protein involved in the de-repression of the TGFβ/SMAD2/MAD signaling
complexes (Baudino et al., 1998). SMRT competes with NOTCH for RBP-Jk binding
whereas SKIP promotes NOTCH to RBP interaction, and the binding of SMRT or
NOTCH to SKIP is mutually exclusive (Zhou et al., 2000). The structure of EBNA2
and NOTCH-IC is organized so that the process of interference with the RBP-Jk
complex is biphasic: the CR6 domain in EBNA2 and the RAM domain in NOTCH-IC
bind to the repression domain of RBP-Jk, tethering the proteins close to promoter
sequences whereas CR5 of EBNA2 and the Ankyrin domain of NOTCH-IC, bind to
SKIP, displacing SMRT and recruiting HATs that open the chromatin structure (Zhou
et al., 2000) (Figure 1.7). A second phase, after removing the block, is to enhance
transcription; this is mediated by a transactivation domain TAD, which is positioned
at the C-terminus in the EBNA2 and at the N-terminus of the activated NOTCH
fragment (Hayward, 2004). The mechanisms are remarkably similar but still the two
proteins recruit unique co-transcription factors, p100 and SWI for EBNA2 and GCN4
and MAML1 for NOTCH-IC, suggesting that EBNA2 may usurp a portion of the
NOTCH pathway but still retain characteristics that work in favor of virus infection.
This was clearly shown by functional comparison of EBNA2 and NOTCH.
NOTCH1-IC can partially replace EBNA2 in the maintenance of proliferation state in
LCLs (Gordadze et al., 2001). EREB2.5 cells were starved of estrogen and were
transduced with a lentivirus vector expressing NOTCH1-IC. Stable cells
(NOTCH+/EBNA2-) grew more slowly than estrogen treated EREB2.5 cells. c-MYC,
53
CD21 and CD23 were all induced but LMP1, which depends on EBNA2, was not
induced by NOTCH. Similar results were obtained by Strobl et al, by expressing the
conditional murine NOTCH1-IC fused to the estrogen receptor, in P3HR1 BL cells,
which are deleted for the EBNA2 locus (Strobl et al., 2000). Again c-MYC and CD21
but not CD23 were induced whereas the Ig-µ promoter was inhibited. LMP2A was
also induced but not LMP1. The induction of LMP2A is very interesting because this
latent gene is expressed in germinal centers by memory B cell when re-circulating,
providing survival signals. The effects of NOTCH signaling depend on the cell stage
and cellular environment, so it is crucial to consider the effects of EBV infection in
relation to the differentiation stage of the infected B cells.  In fact, Hisieh et al, have
shown that NOTCH2-IC and NOTCH1-IC have comparable effects on cell
differentiation and both bind to RBP-Jk, extending interest in the EBNA2/NOTCH
interaction to other members of the NOTCH family that are expressed in different
stages of development (Hsieh et al., 1997). Last, Hofelmayr et al, have shown that
NOTCH1-IC can efficiently maintain cell proliferation of an LCL, if LMP1 is
ectopically expressed (Hofelmayr et al., 2001). This work again indicates, that
although similar to NOTCH-IC, EBNA2 has peculiar and independent functions,
consistent with the transcription activity depending also on additional adaptor proteins
other than RBP-Jk.
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Figure 1.7.  EBNA2 and NOTCH-IC proteins share similar structure. Interaction with the
RBP-Jk repressor DNA binding factor. Both proteins remove a repression induced by
RBP-Jk.
54
1.2.6 EBV types
EBV strains carry polymorphisms of specific loci encoding latency proteins, namely,
EBNA1 (Allday & McGillivray, 1985, Habeshaw et al., 1999), EBNA2 and EBNA3s
(Midgley et al., 2003, Gorzer et al., 2006), and LMP1 (Lin et al., 1995, Tierney et al.,
2006). The most evident polymorphism is found in the EBNA2 locus, according to
which EBV has been classified into two different types: EBV type 1 and EBV type 2,
also known as type A and B (Adldinger et al., 1985, Mcgeoch, 2005). From the
epidemiological point of view, EBV type 1 and type 2 are very different. EBV type 1
is present world wide whereas EBV type 2 is found at the same rate as EBV type 1
only in certain regions of Africa (Zimber et al., 1986, Young et al., 1987), New
Guinea (Young et al., 1987). Both are present in healthy individuals and in those
affected by endemic BL. HIV positive patients have a high risk of developing EBV
positive lymphomas arising in end-stage AIDS. In these people a type 2 EBV strain is
found in 25 to 50% of EBV genome-positive cases, representing a much higher
frequency than in the healthy population (Boyle et al., 1991, De Re et al., 1993, Yao
et al., 1998). Perhaps as a consequence, healthy homosexual men in western society
were also found to present an unusually high EBV type 2 infection rate (Van Baarle et
al., 2000). Several studies in the past made use of the ability of EBV to transform
resting human B cells from blood into LCLs. As a system to detect the EBV type, this
had the consequence that the less efficient EBV type 2 may have been
underestimated. Most recently, studies using highly sensitive heteroduplex PCR
amplification of polymorphic loci have described a more complex picture showing
that the blood of IM patients simultaneously contains different EBV strains, most
probably as a result of multiple infection from one source, or by serial acquisition
55
(Sitki-Greenet al., 2004, Tierney et al., 2006). Although EBV type 2 infection in
western countries may have been underestimated on the basis of the less efficient
transformation ability, EBV type 1 remains by far the most common in this area. The
genomes have several polymorphic loci. A recent analysis and comparison of EBV
type 1 and type 2 sequences confirmed that the two types were largely colinear and,
apart from the known divergent alleles, extremely close (Dolan et al., 2006). It is
worth speculating on the reason why the geographic distribution of the two EBV
types is so remarkably different. The restriction of type 2 EBV to specific sub-regions
of the world is not easy to explain. EBV type 2 infections, as said previously, are
more common in sub-equatorial Africa, Papua New Guinea, Brasil and the Far East. It
has been proposed that because of its lower efficiency at transforming B cells, type 2
EBV can more easily thrive and evolve in those regions where malaria or HIV are
endemic because they subject the immune system to a constant pressure (Goldschmidt
et al., 1992). In support of this hypothesis, it has been shown that constant exposure to
Plasmodium falciparum decreases the host immune-surveillance as a consequence of
a weakening of the T cell response (Moormann et al., 2007). On the other hand, it has
to be stressed that EBV type 2 is found at the same level of type 1 in some other
regions of the world where malaria or HIV are not endemic.
Moreover, this theory stems from literature based on the initial observation
made by Dennis Burkitt, that BL cancers were geographically following the pattern of
malaria infection. Some more recent epidemiological observations (Orem et al., 2007)
have challenged this axiom, since BL incidence has been shown to be extremely
heterogeneous in African areas where malaria is at the same high level. Another
possible explanation for this epidemiological asymmetry can be found in the
evolutionary analysis of EBV. It has been proposed in fact that early in human
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evolutionary history, two host populations infected with EBV became isolated. EBV
then co-evolved separately and diverged into two lineages, with selective pressure
working on specific genes that were mutating more rapidly, EBNAs and LMP1
(McGeogh and Gatherer, 2006). Subsequently, the viral strains have started mixing up
again after the two populations came again into contact.
EBV is strongly associated to several serious pathologies but few of them are
characterized by an EBV latency III pattern of expression and consequently EBNA2
expression. Typical diseases of this kind are lymphomas in post-transplant patients
(PTLD), primary immunodeficiency (XLP) and AIDS patients, although a restricted
pattern of expression has been described as well (Oudejans et al., 1995).  PTLDs can
arise at different time after immunosuppression, from several months to years. It can
manifest as a B cell hyperplasia or a B cell lymphoma; in both cases up to 90% of the
cells are EBV positive (Snow & Martinez, 2007). At least in the case of early PTLD,
the lesion results from an expansion of cells directly transformed by EBV (Timms et
al., 2003). They can be mono or poly-clonal and they show markers of naïve cells and
post germinal memory B cells, supporting the hypothesis of a direct infection of
memory B cells by EBV. It is easy to imagine how EBV can drive the progression of
the lesions in the absence of a defence from the host. EBNA2 activates signalling
cascades that cause proliferation, as well as cell activation, in cooperation with the pro
survival signalling provided by the LMP family.
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1.3 Aims of this thesis
This thesis focuses on the functional characterization EBNA2 type 1 and type
2 and the identification of differences and similarities in the effects on cell and
viral gene regulation.
EBNA2 type 1 regulation of expression in B cells
• What are the genes induced by EBNA2 Type 1 in LCLs?
• What are the genes involved in B cell proliferation and NOTCH
pathway?
EBNA2 type 1 and type 2 functional characterization
• What are the cellular targets of EBNA2 type 2?
• Do EBNA2 type 1 and type 2 gene regulation differ for a number of
key genes linked to proliferation?
Induction of LMP1
• Do EBNA2 type 1 and type 2 induce LMP1 equally?
58
2. MATERIALS AND METHODS
2.1 Solution and chemicals
2.1.1 Cell culture
2.1.1a Suspension cells: The medium used for suspension cells was Roswell Park
Memorial Institute 1640 (RPMI 1640) from Gibco-BRL.  Phenol Red free RPMI was
used to grow EREB2.5 cells.
2.1.1b Adherent cells: Adherent cells were maintained in Dulbecco's Modified Eagle's
Medium (DMEM) from Gibco-BRL.
2.1.1c Freezing Medium: To freeze cells, a DMSO/FCS solution (1/9, v/v) was used.
2.1.1d Foetal calf serum: All media were supplemented with heat inactivated foetal
calf serum (FCS) from Autogen Bioclear. FCS was inactivated at 56°C for 20 minutes
and used at 10% (v/v). In LCL generation experiments, cells were maintained with
20% (v/v) FCS.
2.1.1e Penicillin/Streptomycin: All media were supplemented with 2 mM L-
Glutammine and 50 Units/ml penicillin and streptomycin and stored at 4°C.
2.1.1f G418: Gentamycin from Gibco was dissolved at 100mg per ml, filter sterilized
and stored at -20°C. The supplemented medium was stored at 4°C.
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2.1.1g Puromycin: Stock powder was dissolved at 2.5 mg/ml (2500X) in sterile PBS
and filtered using Nalgene syringe filters.
2.1.1h β-estradiol: β-estradiol from Sigma was dissolved in 100% ethanol at a final
concentration of 1mM (5.45mg/20ml) and stored at 4°C as a 1000X stock.
2.1.1i Protein synthesis inhibitors: Cycloheximide and anisomycin were prepared at
100X stock by respectively dissolving at 5mg/ml and 2.6mg/ml in sterile PBS and
then filter sterilising. Stocks were maintained at 4°C.
2.1.2 Calcium phosphate transfection
2.1.2a 2XHBS pH 7.05: 500 ml of stock solution was prepared by adding to 450 ml of
sterile water: 280mM NaCl, 10mM KCl, 1.5mM Na2HPO4, 12mM dextrose (D-
glucose), 50mM HEPES. The pH was then adjusted to 7.05 using NaOH and the
volume topped up to 500ml. The solution was filter sterilised and stored in 20 ml
aliquots at -20°C.
2.1.2b 2M Calcium Chloride: 5.88g of CaCl2 (FW=147) was dissolved in 20 ml of
water, filter sterilised and stored at -20°C in 5ml aliquots.
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2.1.3 Microarrays and RNA work
2.1.3a Denhardt's 50x: Ficoll 1% (w/v), Polyvinylpyrrolidone 1% (w/v), Bovine
serum albumine 1% (w/v) was dissolved overnight in MiliQ water and Filter
sterilised.
2.1.3b 20x SSC: 175.3g NaCl and 88.2g Sodium Citrate were dissolved in 800ml
water.
The pH was adjusted to 7.0 with 1M sodium hydroxide and the volume made
up to 1 litre. The solution was then filter sterilised and stored at RT
2.1.3c Hybridisation solution: 6x Denhardt's solution, 5x SSC, 60mM TrisHCl pH7.6,
0.12% Sarkosyl, 48% (v/v) Formamide was dissolved in MiliQ water.
2.1.3d Washing solutions:
Washing Solution I: 2x SSC in water
Washing solution II: 0.1x  SSC, 0.1% SDS in water
Washing solution III: 0.1x SSC in water
2.1.3e Chamber Buffer: 40% (v/v) Formamide and 2x SSC was dissolved in water
and stored at RT
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2.1.3f Diethylpyrocarbonate (DEPC) treated water: 0.1% (v/v) DEPC was added to
MiliQ water and incubated at room temperature for 30 minutes. The solution was then
autoclaved to inactivate the DEPC and stored at room temperarue.
2.1.4g Acrylamide Gel Mix: 80ml monomer solution of acrylamide/bis (19:1), 40%
(w/v),  and urea, 20ml of buffer reagent  (containing 5X TBE), 100µl 20% (w/v)
Ammonium Persulphate (AMPS) and 10µl Tetramethyl-ethylene-diamine were mixed
in the listed order, poured into the glass plates and cover with water saturated butanol.
2.1.4 Western Blot and Protein expression
2.1.4a SDS Running Buffer: 241.6g Tris-base, 1152g glycine, 80g SDS were
dissolved in water and made up to 8 litres.
2.1.4b Western Blot Transfer Buffer: 150ml Protein Running Buffer, 700ml 100%
Ethanol were dissolved in 2150ml water
2.1.4c Western Blot Washing Buffer: PBS and 0.05% (v/v) Tween 20 (Sigma) were
dissolved in water and stored at room temperature
2.1.4d Western Blot Blocking Solution: 10% (w/v) fat free dried milk powder
(Marvel) was reconstituted in washing buffer and stored at 4°C
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2.1.4e Western Blot Stripping Buffer: 2% (w/v) SDS, 62.5mM Tris-HCl pH 6.8 and
100mM 2-Mercaptoethanol were dissolved in water and used immediately.
2.1.4f Water saturated butanol: 250ml Butanol and 250ml dH20 were mixed and left
over night to separate; stored at RT.
2.1.4g RIPA Buffer: to prepare 5 ml of buffer the following ingredients were added to
4150ul of sterile PBS, 200µl of 25X Complete stock protein inhibitors, 500µl NP40
10% (v/v) , 50 µl SDS 10% (w/v), 25 mg NaDeoxycholate, 50 µl NaOrthovanidate
(100mM) and 50 µl PMSF (10mg/ml in isopropanol). The solution was filter
sterilised and stored at -20°C in 500µl aliquots.
2.1.4h Coomassie Blue staining/destaining: 40% Methanol, 10% Acetic acid, 1g/L R-
250. Destain was 40% Methanol, 5% Acetic acid (v/v).
2.1.4i BL21(DE) non denaturing/denaturing lysis buffer: 1M NaCl, 50mM Tris pH
7.4, 5% (w/v) glycerol, 1% (v/v) Triton X-100, 50 µl PMSF (10mg/ml in
isopropanol), 20mM imidazole; denaturing buffer was the same with 8M urea.
2.1.4l Ni-NTAWashing Buffer: 1M NaCl, 50mM Tris pH 7.4, 5% (v/v) glycerol, 1%
(v/v) Triton X-100, 50 µl PMSF (10mg/ml in isopropanol), 20mM imidazole (8M
UREA in denaturing conditions).
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2.1.4m Ni-NTA Elution Buffer: 1M NaCl, 50mM Tris pH 7.4, 5% glycerol, 1% (v/v)
Triton X-100, 50 µl PMSF (10mg/ml in isopropanol), 200mM imidazole, (8M Urea in
denaturing conditions).
2.1.5 Solutions for nucleic acids extraction and analysis
2.1.5a Agarose gel: The agarose was mixed in 1X TBE at the required percentage and
melted in a microwave oven. When the solution had cooled down, 0.5µg/ml of
ethidium bromide was added and the gel was poured into the running tray.
2.1.5b 1M Tris-HCl pH 6.8, 7.6, 8.8: 121.1g of TRIZMA-base was added to 900 ml
of water, the pH adjusted with HCl and the volume made up to 1000 ml. The solution
was then autoclaved and stored at RT.
2.1.5c 0.5M EDTA pH 8.0: 186.1g of EDTA salt was dissolved in 900ml of water and
stirred until completely dissolved. The pH was adjusted with NaOH, and the solution
was made up to 1L, autoclaved and stored RT.
2.1.5d TE: 10mM Tris-HCl pH 7.6 and 1mM EDTA pH 8.0 in water
2.1.5e 10X TBE: 108g TRIZMA-Base, 55g Boric acid and 40 ml of EDTA pH 8.0
were added to 900ml of water. When dissolved the solution was made up to 1L and
autoclaved
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2.1.5f 5M NaCl: 292.2g of NaCl was dissolved in water (to final volume 1L) and
autoclaved.
2.1.5g 3M NaAcetate pH 5.2: 408.1g of NaAcetate(3H2O) were dissolved in 900ml of
water. The pH was adjusted with Acetic acid to 5.2. The solution was topped up to 1L
and autoclaved.
2.1.5h 20X SSC: For  2L of final solution, the following ingredients were dissolved in
water: 176.4g tribasic NaCitrate (2H2O) and 350.6g NaCl. The solution was
autoclaved.
2.1.5i STET: 8% (w/v) sucrose, 0.1% (v/v) TritonX-100, 50mM EDTA, 50mM Tris-
HCl pH8.0.
2.1.5l 10% SDS: 100g of SDS salt was added to 1L of water and the solution was
stirred at 50°C until completely dissolved. The solution was then filter sterilised and
stored at RT
2.1.5m Suspension Buffer: 50mM glucose, 25mM Tris-HCl, 10mM EDTA in water.
Autoclaved
2.1.5n Lysis Buffer: 0.2M NaOH, 1% SDS in water
2.1.5o Neutralization Buffer: 3M Potassium acetate in water. Autoclave.
65
2.2 Nucleic Acids Protocols and construction of vectors
2.2.1 Agarose gel electrophoresis: DNA samples were diluted in agarose gel loading
buffer and loaded on an agarose gel containing 0.5µg/ml ethidium bromide. The
percentage of agarose was adjusted according to the size of the DNA fragments and
the purpose of the technique; 0.8/2% (w/v) agarose gels were used during the work.
To determine the size of the fragments, 1µg of a 1kb or 100bp ladder was loaded on
the gel along with the samples. The electrophoresis was performed in 1X TBE and the
voltage and time were adjusted according to the purpose of the experiment, typically
80V. The nucleic acid fragments were visualized using a Syngene transilluminator
ultra-violet (UV) light source and Genesnap software.
2.2.2 Phenol-Chloroform purification and ethanol precipitation of nucleic acids:
To purify nucleic acids from cell lysates and enzyme reactions, the DNA/RNA
solution was diluted to at least 100µ l and an equal volume of
phenol:chloroform:isoamylalcohol (25:24:1) (Sigma) was added and mixed
thoroughly, inverting vigorously or vortexing the sample when possible. After
centrifugation (13,000 rpm, 5 minutes), the aqueous phase was transferred to a fresh
tube. The extraction was repeated for Calf intestinal phosphatase reactions. The
nucleic acid was then precipitated by adding 1:10 (v/v) of 3M NaAcetate pH 5.2 and
2.5 volumes of 100% ethanol and collected by microfuging at 13,000 RPM for 10
minutes. The pellet was washed with 70% ethanol and dried for two minutes at RT
then resuspended in TE or MilliQ water (DEPC treated for RNA).
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2.2.3 Quantification of nucleic acids: Purity and concentration of nucleic acids was
determined by measuring the absorbance at wavelengths 260nm and 280nm using a
spectophotometer (Unicam Heλiosβ). The concentration was calculated from the
260nm reading assuming an absorbance of 1.0 at this wavelength corresponds to
50µg/ml for double stranded DNA and 40µg/ml for RNA. The purity was calculated
from the A260/A280 ratio. Pure DNA has a ratio of 1.8 in sterile water and pure RNA
has a ratio between 1.9 and 2.1 in 10mM Tris-HCl pH 7.5.
2.2.4 Synthesis of cDNA from total RNA: cDNA was prepared using the Protoscript
first strand cDNA synthesis kit (New England Biolabs). Before reverse transcription,
RNA samples were treated with RQ1 RNase free DNase (Promega) to degrade DNA
that could interfere with further steps. The reaction was the following:
1µg Total RNA 1-8 µl
10X RQ1 Buffer 1µl
RQ1 DNase 1µl
Nuclease free water to 10µl
Incubated at 37ºC for 30 minutes
The RNA was then purified using phenol/chloroform extraction and ethanol
precipitation and resuspended in DEPC water. The sample was amplified with
random primer or oligo dT primers using the following reactions:
Total RNA 1µg
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Primers (Random, 15µM/OligodT, 50µM) 2µl
dNTP Mix (ATP, TTP, CTP,GTP 2.5mM
each)
4µl
Nuclease free water to total volume of
16µl
The solution was heated for 5 minutes at 70°C and put promptly on ice.
Mix from step 1 16µl
10X RT buffer 2µl
RNase inhibitor 1µl
M-MulV Reverse transcriptase 1µl (25U/µl)
Final volume 20µl
The reaction was incubated at 42°C for 1 hour and then the enzyme was inactivated at
95°C for 5 minutes.  The solution was then treated with RNaseH (2U/µl) by adding
directly 1µl and incubating it at 37°C for 20 minutes. This enzyme was then
inactivated at 95°C for 5 minutes.
2.2.5 Amplification of DNA by polymerase chain reaction (PCR): DNA was
synthesised by PCR using Taq or Pfu DNA polymerase (Promega) using the
following reaction or modification of it:
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Template 50ng plasmid, 500ng genomic
10X buffer (20mM Tris pH8, 100mM
KCl 0.1mM EDTA, 1mM DTT, 50%
glycerol, 0.5% NP40 and 0.5% Tween)
5µl
25mM MgCl2 (not in Pfu) 3µl (1.5mM)
Forward primer 1µl (10µM)
Reverse primer 1µl (10µM)
25mM dNTP 0.3µl (0.2mM)
Taq/Pfu 0.2µl (1U)
sterile water to 50µl
Cycling parameters were adjusted accordingly to the purpose and condition of the
experiment but would typically be:
95°C                         3 min
95°C                         1min
Annealing                1min
Elongation               1 min
Final elongation      7 min
 The annealing temperature used was the melting temperature minus 4 or 5°C. The
melting temperature was calculated using the following formula: Tm=81.5 +
(0.41x%GC) - 675/bp primer length.
X 30 cycles
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2.2.6 Restriction nuclease digestion of DNA: Digestions were performed using NEB
enzymes, buffers and BSA when required. The volume was adjusted accordingly to
the amount of DNA to digest (20µl up to 2 or 3µg of DNA, then 5µl more for every
1µg of additional template). Fragments were separated by gel electrophoresis and gel
extracted.
2.2.7 Extraction of DNA from agarose gel: The slice of gel containing the fragment
was extracted using a scalpel under UV light and the DNA was extracted using the
Qiagen QIAquick gel extraction kit. The agarose was dissolved by adding three
volumes of buffer QG and incubating the solution at 50°C for 10 minutes. The
solution was then loaded on a QIAquick silica-gel column microfuged at 13,000 RPM
for 1 minute to bind the DNA. The column was washed with 750µl of buffer PE and
the DNA was eluted with 30µl of 10mM Tris-Cl pH 8.5 under the same centrifugation
conditions.
2.2.8 Removal of 5' phosphate groups from DNA fragments: The 5' phosphate
group was removed from the opened vector before ligation in order to diminish
background from self-ligation and re-circularization. 1.5 µl of Calf intestinal
phosphatase (CIP) (10U/µl) was added to the restriction digestion in a volume of
150µl and incubated at 37°C for 1 hour. The DNA was then purified with two
Phenol/Chloroform extractions and ethanol precipitation.
2.2.9 Ligation of vector and insert: The insert amount was calculated by using the
following formula:
ng of insert: (ng of vector x kb size of insert/kb size of vector) x 3
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1:3 vector insert was used for sticky end ligations and 1:5 for blunt end ligations.
A typical ligation was performed using 1µl of T4 DNA ligase (400U/µl) in a final
volume of 15µl and incubated at 16°C overnight. The control reaction was set up
using the vector alone.
2.2.10 Preparation of chemically competent HB101 bacteria: A single colony from
an LB plate was inoculated in 2ml LB medium and the culture was incubated
overnight at 37°C with shaking.  Then the culture was diluted 1:100 in LB medium
and grown at 37°C with shaking until the absorbance at 600nm was between 0.3 and
0.5. The culture was centrifuged (800xg for 5 minutes) and the pellet resuspended in
half the original volume of ice cold 50mM CaCl2 followed by incubation on ice for 10
minutes. The mixture was centrifuged (800xg for 5 minutes) and the pellet
resuspended in one tenth the original volume of ice cold 50mM CaCl2. These cells
were snap frozen on dry ice and stored at -80°C.
2.2.11 Plasmid transformation of chemically competent bacteria: 10µl of ligation
was mixed with 50 µl of chemically competent HB101 or XL1-Blue E.coli and
incubated on ice for 30 minutes. The bacteria were then heat shocked at 42°C for 2
minutes and left at RT for another 5 minutes. 200µl of warm LB medium was added
to the transformation and incubated at 37°C for 1 hour while shaking. Bacteria were
then plated on to selective LB agar (normally 50µg/ml ampicillin) and incubated
overnight at 37°C.
2.2.12 Isolation of Plasmid DNA from bacterial cultures - Mini preparations:
Individual colonies were picked from a selective LB agar plate, inoculated in 3ml of
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selective LB  (normally 50µg/ml ampicillin) and incubated overnight at 37°C while
shaking. The next day, 1.5ml of the culture was microfuged and the bacteria
resuspended in 100µl of resuspension buffer, lysed in 200µl of lysis buffer (5 minutes
on ice) and purified from cell debris with 150µl of neutralisation buffer (10 minutes
on ice and centrifuged at 14,000 RPM for 10 minutes). The supernatant was recovered
and purified with a Phenol/Chloroform/iso-amylalcohol (25:24:1, v/v/v) extraction.
The aqueous phase was then ethanol precipitated and resuspended in 40µl of TE.
2.2.13 Isolation of plasmid DNA from bacterial cultures - Maxi preparations:
Maxi preparations were performed using the Qiagen Endofree plasmid kit starting
from a 250ml overnight bacterial culture. The technique is based on the properties of
an Anion-exchange resin column which operates under gravity flow. RNA, proteins
and low molecular weight impurities are removed by medium salt washes whereas
plasmid DNA is removed by a high salt wash. The salts are removed and the DNA
concentrated by isopropanol precipitation. The protocol was performed as indicated in
the manual.
2.2.14 Genomic DNA extraction: 5X106 AG876 cells were pelleted by centrifugation
and washed twice in 50 ml TBS (140mM NaCl, 10mM Tris-HCl pH 7.5). Cells were
resuspended in 20ml of NE10T buffer (10mM NaCl, 10mM EDTA pH 7.5 and 10mM
Tris-HCl pH 7.5). Then SDS was added to 1%. The solution was incubated overnight
at room temperature with 0.3mg/ml of proteinase K. The cleared lysate was extracted
twice with Phenol/Chloroform and then with Chloroform. The DNA was precipitated
in 2.5 volumes of 100% ethanol and washed in 70% ethanol. The DNA pellet was
resuspended in TE adjusting the volume to a final concentration of 1µg/µl.
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2.2.15 Generation of pAG1 vector homologue of p554 vector: p554 is a 27,428 bp
vector expressing EBNA2 type 1 from the Wp promoter. To build the pAG1
homologous vector expressing EBNA2 type 2, the p554-4 plasmid was used. p554-4
is a 28428 bp vector bearing the ER/EBNA2 fusion protein (Kempkes et al., 1995).
The methionine of the ER and coincides with an EcoRI restriction site whereas a
unique NotI site defines the end of the 3' UTR of EBNA2 (Figure 2.3A).
As a first step the vector was digested HindIII/NotI. Three fragments were
generated: a 25 kb fragment representing the vector backbone, a 3 kb fragment which
corresponds to the fusion gene lacking a small fragment included in the third
HindIII/HindIII piece of 700 bp. All three fragments were recovered and purified. The
small fragments were purified using a Qiagen kit for gel extraction whereas the big
fragment was extracted directly from gel using centrifuge spinning directly from the
gel (section 2.2.6). The HindIII/NotI fragment of 3 kb, containing the fusion protein
was inserted at the same restriction enzyme sites in pBSSK+, generating the
intermediate pAGint1 (Figure 2.1A). In order to swap between the two EBNA2
types, the locus of EBNA2 type 2 was Pfu amplified amplified from 200 ng of AG876
genomic DNA, spanning from the initiator ATG to the NotI in the 3’ UTR. Pfu
generates blunt ends. In order to clone the fragment in the TOPO vector the PCR
product was left at 72°C for 15 minutes with Taq Polymerase in the presence of
dATP. The primers as expected amplified a region of 2.1 kbp, which was gel purified,
sub-cloned in the TOPO-TA vector and sequenced. The sequence analysis showed a
perfect match between the amplified product and the AG876 wild type sequence. To
swap between types, primers identical to the ones used for amplification from the
genome but with EcoRI and NotI overhanging respectively at the 5' and 3' ends were
used. The amplified product was then digested EcoRI/NotI and inserted in pAGint1 to
73
generate pAGint2. (Figure 2.1B) The 700 bp HindIII fragment was then inserted into
the HindIII site in pAGint2, generating the pAGint3 (Figure 2.1C). The estrogen
receptor was then excised cutting pAGint3 with EcoRI and re-ligating the vector to
obtain pAGint4 (Figure 2.2A). pAG1 was generated by cutting the HindIII/NotI
fragment from pAGint4 and cloning it into p544-4 HindIII/NotI (Figure 2.2B). The
final vectors were sequenced.
2.2.16 Generation of pERT2 vector homologue of p554-4 vector: pERT2 was
assembled starting from pAGint3 from the previous cloning. In this case the HindIII
fragment was cloned into p554-4 to create pInt4’ (Figure 2.3A) after that the 700bp
HindIII fragment was reintroduced into pInt4’ to obtain pERT2, expressing EBNA2
type 2 fused with the estrogen receptor and under the control of the Wp promoter
(Figure 2.3B).
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EcoRI EcoRI NotI
ER EBNA2 T1
HindIII
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EcoRI NotI
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Int 3
HindIII
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A
B
C
Figure 2.1A, B and C. Construction of pAG1 vector
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Figure 2.2A and B. Follows construction of pAG1 vector
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Figure 2.3A and B. Construction of pERT2 vector
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2.3 Cell culture protocols
2.3.1 Viable cell count: Cells were stained with trypan blue solution (Sigma) at 1:1
and the cell number  determined by light microscopy using a haemocytometer
2.3.2 Cell lines in suspension:
EREB2.5 + P3HR1; p554-4 RPMI, P/S, G,
Est
Conditional
ER-EBNA2T1
IB4 + B95-8 RPMI, P/S, G EBNA2(+)
LCL3 + B95-8 RPMI, P/S, G EBNA2(+)
AG876 + GroupIII BL
EBV type 2
RPMI, P/S, G EBNA2(+)
Daudi + ΔEBNA2EBV
GroupI/II
RPMI, P/S, G EBNA2(-)
Daudi -
EBNA2T1/T2
+ ΔEBNA2EBV
p554-4; pERT2
RPMI, P/S, G
G418
(400µg/µl)
Conditional
ER-
BNA2T1/T2
Akata 31 - GroupI BL RPMI, P/S, G EBNA2(-)
Akata 31-
EBNA1-
EBNA2T1/T2
- pPURO-EBNA1
p554-4; pERT2
RPMI, P/S, G,
Puromycin
(1µg/µl), G418
(1µg /µl)
Conditional
ER-
EBNA2T1/T2
TABLE 1: Cells in suspension were maintained in a 37°C humidified incubator with 10%
carbon dioxide. All LCLs and BLs were maintained between 4X105  and 1X106  cells/ml by
passaging them at 1:3 two times per week.
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2.3.3 Adherent cell lines: The transformed embryonic kidney cell line 293 was
maintained as a monolayer in supplemented DMEM. When confluent the cells were
suspended by washing twice in 1X PBS before detaching with trypsin-EDTA
(GIBCO-BRL) and seeded at 1:20 dilution in new flasks.
2.3.4 Freezing cells: 5X106 cells were centrifuged at 800 x g for 5 minutes at 4°C and
resuspended in 1 ml of cold freezing medium. The cryovials were then placed in a
Nalgene Cryo 1C freezing container overnight at -80°C. The vials were then
transferred to liquid nitrogen.
2.3.5 Removal from liquid nitrogen: Cells were thawed rapidly to RT and 10 ml of
medium was added slowly with agitation to dilute the DMSO. Cells were pelleted by
centrifugation (800 x g, 5', 4°C) and the supernatant decanted. The pellet was
resuspended in 10 ml of medium, transferred to a tissue culture flask and placed at
37°C.
2.3.6 Cell harvesting: The cells were centrifuged (800 x g, 5', 4°C), and washed in
1X PBS. The supernatant was removed, the pellet snap frozen in dry ice and stored at
-80°C.
2.3.7 Estrogen starvation and induction of EREB2.5 cell line: EREB2.5 cells were
estrogen starved for 5 days before induction.  Cells were washed twice by
centrigugation at 1,300 RPM for 5' at 4°C from unsupplemented RPMI and
resuspended at 5x105 cells/ml in supplemented RPMI without estrogen. After 4 days,
cells were counted again and resuspended at the same density, in fresh supplemented
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RPMI medium, without estrogen. On the fifth day, protein synthesis inhibitors (PSI)
were added to the suspension and left acting for two hours in the 37°C incubator.
Control aliquots were not treated with PSI. Then estrogen was added to the sample or
the same volume of solvent (ethanol) as control to the PSI treated suspensions and to
the untreated ones. The induction was carried for 4 hours in the 37°C incubator. To
harvest, cells were washed twice by centrifugation in unsupplemented medium. The
medium was removed completely and the cells were snap frozen in dry ice and stored
at -80°C.
2.3.8 3H-thymidine incorporation assay: Aliquots of 200 µl of medium containing
0.5X105 EREB2.5 cells were placed in 96 well plates. 10µl (1µCi) of 3H-thymidine
(Amersham) diluted 1/10 in phenol red free medium RPMI 1640 was added to each
well and the cells were incubated at 37°C for 2 hours before harvesting onto a
filtermat (Camo) using a cell harvester (Skatron). Thymidine incorporation was then
determined by placing the filter in 5 ml of Ecoscint A (National Diagnostic) and
counted using a scintillation counter (Beckman LS6500). Filters were stored for at
least 36 hours at RT before counting to avoid chemiluminescent background.
2.3.9 Propidium iodide staining: 1X106 cells were washed in PBS and fixed in 80%
(v/v) ethanol at 4°C for 60 minutes. Cells were then collected by centrifugation and
re-hydrated in 3 ml 1X PBS on ice for 1 hour. Cells were then pelleted and
resuspended in 400 µl propidium iodide staining buffer. Samples were incubated in
the dark for 30 minutes and then analyzed by flow cytometry using the ExCalibur cell
sorter and CELLQuest software. At least 10,000 events were registered.
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2.3.10 Calcium phosphate-mediated transient transfection in 293 cells: 5X105 293
cells were seeded on a 6 cm plate and incubated overnight at 37°C. The cells were
transfected with 1 ml of transfection mix, consisting of 440 µl of water plus DNA,
500µl of 2X HBS and 60µl of 2M CaCl2, which was added drop wise while mixing.
The transfection mix was incubated at 37°C for 30 minutes, and the cells fed with 9
ml of fresh medium. After this time the mix was added to the plates containing the
cells and incubated over night at 37°C. The cells were then washed three times with
1X PBS and fed with 10 ml of fresh supplemented medium. The cells were harvested
48 hours later by removing the medium, scraping the cells from the plate and washing
twice in 1X PBS.
2.3.11 Lipofectamine mediated transient transfection for detection of protein
expression:
5X105 cells were seeded on to 6 well plates and incubated overnight in 4 ml of
supplemented medium. For detection of protein expression, cells were transfected at
90% confluence; 5 to 10 µg of vector was combined with 8 µl of lipofectamine,
mixed and incubated for 20 minutes before being added to the cells. Cell were
harvested 24 hours after transfection by scraping the plate, washing with 1X PBS and
snap freezing the pellets.
2.3.12 Lipofectamine mediated transfection for RNAi of target genes: 2.5X10
5
cells were seeded on 12 well plates and left over night. Cells were transfected at
30/40% confluence by using 1.8 µg of DNA combined with 2µl of lipofectamine.
Puromycin selection (1µg/µl) was started 24 hours after transfection. Once confluence
was reached, cells were suspended using trypsin-EDTA and seeded in 12 well plates
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at different dilutions. Selection was maintained for five days, after which cells were
counted and harvested. The medium was replaced every two days.
2.3.13 Transient transfection in B cells by Amaxa nucleofection: LCLs were
diluted two fold on two consecutive days prior to nucleofection. 5X106 cells were
centrifuged, the supernatant was completely removed and the pellet resuspended in
100 µl of room temperature Nucleofector solution T (Amaxa biosystems). The cells
were mixed with 5 µg of plasmid in a maximum volume of 5 µl endotoxin free water
and transferred to an Amaxa cuvette. EREB2.5 cells were nucleofected using the
program A-23. 500 µl of pre-warmed medium was added to the transfection and the
whole mix transferred to a flask containing 5.5 ml of supplemented medium and
incubated at 37°C over night. The following day, the selection was started by adding
1µg/µl puromycin in a final volume of 12 ml. Samples were taken at days 6, 9, 12 and
15 days after transfection for cell counts, RNA and protein extraction and propidium
iodide staining.
2.3.14 Stable transfection of BL cell lines by electroporation: Cells were diluted
two fold for two consecutive days prior to transfection. 2X107 cells were centrifuged,
washed twice in serum free medium and then resuspended in 1 ml of serum free
medium, sufficient for four transfections. DNA was added to 250µl of the cell
suspension and placed into a Bio-Rad Gene Pulser cuvette (0.4 mm electrode gap).
The mix in the cuvette was incubated on ice for 10 minutes. The electroporation was
performed at 250 V and 960 µF on a Bio-Rad Gene Pulser. After electroporation, the
cells were incubated for ten minutes at 37°C to recover. After incubation 0.5 ml of
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supplemented medium was added to the cuvette and cell were placed into flasks
containing 5.5 ml of warm supplemented medium. 48 hours later, 6 ml of medium
containing the selective drug was added to the cells obtaining a final 12 ml volume. 2
ml aliquots were then placed into 24 well dishes and the medium with selection was
refreshed every 3 days. Cells were not passaged to larger wells until clear outgrowth
occurred. This period depended on the type of selection and varied from a week to a
month.
2.3.15 Short hairpin RNA interference (shRNAi) of target genes in EREB2.5
cells: shRNAi was performed in EREB2.5 cells to assay the effect of gene knock
down on proliferation. puro-oriP-SUPER vectors express short hairpin RNAs from
the H1 promoter and can be selected by puromycin administration. They were created
by cloning the H1 expression cassette into puro-oriP (a puromycin resistant version of
PHEBO). 5X106 EREB2.5 cells were transfected with 5µg of puro-oriP-SUPER
vectors expressing the RNAi sequences against the target gene, against the p53 or the
empty vector as control. Puromycin selection was started 24 hours after transfection.
Cells were re-fed with estrogen-supplemented medium every second day and cells
were counted at day 6 after transfection and during the following days. Aliquots were
harvested for western blotting analysis, RNA extraction or propidium iodide staining.
19 bp target sequences were chosen using the Oligoengine3 RNAi design tool,
available on-line. shRNAi oligos were composed of the 19 bp RNAi sequences
separated from their complementary sequence by a 9 bps spacer that allows the
formation of an hairpin. A BglII site at the 5’ end and a HindIII site at the 3’ end
allowed the cloning of the shRNAi sequences in the puro-oriP-SUPER vector after
the H1 promoter.
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2.4 RNA protocols
2.4.1 Total RNA extraction from LCLs: Total RNA was extracted by using the
RNeasy Maxi kit from Qiagen. Biological samples were first lysed and homogenized
in a highly denaturing guanidine isothiocyanate (GITC) containing buffer, which
immediately inactivates RNases to ensure isolation of intact RNA. The RNA was
purified using selective binding properties of a silica-gel-based membrane. The
protocol was performed as recommended in the kit. The average final yield ranged
between 0.8 or 1 µg/ml. Generally about 500 µg of total RNA was recovered from
600 ml of EREB2.5 cell culture. The RNA was stored at -80°C.
2.4.2 The RNase protection assay (RPA):
2.4.2.a Production of markers from pBR322: DNA markers were prepared by end
labelling MspI digested pBR322 with 32P-dCTP (Amersham) using Klenow fragment
DNA polymerase in the following reaction:
pBR322-MspI digested DNA 1µl (1µg)
10x Klenow Buffer (55mM TrisHCl, pH7.2, 100mM MgSO4,
50% glycerol)
2µl
2mM dATP, dGTP and dTTP mix 1µl
32P-dCTP (3000µCi/mmol) 1µl (0.03mM)
Klenow fragment of DNA polymerase I (5U/µl) 1µl
sterile water to 20µl
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The markers were purified using Micro Bio-spin P-30 Tris Chromatography columns
(Bio-rad) and 8000 cpm were loaded on to a 6% polyacrylamide gel to act as markers.
2.4.2.b 32P-radiolabelling of the RNase protection assay probe by in vitro
transcription: The probe was synthesised using the Ambion Maxiscript kit in the
following reaction:
10X buffer 1µl
10mM ATP 0.5µl
10mM CTP 0.5µl
10mM GTP 0.5µl
0.06mM UTP 0.75µl
H2O 1.25µl
32P UTP (800Ci/mmol) 2.5µl (0.06 mM, 10mCi/µl)
RNAPol (20U/µl) 1µl
1ug/10ug Linearized plasmid (GAPDH/Other genes) 2µl
Final volume 10µl
The reaction was incubated for 45 minutes at 37°C. To remove the template DNA, a
DNase digestion was performed by adding 1ul of Turbo DNase1 and incubating at
37°C for a further 15 minutes. In order to have a primarily full-length product, the
probe was gel purified by running it on 5% acrylamide/8M Urea gel. Each sample and
the marker were mixed with 5µl of DNA loading buffer (125mM Tris-HCl pH 6.8,
20% (v/v) glycerol and 0.01% (w/v) bromophenol blue, dissolved in dH2O) ,
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denatured for 5 minutes at 95°C and loaded on to the gel. The gel was run at 20W.
The probe was recovered from the gel by cutting it out after locating it with 30
seconds exposure to an X-ray film (Hyperfilm, Amersham) developed using a Fugi
Xray film processor RGII. The gel was re-exposed to check the correct recovery.
Elution of the probe was performed by adding 100ul of elution buffer (0.5M
ammonium acetate, 1mM EDTA and 0.2% (w/v) SDS, RPAIII kit; Ambion) and
incubating at 65°C for at least 1 hour. The activity of the radiolabelled probe was
counted on the scintillation counter (Beckman LS6500).
To synthesise multi template probes, the RiboQuant in vitro transcription kit
(Pharmingen) was used. The following reaction mix was prepared and incubated at
37°C for 1 hour.
5x Transcription Buffer 4.0µl
RPA probe template set (50ng/µl) 1.0µl
CAGU pool (GTP/CTP/ATP 2.75mM
each, UTP 61µM)
1.0µl
100mM DTT 2.0µl
RNase-inhibitors (40U/ml) 1.0µl
32P-UTP (3000µCi/mmol) 2.5µl (0.06mM)
T7 RNA polymerase (20U/ml) 1.0µl
sterile water 7.5µl
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The reaction was terminated by the addition of 2µl DNaseI (1U/µl) to remove
template DNA and incubated at 37°C for a further 30 minutes. Phenol/chloroform
extraction of proteins and ethanol precipitation was then carried out. The probe was
resuspended in 50µl hybridisation buffer (RPAIII kit; Ambion) and counted using a
scintillation counter (Beckman LS6500).
2.4.2.c Probe-RNA hybridization: The RPA was carried out using the RPAIII kit
(Ambion). 50,000 counts of probe was added to each sample and to a yeast negative
control sample. The volume was reduced on the speed-vac if it exceeded 5ul. 10µl of
hybridisation buffer was subsequently added. The samples were vortexed for 1 minute
to mix and incubated at 95°C for 5 minutes to unfold secondary structures. The
hybridisation was carried out for 16 hours at 42°C. 1.5µl of RNase A/T1 (RNase A
0.25U/µl, RNase T1 10U/µl) was then added in 150ul of RNase digestion buffer to
remove imperfect hybrids and single stranded RNA. The reaction was incubated at
37°C for 30 minutes and terminated by precipitation with 225ul of RNase inactivation
solution and 150ul of ethanol. The samples were microfuged at 13,000 rpm for 15
minutes at 4°C. The samples were resuspended in 10µl of sample buffer II and heated
for 5 minutes at 95°C. Then the samples were run on a 6% poly acrylamide gel. 8,000
counts of radiolabelled marker and 500 counts of undigested probe in sample buffer II
were also loaded on the gel after incubation at 95°C.
The gel was run for 2 hours at 45W and then transferred to 3mm Whatman paper and
vacuum dried for 2 hours at 80°C in a vacuum drier (Bio-Rad gel drier model 583).
The radioactive products were detected using a phospo-imager screen (Molecular
Dynamics), which was scanned after 1 to 3 days by using a Molecular Dynamics
scanner (STORM 860) and analysed by ImageQuant 5.0 software.
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2.4.3 cDNA spotted array hybridisation and analysis protocol: The technology
was based on the use of human high-density cDNA expression arrays (The Sanger
Wellcome Trust Institute). Each array bears about 15,000 sequences representing
selected genes PCR amplified in defined regions. The arrays were hybridized with
cDNA fluorescently labeled with two different dyes: dCTP-Cy3, dCTP-Cy5
(Amersham). Both Cy-3 and Cy5 labeled cDNA were hybridized on to the same array
and the relative intensity was read by two laser sources specific for each dye. The
incorporation of the two dyes into the cDNA product is not equally efficient, for this
reason both sample and control were dye swapped to control for artifacts:
Sample (50µg) Control (50µg)
dCTP-Cy3          + dCTP-Cy5 Array hybridization
dCTP-Cy5          + dCTP-Cy3 Array hybridization
The first strand cDNA was produced from 50µg of purified total RNA by using the
Superscript III RT kit (Invitrogen). The total RNA was ethanol precipitated together
with 1µl of control bacterial RNA. Pellets were washed in Ethanol and air-dried.
cDNA synthesis was primed using HPLC purified oligodT mix (Operon). The mix
contained 3 populations of 17bp dTTPs primers ending either with a G, A or a C. The
final mix had a concentration of 2µg/µl (0.67µg/µl each). The primers were annealed
to the template by resuspending the RNA in 12.9µl of DEPC treated water and 2.5µl
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of primers mix. The reaction was incubated at 70ºC for 10 minutes and then placed on
ice for two minutes.
The following reaction was used to produce fluorescently labelled cDNA:
50µg RNA + primer mix 15.4µl
5X First strand buffer 6µl
0.1M DTT 3µl
dNTP (25 mM dGTP, dTTPand dATP and 10mM dCTP) 0.6µl
Cy3 or Cy5 (1mM stock) 3µl
Superscript RT(200U/µl) (Invitrogen) 2µl (400U)
The reaction was incubated for 1 hour at 42°C in the dark to avoid the deterioration of
fluorophores. The RNA was removed from the hybrids by adding 1.5µl of 1M NaOH
and incubating the reaction at 70°C for 20 minutes. The reaction was performed in the
dark.  The pH of the solution was then re-equilibrated by adding 1.5µl of 1M HCl.
Still keeping in the dark, the labelled cDNA was then purified through G50 Sephadex
columns. The columns were prepared by centrifugation at 4,000 RPM for 1 minute.
The samples were applied to the columns and centrifuged under the same conditions.
 Cy3 and Cy5-cDNAs were mixed together and precipitated in the following reaction:
Cy3-cDNA + Cy5-cDNA ≈ 50µl
polyA DNA (2µg/µl) 4µl
COT1 DNA (1µg/µl) 4µl
Ethanol 218µl
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The reaction in incubated at -20°C for 20 minutes and centrifuged at 4°C for 10
minutes at maximum speed.
2.4.4 Arrays hybridization: The cDNA pellets were resuspended in 40µl of
hybridisation solution (see solution section 2.1.2), and 8µl of DEPC treated water,
incubated at 100°C for 5 minutes and left to cool down to room temperature. The
arrays had been prepared by incubating in hybridisation solution for more then 3
hours at 42°C and before hybridisation were spun dry for 10 seconds at 1000 RPM.
The cDNA mix was applied drop-wise on each array, covered with a cover slip and
placed in a hybridisation chamber for more then 16 hours at 42°C. The following day,
the arrays were recovered from the chamber and washed as follows:
Washing solution I (see solution section 2.1.2) 15 minutes, 5 minutes
Washing solution II 4 x 15 minutes
Washing solution III 6 x 5 minutes
After the washes the arrays were centrifuged at 1000 RPM  for 5 minutes to remove
the excess liquid and stored in a dry environment at RT.
2.4.5 Array scanning: The image was acquired using the software Scanarray
(GsiLumonics) and a Scanarray 4000 XL machine (Packard), which uses two laser
sources to excite both fluorophores. A quick scan was performed at 50µm resolution,
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with 100% laser power and the photomultipler tube (PMT) gain adjusted until two or
three spots were bleaching out. When a satisfactory PMT gain was identified, the final
image was acquired at 10µm resolution. Scanarray generates two images per array:
one derives from the Cy-3 excitation and one from the Cy-5 excitation.
2.4.6 Quantification of the expression: The variations in gene expression were
determined by the relative intensity of the labelled sample cDNA against the labelled
control cDNA. The fluorescence intensity was read using the Quantarray,TM software
(GsiLumonics). This software also links each spot on the array to its specific gene
identifier by using a Clone Tracker File available on line (Http://www.sanger.ac.uk
/Projects/Microarrays/informatics/datafiles.shtml). The protocol contains also
information on the geometry of the array, the settings and method for background
subtraction. The two images generated by Scanarray are loaded together in the same
window and overlapped. The image representing gene expression intensities of the
control was always loaded first. The next step was to manually align the overlapped
image to the formatted grid associated to the clone tracker file. This was carried out
using the option “Specify location” which allows the experimenter to manually
determine the first spot on the array. This landmark is used by the software to overlap
the grid to the spots when the option "Edit pattern" is chosen. If the circles of the grid
are centred on the spots, the option “locate spots” will produce an interactive grid that
permits the researcher to modify it at the single spot level. Spots whose pattern was
clearly affected by dust, scratches, or very high background were manually selected to
be ignored during the next analysis (Figure 2.4). After the whole grid had been
checked spot by spot, the data were exported to an Excel spreadsheet using the option
91
“Quantarray Macro”. During this procedure the data were background subtracted and
normalized.
2.4.7 Loading data into Genespring: The final step of the microarray analysis is the
production of interactive images that can be used to visualize gene expression, study
gene pathways and make statistical analysis. The software that allows all these
procedures is Genespring,TM (Agilent). Genespring will also repeat the normalisation
and the background subtraction of the data. The data were background subtracted at
the single spot level (by using the background pixels around each spot) and at sub-
array region level using the “lowess” normalisation option.
Settings:
Per spot normalisation Use values over 10
•  48 grids per array
•  15k sequences
•  overexpressed: red
•  down-regulated: green
•  no variation: yellow
Bacterial
RNA
Spot crossed out
Figure 2.4. Representation of a sub region (grid) of a cDNA spotted array. Each spot is checked manually
and crossed out when dust or high background impair the reading.
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Per chip normalisation Use distribution of all genes using the
50th percentile value
Per gene normalisation OFF
Use background correction Use values over 0.01
Scatter plots were generated from the data retrieved. Pools of genes whose expression
was either two fold higher or lower in the sample compared to the control were taken
into consideration for further analysis.
2.5 Protein protocols
2.5.1 Extraction of cell proteins by RIPA Buffer lysis: Cell pellets were extracted
with two volumes of RIPA buffer and lysed by pipetting up and down until complete
dissolved. The solution was then placed in ice for 5 minutes and centrifuged at 14,000
RPM for 10 minutes at 4°C. The supernatant was transferred to a clean Eppendorf
tube and stored at -80°C.
2.5.2 Calculation of protein concentration: Protein concentration was calculated
using the Biorad DC protein assay. A standard curve was produced in order to
measure the protein concentration of the samples. 2µl of each sample to be measured
was mixed with 18µl of RIPA buffer.  100µl of reagent A (Alkaline copper tartarate
solution) and 2µl of reagent S were added to each sample, followed by 800µl of
reagent B (Folin reagent) and incubating at RT for 15 minutes. The sample
concentrations were measured by reading the absorbance at 750nm using a
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spectrophotometer (Unicam Heλiosβ) and comparing it with the standard curve
samples.
2.5.3 SDS Polyacrylamide gel: 50µg protein samples were run on 10 or 12.5 %
polyacrylamide gels together with the Full Range Rainbow Marker (Amersham) as
size markers. Proteins or markers were mixed with 2X sample buffer, boiled for 5
minutes and loaded. SDS-PAGE resolving gel and stacking gels:
SDS-PAGE resolving gel 10%
30% (v/v) acrylamide/Bis solution (29:1) (Bio-Rad) 10ml
1M Tris-Cl pH 8.8 11.2ml
10% SDS 300µl
sterile water 6.2ml
20% (w/v) AMPS 25µl
TEMED 20µl
SDS-PAGE Stacking gel 5%
30% (v/v) acrylamide/Bis solution (29:1) (Bio-Rad) 1.67ml
1M Tris-Cl pH 8.8 1.25ml
10% SDS 100µl
sterile water 7ml
20% (w/v) AMPS 25µl
TEMED 10µl
 The gel was run overnight at 50V or at 160V for about 4 hours.
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2.5.4 Western blotting: Transfer on to the nitrocellulose membrane was performed at
40mV overnight. The sandwich was set up according to the following scheme:
After transfer the membrane was blocked in blocking solution (10% (w/v) fat free
dried milk powder (Marvel) reconstituted in washing buffer and stored at 4°C) for 1
hour at room temperature on a shaker. The primary antibody was diluted in blocking
solution, added to the membrane and placed overnight with shaking at 4°C. The next
day the membrane was washed in washing buffer (3 times for 15 minutes) then 25ml
of a horse-radish peroxidase (HRP)-conjugated secondary antibody (1:2000 dilution
in 25 ml of blocking buffer) was added and incubated at room temperature for 1 hour.
The membrane was washed again with three 15 minute washes.
2.5.5 Enhanced chemi-luminescence (ECL): Results were obtained using ECL
western blotting detection reagents (Amersham Pharmacia Biotech). Equal volumes
of detection reagent A and B were mixed and added to the membrane, which was then
wrapped in the Saran wrap and placed in a film cassette. Autoradiography film
Negative pole
Positive pole
Sponge
3mm whatman
SDS polyacrylamide gel
Nitrocellulose
3mm Whatman
          Sponge
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(Hyperfilm; Amersham) was then exposed to the membrane and developed using a
Fugi film processor RGII.
2.5.6 In Vitro Translation: EBNA2 type 1 and type 2 sequences were amplified
from p554 and pAG1 and cloned into pSP64 expression vector using primers with
overhanging sequences carrying XbaI (5') and EcoRI (3') restriction sites.
T1Fw: -TGCTCTAGAATGCCTACATTCTATCTTGCGTTAC-
T1rev: -CGGAATTCTTATTACTGGATGGAGGGGCGAGGTCTT-
T2Fw: -TGCTCTAGAATGCCTACATACTATCTTGCGAGGTCTT-
T2rev: -CGGAATTCTTATTACTGAGTGGAGGTGCGAGGTCTT-
The amplified products were cut and ligated into pSP64 expression vector digested
with the same restriction enzymes. In vitro translation was performed using the TnT
reticulocyte lysate system (Promega), using 1µg of template vector and 2µl of
10mCi/ml 35S-methionine, in a 50 µl final reaction. Empty vector was used as control.
A titration of the same amount of amplified product from type 1 and type 2
translations was run on SDS-PAGE and exposed on a phosphorscreen using a
phosphorimager. The same filter was also blotted with PE2 antibody and developed
by ECL signal amplification. Images were read and compared using the
ImageQuant5.0 software.
2.5.7 ELISA: The Quantikine R&D systems kit (DLB50) was used to reveal the
concentration of IL1-β in different B cell lines. AKATA31-T1/T2 or EREB2.5 cells
with or without estrogen treatment were extracted in 200µl lysis buffer. This material
was added to the ELISA kit and incubated for 2 hours with the primary antibody
provided with the kit then washed 3 times. This was followed by a1hr incubation with
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secondary antibody and other three washes. The development was performed
incubating for 20 minutes with substrate solution in the dark then adding stop
solution. The plate was read at 450nm within 30 minutes, correcting at 540 nm.
2.5.8 Production of monoclonal antibodies against DNASE1L3 and DTX1:
Carboxy terminal fragments from the coding region of the DNASE1L3 and DTX1
genes were cloned into a modified version of the pET15b vector. This vector had been
engineered in the polycloning site, in order to clone fragments flanked by XmaI (N
terminus) and BamHI (C terminus) sites. A 417 bp fragment was cloned out of the
DNASE1L3 sequence, producing a fusion polypeptide sequence of 173 amino acids,
whereas from DTX1 CDS a fragment of 615 bp was cloned resulting in a fusion
polypeptide of 204 amino acids. The sequence for a 6X-HIS tag is located after the
starting codon and in front of the cloning sites that are followed by a stop codon:
The fragments were amplified from cDNA obtained from estrogen induced EREB2.5
cells by Pfu-PCR using the following primers:
DNASE1L3FW (XmaI):    CAGCCCCGGGAGCCCTTTGTGGTCTGGTTCCAA
DNASE1L3Rev (BamHI): GCGCGGATCCCTAGGAGCGTTTGCTCTTTGTTT
DTX1FW (XmaI):            GAGCCCCGGGCTGGTCACAGCATCAGGCTACGA
T7P                6X-HIS    MCS              T7T
ATG                          TAA
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DTX1REV(BamHI):
GCGCGGATCCCTAGGTCTTGTGGTGGATCTCGTTCC
The amplified products were digested with XmaI and BamHI, and cloned in the
pET15b vector digested with the same enzymes. The ligated vectors were transformed
into T7 polymerase negative E. Coli strains and the purified plasmid DNA sequenced
using the T7 promoter primer (TAATACGACTCACTATAGGG) and the T7
terminator primer (GCTAGTTATTGCTCAGCGG).
The protein expression was carried out in the BL21(DE3) strain, expressing T7
polymerase in the presence of IPTG. Small scale experiments were carried out
transforming BL21 cells with the expression vectors and incubating overnight at
37°C. The following day single colonies were picked and grown in 5 ml of LB/Amp
medium. Colonies were grown until they reached A600 >2. At this point the culture
was diluted 1:50 in fresh LB/Amp medium and grown to A600= 0.4 then IPTG was
added at a final concentration of 0.5 mM and left for 4 hours. After this time, the
same number of induced cells and control cells were pelleted and lysed directly in
protein sample buffer aided by sonication on ice using a Heat-System, inc sonicator. 5
µl of each lysate was run on a 12% SDS-PAGE and the gel was stained for one hour
in Coomassie blue solution and de-stained overnight. Fragments of the expected size
were detected only in the induced colonies (Figure 2.5A). Protein expression was also
assessed at different temperatures but 37°C was always found to be the best (Figure
2.5B). The anti-HIS tag antibody recognized proteins in western blotting the same
size as of those identified by Comassie blue staining (Figure 2.5C).
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DTX   D1L3            DTX D1L3
                                       1ng
Comassie                 WB         
staining
Figure 2.5A. Comassie blue staining of SDS-PAGE run with protein extract from IPTG induced BL21
cells expressing DTX1 and DNASE1L3 fragments. 5B . Expression of DTX1 and DNASE1L3
fragments at different temperatures. 5C. HIS-TAG antibody against the expressed fragments.
              DNASE1L3          DTX1
               S            I          S           I
   DNASE1L3                 DTX1
 FL      Ct        Ct           Ct        Ct
 37°     30°       37°        30°      37°
A
B
C
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For large scale expression and purification, 20 ml of LB broth containing ampicillin
was inoculated and grown at 37°C overnight with vigorous shaking. The following
day, one litre of LB broth containing antibiotics was inoculated at 1:50 with the
overnight culture and grown until OD600 of 0.6. A small aliquot was taken at this time
before induction with IPTG. IPTG was added at a final concentration of 1 mM and
the culture was incubated for 5 hours. The cells were harvested by centrifugation and
the pellet was snap frozen and stored overnight at -80°C.
The following day the pellet was thawed on ice and the cells were resuspended in cell
lysis buffer containing 20mM imidazole at 5ml per gram of cells. Lysozyme 1mg/ml
was added to the culture. Cells were sonicated on ice at 200W power, using cycles of
10 seconds sonication and ten seconds of cooling period. Lysates were centrifuged at
4°C to pellet cellular debris. The supernatant was saved and supplemented with DTT.
The insoluble fractions were dissolved in denaturing buffer containing guanidine
HCL and Urea with sonication. 1 ml of 50% Ni-NTA slurry was added to 4 ml of
cleared lysate and mixed gently with shaking for one hour at 4°C. The solutions were
then loaded on to Nickel charged columns and the columns washed twice in wash
buffer. The columns were eventually eluted four times with 0.5ml of elution buffer
containing 200mM imidazole. 5µl samples of eluted fractions were loaded on an
SDS-PAGE gel. Both proteins were present in the insoluble fraction (Figure 2.6A, B).
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             B                                UNSOLUBLE FRACTION
                       DNASE1L3                                                              DTX1
    E1       E2        E3       E4     E5                        E1        E2        E3        E4
                    DTX1                                                      DNASE1L3 
Purification of His-tagged DTX1 and DNASE1l3
proteins
DNASE1L3 full lenght
Used at 2M urea solution to immunize mice 
                    DTX1                                                      DNASE1L3 
Purification of His-tagged DTX1 and DNASE1l3
proteins
DNASE1L3 full lenght
Used at 2M urea solution to immunize mice 
  DTX1          DNASE1L3   
Ni-NTA Agarose purification of DTX1 and DNASE1L3 Ct His-Ct fragments
8M UREA dissolved 
Insoluble fraction
Soluble fraction
1st    2nd   3rd  4th    1st  2nd   3rd    4th       Eluted fractions
DTX1          DNASE1L3   
Ni-NTA Agarose purification of DTX1 and DNASE1L3 t His-Ct fragments
8M UREA dissolved 
Insoluble fraction
Soluble fraction
1st  2nd 3rd  4th    1st 2nd 3rd    4 h       Eluted fractions
A          SOLUBLE FRACTION
         DNASE1L3                                                         DTX1
      E1       E2        E3                                      E1        E2         E3
Figure 2.6A. Eluted fractions from Ni-charged columns. Eluates from the soluble fraction of BL21 cells.
2.6B. Eluates from the unsoluble fraction of BL21 cells.
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The solutions were dialyzed against TE containing 2M UREA overnight in order to
reduce the concentration of UREA to a level not toxic for mouse inoculation. The
samples were then sent to 4th Military Medical School, Xian, China to produce
monoclonal antibodies in a collaboration with Dr Boquan Jin. This resulted in several
clones of hybridoma supernatant and ascites from both DTX1 and DNASE1L3
inoculations. The western blottings in figure 2.7A, B and C show respectively the list
of hybridoma obtained against DNASE1L3, the western blotting of these against the
purified fusion proteins and against cell extracts. The same procedure was used for
DTX1 and is shown in figures 2.8A, B and C. The clones that showed a higher
affinity were used to perform western blotting on protein extracts from EREB2.5 cells
induced and not induced with estrogen. DNASE1L3 failed to identify any signal in
EREB2.5 cell extracts whereas DTX1 recognized a band of the expected size showing
as well an induction in response to estrogen administration. This western blotting is
also shown in the results chapter in figure 3.12.
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111098321 7654 12 13
10 kDa
DNASE1L3 Antibody Clone:
23 kDa
60ng 12ng 6ng
B
A
C
DNAse1L3
10-6IgG112
10-5IgM/G113
10-6IgG111
10-6IgG110
10-6IgG19
10-4IgM/G18
10-6IgG17
10-6IgM6
10-5IgM5
10-4IgM/G14
10-7IgG13
10-7IgG12
10-6IgG11
Ascites titreIg IsotypeClone No.
Figure 2.7A. DNASE1L3 antibody clones from mouse ascites 2.7B. Western blotting on
DNASE1L3 expressed fragment using aliquots from the 13 clones. 2.7C. Serial dilution of
clone 4 against DNASE1l3 fragment
Clone 4
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DTX-1 Antibody Clone:
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Cl
6ng30ng
––7
10-5IgG12
10-6IgG13
10-6IgM/G14
10-6IgM5
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DTX-1
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Ascites titreIg IsotypeClone No.
C
Clone 8
Figure 2.8A. DTX1 antibody clones from mouse ascites 2.8B. Western blotting on DTX1
expressed fragment using aliquots from the 13 clones. 2.8C. Serial dilution of clone 4
against DTX1 fragment.
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2.6 PCR primers and oligonucleotides
GAPDH PCR primers:
GAPDH Forward primer: 5’ TGC ATC CTG CAC CAC CAA CT 3’
GAPDH Reverse primer:  5’ CGC CTG CTT CAC CAC CTT C 3’
PCR cycle:
94°C 2 min
94°C 30 sec
55°C 30 sec  X 25 cycles
72°C 30 sec
Product: 350 bps
PCR primers for amplification of EBNA2 T2 genomic sequence:
EBNA2T2-EcoRI Forward primer: 5’ GCG AAT TCA TGC CTA CAT ACT ATC
TGC CGT TAC 3’
EBNA2T2-NotI Reverse primer: 5’ TAT CAA ATG CGG CCG CCT GCT GCC
CAT GGA ATG CTC A 3’
PCR cycle:
94°C 5 min
94°C 1 min
62°C 1’ 30 “ X 36 cycles
72°C 5 min
Product: 2,070 bps
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PCR primers to clone EBNA2 T1 and T2 coding sequences from p554 and pAG1 into
the modified p294 vector:
EBNA2T1-XbaI Forward primer: 5’ TGC TCT TAG AAT GCC TAC ATT CTA
TCT TGC GTT AC 3’
EBNA2T1-EcoRI Reverse primer: 5’ CGG AAT TCT TAT TAC TGG ATG GAG
GGG CGA GGT CTT 3’
PCR cycle:
94°C 5 min
94°C 1 min
60°C 45 sec X  26 cycles
72°C 5 min
Product: 1,468 bps
EBNA2T2-XbaI Forward primer: 5’ TGC TCT AGA ATG CCT ACA TAC TAT
CTT GCG TTA 3’
EBNA2T2-EcoRI Reverse primer: 5’ CGG AAT TCT TAT TAC TGA GTG GAG
GTG CGA GGT CTT 3’
PCR cycle:
94°C 5 min
94°C 1 min
60°C 45 sec X  26 cycles
72°C 5 min
Product: 1,343 bps
IRF4 PCR primers:
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IRF4 Forward primer: 5’ GCT CTA TGC GAA AAG ACT GTG CC 3’
IRF4 Reverse primer: 5’ TAG CCC CTC AGG AAA TGT CCA CTG 3’
PCR cycle:
94°C 5 min
94°C 1 min
60°C 45 sec X 28 cycles
72°C 45 sec
Product: 315 bps
CD69 PCR primers:
CD69 Forward primer: 5’ GTC CCC CAT TTC TCA ACA CGT CAT G 3’
CD69 Reverse primer: 5’ ACC CAG TGT TCC TCT CTA CCT GCG 3’
PCR cycle:
94°C 5 min
94°C 1 min
58°C 45 sec X 28 cycles
72°C 45 sec
Product: 333 bps
C1orf38 PCR primers:
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C1orf38 Forward primer: 5’ CGT CCA CTT TAT CAA ACC GCT G 3’
C1orf38 Reverse primer: 5’ CTC ATC TCC ACG AAA CTG C 3’
PCR cycle:
94°C 5 min
94°C 1 min
58°C 45 sec X 28 cycles
72°C 45 sec
Product: 333 bps
DTX1 PCR primers:
DTX1 Forward primer: 5’ CTG ATG CCT GTG AAT GGT CTG G 3’
DTX1 Reverse primer: 5’ GAC GAC GGG TCG TAG AAG TTG C 3’
PCR cycle:
94°C 5 min
94°C 1 min
58°C 45 sec X 28 cycles
72°C 30 sec
Product: 278 bps
DNASE1L3 PCR primers:
DNASE1L3 Forward primer: 5’ TGG GGA AAG CAA GCA GGA AGA C 3’
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DNASE1L3 Reverse primer: 5’ TTG GAA CCA GAC CAC AAA GGG CTC 3’
PCR cycle:
94°C 5 min
94°C 1 min
60°C 45 sec X 28 cycles
72°C 45 sec
Product: 327 bps
ADAMDEC1 PCR primers:
ADAMDEC1 Forward primer: 5’ CTC TCC CTA CAA AAA ACC AAG CAC 3’
ADAMDEC1 Reverse primer: 5’ TGT GTG AAG TAT CCT CTC TCA ACC CG  3’
PCR cycle:
94°C 5 min
94°C 1 min
58°C 45 sec X 28 cycles
72°C 30 sec
Product: 190 bps
CXCR7 splice variant (splice 1 and 3) PCR primers:
CXCR7 Forward primer: 5’ CAG CTT CAG ATC TGG GTA TTT ATC C 3’
CXCR7 Reverse primer: 5’ TGG GCA TGT TGG GAC ACA TCA CC 3’
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PCR cycle:
94°C 5 min
94°C 1 min
60°C 1 min X 31 cycles
72°C 45 sec
Products: 358/252
CXCR7 alternative splice (splice 2) PCR primers
CXCR7 Forward primer: 5’ GCAGCCAGCAGAGCTCACAGTTG 3’
CXCR7 Reverse primer: 5’ TGGGCATGTTGGGACACATCACC3’
PCR cycle:
94°C 5 min
94°C 1 min
58°C 1 min X 31 cycles
72°C 45 sec
Products: 250
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2.7 Antibodies
Antigen Antibody Source Application/dilution
EBNA1 Human serum EBV + source
EBNA2 Mouse polyclonal (PE) DAKO WB 1 in 500
LMP1 Mouse monoclonal CS 1-4 DAKO WB 1 in 500
BCL6 Mouse monoclonal (D8) Santa Cruz WB 1 in 1000
CyclinD2 Mouse monoclonal BD
Pharmingen
WB 1 in 500
CXCR7 Rabbit polyclonal (12870) AB-CAM IHC 1 in 100
DNASE1L3 Mouse monoclonal (clone 4) * WB 1 in 200
DTX1 Mouse monoclonal (clone 8) * WB 1 in 200
IL1ß Rabbit polyclonal (2105) AB-CAM WB 1 in 100
IRF4 Rabbit Polyclonal (27508) AB-CAM WB 1 in 1000
c-MYC Mouse monoclonal (9E10) Santa Cruz WB 1 in 500
P53 Mouse monoclonal D01 Oncogene WB 1 in 1000
RUNX3 Rabbit polyclonal RUNX3 Active motif WB 1 in 500
* DTX1 and DNASE1L3 were obtained through the LICR collaborative program
with Boquan Jin at the 4th Military Medical School, Xian, China.
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3. Direct targets of EBNA2 type 1 in EREB2.5 cells
3.1 Introduction
Identification of the genes induced by EBNA2 is the aim of this chapter. To
know EBNA2 target genes is crucial not only for the understanding of the
establishment of EBV latency but also to gain insights into the molecular physiology
of B cell activation and proliferation. c-MYC (Kaiser et al., 1999), RUNX3 (Spender
et al., 2001), p55 alpha subunit of PI3K (Spender et al., 2006), CD21 (Larcher et al.,
1995) and BAFT (Johansen et al., 2003) are some of the established direct targets of
EBNA2 in B cells. During the last three years, several studies have been carried out to
identify EBNA2 target genes in B cells. All the studies made use of microarray
techniques to obtain a comprehensive picture. Zhao et al in 2006 transformed resting
B cells using a recombinant EBV genome expressing a conditional EBNA2 fused to a
4-hydroxytamoxifen dependent estrogen receptor (Zhao et al., 2006). After they
obtained stably growing lymphoblastoid cells, 4-hydroxytamoxifen was withdrawn
for a period of 24h so that EBNA2 was no longer active. By comparing gene
expression in the presence and the absence of EBNA2, along with the wild type LCL
as a control, they identified 87 genes related to EBNA2 function. This system,
although elegant, has several drawbacks. The cells that were obtained by infection
with the recombinant virus were similar to wild type LCLs but they required 15%
FCS to maintain growth and they were very sensitive to dilution, undergoing
apoptosis when grown at concentration higher then 3X105/ml (Zhao et al., 2006). This
suggests that some aspect of cytokine metabolism might be altered.  Moreover, all
virus and cell genes that are controlled by EBNA2 induction, either directly and
indirectly, will be affected and therefore in this system, there was no separation
between the direct effects due to EBNA2 and the downstream effects. In fact, out of
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81 genes identified by that microarray analysis, only 27 genes were reported to be
expressed in EBNA2 conditional cells at the same level as in wild type LCLs. Schlee
et al, performed proteome analysis using the EREB2.5 cell lymphoblastoid line that
has very similar growth to an LCL containing the wild type EBV (Schlee et al., 2004).
EBNA2 is fused with the estrogen receptor and is expressed from the wild type
promoter from the p554-4 vector. By starving the cells for estrogen for three days and
re-feeding them for 24 hours, 9 proteins that may be targets of EBNA2 were
identified. As a control, proteomic analysis was also performed on EBV immortalized
primary B cells. The nine proteins identified correspond to oxidative stress responses,
protein metabolism and catabolism, and only one was linked to cell growth. The result
was quite unexpected since most of the genes that are regulated by EBNA2 showed
no variation at the protein level but this is the only work making use of a proteomics
approach. Maier et al, in 2006, studied the effects of EBNA2 in isolation from other
viral factors. To do so, the p554-4 vector expressing EBNA2 protein fused to the
estrogen receptor was stably transfected into the EBV negative Burkitt lymphoma
cells (BL41) and the BJAB EBV negative Lymphoma cell line (Maier et al., 2006).
Microarray studies were performed on these cells in the absence or in the presence of
estrogen. The list of genes identified was very large and detailed and included most of
the EBNA2 targets already described in the literature. In this case, estrogen
administration was for 24 hours in the absence of protein synthesis inhibitors; during
this period, the targets of EBNA2 might already exert their secondary function. At
this point it would be very complicated to dissect direct effects of EBNA2 from its
downstream effects. This separation is crucial to understand metabolic events related
to EBNA2 function in the B cell.
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In the present work, experiments were performed on the EREB2.5 cell line
already used in Spender et al in attempts to separate direct targets of EBNA2 from
secondary targets (Schlee et al., 2004, Spender et al., 2001, Spender et al., 2006). In
this case estrogen starvation was prolonged for 5 days. During this period no signs of
apoptosis were noticed in the cells (Spender et al., 2001) but all EBNA2 target genes
are down regulated. On the fifth day, cells were treated for 2 hours with protein
synthesis inhibitors, PSI, before adding estrogen (still with PSI) in order to select
direct targets, and eliminate signals from the secondary targets. Two different
microarray systems were used during this work: Hver 2.1.1 cDNA spotted microarray
(Wellcome Trust Sanger Institute) and 44k whole human genome 60-mers
microarrays (AgilentTechnology). Out of 44,000 genes represented on the array, 50
direct target genes, whose expression was consistently increased by EBNA2
induction, were identified in three independent experiments. Previously known
EBNA2 targets were confirmed and several novel targets were identified, whose
induction ranged from 2 to 20 fold compared to the control. Many of these genes,
were confirmed by RT-PCR. Interferon Regulatory Factor 4, IRF4 and Deltex
Homolg 1, DTX1 were confirmed for the first time at the protein level as EBNA2
targets in EREB2.5 cells.
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3.2 Results
3.2.1 The EREB2.5 cell as a system for separation of direct and
secondary targets of EBNA2
RUNX3 and c-MYC are known direct targets of EBNA2 whereas CyclinD2 is
known to be a secondary target (Kaiser et al., 1999, Spender et al., 2001, Spender et
al., 2002). Protein expression levels of RUNX3, c-MYC and CyclinD2 target genes
were routinely tested each time a new aliquot of EREB2.5 cells was thawed to ensure
the system was performed correctly. EREB2.5 cells were estrogen starved for 5 days
and protein extracts were collected after time courses of 0, 4, 6, 8, 24 hours in the
presence or absence of estrogen. The same volume of ethanol, which is the estrogen
diluent, was added to the cells as control. In all assays the levels of protein expression
increased as expected for those genes. c-MYC, showed an initial induction, which
peaked at around 6 hours and then slowly decreased (Figure 3.1).
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Figure 3.1 Western blotting of EBNA2 targets in the presence and absence of estrogen. EREB2.5
cells were treated in the presence of estrogen for up to 24 hours. 50 µg of protein extracts  were loaded on
each lane. RUNX3, (46KDa) c-MYC (63KDa) and CyclinD2  (36KDa) are targets of EBNA2. Actin
(43Kda) is a loading control Est: estrogen (+/-).  The nearest size marker band of the protein ladder is
reported for each detected protein.
50KD
60KD
40KD
40KD
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3.2.2 Selective induction of EBNA2 direct targets in EREB2.5 cells
Protein synthesis inhibitors were used to separate EBNA2 direct targets from
secondary targets. EREB2.5 cells were estrogen starved for 5 days at 5X105/ml. On
the fourth day of starvation, the cells were resuspended at the same dilution in
estrogen free medium. On the fifth day, protein synthesis inhibitors, PSI, were added
two hours before estrogen addition. Estrogen administration was for 3 hours in the
presence of PSI. Cells were harvested and washed in cold PBS and snap frozen. Total
RNA was extracted with Trizol and the quality and integrity of the RNA was checked
by 260/280nm absorbance ratio and by performing an RNase protection assay, RPA.
RPAs were used also to demonstrate the induction of selected direct but not secondary
targets, respectively c-MYC and CyclinD2 (Figure 3.2). The c-MYC and CyclinD2
probes were part of a RiboQuant custom-made template. GAPDH was used as
control. The RPA showed that only c-MYC mRNA (direct target) is induced but not
CyclinD2 mRNA (secondary target) confirming that this system efficiently separates
direct targets of EBNA2 from secondary targets. These RNAs were used in following
microarray experiments.
3.2.3 Microarray hybridization and analysis: cDNA spotted
microarrays
cDNA spotted microarrays Hver2.1.1 carry 15,000 probes corresponding to
about 7,000 human genes. The probes had been amplified by PCR from 3’UTR region
and arrayed on slides using a BioRobotics MicroGrid II Pro (Biorobotics) at the
Sanger Institute. Experimental and control cDNA from EREB2.5 cells treated and not
treated with estrogen, were labelled using a dNTP mix containing  Cy3 or Cy5 dCTPs
fluorophores. The resulting labelled cDNAs from experiment and control were then
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hybridized on to the same high-density cDNA expression array (Wellcome Trust
Sanger Institute).
The quality of the hybridization was strongly dependent on the batch of arrays
used and there was also a known difference in Cy3/Cy5 labelling efficiency. To have
a statistically significant number of array results, eight different batches were tested
and more than 60 slides hybridized. Every experiment lot was composed of at least
six microarray slides, which were hybridized with cDNA generated from different
estrogen inductions. Dye swap in the cDNA labelling was also used to reduce the
effect of different dye incorporation. The slides were scanned using the Packard
Microarray analysis system 4000, and the images generated using the Scanarray
Figure 3.2: RNA Protection Assay (RPA) using probes specific for either, direct target (c-MYC) and
indirect target (CyclinD2) of EBNA2, and a GAPDH probe. The RPA was conducted on total RNA
samples extracted from EREB2.5 cells starved for estrogen, treated with PSI, for 2 hours and treated
for 3h with estrogen (+) or untreated (-). 10 µg of RNA was loaded in each lane. The figure reports
results from four separate estrogen induction experiments (1, 2, 3, 4). P: Undigested probe (1% of input
amount); Y: yeast RNA as negative control; L: Size markers (32P labelled pBR322, MspI digest).
      P           +     -     +     -      +       -      +     -      lcl    L
                   P              +      -     +      -     +      -       +      -     lcl     L
                   P             +      -      +     -      +      -       +      -     lcl    L
c-Myc
CyclinD2
GAPDH
Expt:      1          2          3            4
YC
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software, on a PC.  The level of fluorescence on the spots was measured using the
Quantarray software that links each spot on the array to its specific gene identifier,
using a  Clone Tracker  Fi le  protocol ,  avai lable  on l ine
(www.sanger.ac.uk/Projects/Microarrays/informatics/datafiles.shtml). The protocol
contains also information on the geometry of the array, the settings and method for
background subtraction. If the background was too high, the arrays were rewashed
although repeating the experiment or changing batch of slides was always the most
effective solution. Each of the 15,000 spots on the slide was checked by eye on the
computer screen in order to remove those spots that were clearly altered by scratches,
not homogeneous background or grains of dust on the area of the spot. Eventually, the
Genespring software was used to generate graphs (Figure 3.3), ordering genes
according to their expression level in the sample compared to the control. The
software also excludes spots that do not pass basic statistical tests or which cannot be
read due to mechanical alteration of the slide. As a final result, Genespring software
provides a merge value, which is the average of the measurements from each
experiment. To perform Genespring analysis of the arrays, I attended a tutorial 3 day
course at the Wellcome Trust Sanger Institute. In this study, four experiments whose
hybridization passed the quality test imposed by the software and the eye scanning are
presented. The experiments are named after the number of the microarray batch used:
927, 916, 899, 966. Figure 3.3A shows the result of the hybridization on a single
slide, while figure 3.3B shows the merge values from 6 independent hybridizations.
Known targets of EBNA2 were confirmed to be up-regulated, including CR2, CCR7
and GADD45B. c-MYC was detected only in one batch. Sequences from CD23 and
RUNX3 cDNAs were not present on the slides. The fact that c-MYC up regulation
was detected only in one batch could be due to specific characteristics of the slides.
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Some batches resulted in common areas where hybridization signals were masked by
the background. The scatter plots appeared as expected, with most of the genes
undergoing no change.
X-axis: Walter (All Samples) : ...
Y-axis: Walter (All Samples) : ...
Colored by: Walter, All Sampl...
Gene List: all genes (15552)...
100 1000 1e4
100
1000
1e4
wl927-28-08-05tabred.txt (control)
X-axis: Walter (Default Interpr...
Y-axis: Walter (Default Interpr...
Colored by: Walter (Default Int...
Gene List: all genes (15552)...
1000 1e4
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1e4
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Figure 3.3. Scatter Plot generated by Genespring. The plots compare the expressions of cell genes in
EREB2.5 cells treated with estrogens and PSI (sample; Y axis) against EREB2.5 cells treated with PSI
and ethanol (control; X axis). The green lines indicate levels of expression: No variation being the central
one, 2 fold higher the upper one, two folds down the lower one. Red spots correspond to genes which
regulation is increased by estrogen treatment; green spots represent genes whose regulation is decreased.
3A: Scatter plot of a single array. 3B: Merge values of 6 arrays composing one experiment.
A
B
CR2
CCR7
GADD45B
CR2
CCR7
GADD45B
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3.2.4. Identification of new targets
By matching and comparing the results from the different clusters generated
by Genespring analysis of the slides, 7 previously unreported genes were identified
whose expression level was consistently induced following EBNA2 activation (Figure
3.4).
The new genes found were: IRF4, ETS1, DTX1, PTP4A3, DNASE1L3,
PY211, and C1orf38. IRF4 and ETS1 are nuclear transcription factors involved in
activation and differentiation of B cells. IRF4 is part of the Interferon Regulatory
Factors family, is lymphocyte-specific, controls pathways of B cell somatic
hypermutation and promotes differentiation of germinal centres cells (Fillatreau &
Radbruch, 2006, See also section 1.2.4.4). ETS1 (avian erythroblastosis virus E26
oncogene homolog-1) belongs to the ETS family of transcription factors and it is
involved in B cell maturation (Eyquem et al., 2004). DTX1, Deltex-1 is a mammalian
homologue of Drosophila Deltex, and contributes to the Notch pathway by directly
binding the first three ankyrin domains of NOTCH-IC (Jang et al., 2006). DNASE1L3
(DNASE gamma) has recently been associated with formation of double strand breaks
in germinal centres during somatic hyper-mutation (Okamoto et al., 2005). PTP4A3,
belongs to the protein-tyrosine phosphatase family (Sager et al., 2004). C1orf38 gene
(ICB-1, Induced by contact to basement membrane 1 protein) has been discovered
recently and studied as a novel marker for granulocytic and monocytic in vitro
differentiation (Treeck et al., 2002).
3.2.5 Validation of new targets
To confirm the microarray results, a semi-quantitative RT-PCR was
performed on each RNA used in microarray experiments. cDNA was generated using
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M-MuLV reverse transcriptase from total RNA, using oligo dT primers when possible
or random primers when the size of the 3’ exon was longer than 2 kb. Primers were
always designed on different exons across a splice junction of the transcripts in order
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Figure 3.4. Scatter Plot. The details are the same as figure 3.3. 3.4A: Merge of six arrays composing
an experiment. Genes over-expressed in most arrays are highlighted. 3.4B: Expression value of a single
array.
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to avoid amplification from possible genomic DNA contamination. Sequences were
downloaded from the University of California Santa Cruz Genome database
(www.genome.ucsc.edu) and the PCR amplification products were chosen to be
between 200 bp and 600 bp. Primers were tested at different temperatures and number
of cycles; the number of cycles was adjusted according to the abundance of the
specific transcript and conditions well below the PCR saturation point were chosen. 5
µl of a 50 µl PCR reaction was loaded on the agarose gel and visualized by ethidium
bromide staining under UV trans-illumination. For most transcripts, 28 cycles was
found to be optimal for PCR screening. A GAPDH PCR was performed as a control
for each RT-PCR assay.
Among all the genes screened by semi quantitative PCR, DNASE1L3 was the
only gene that showed a pattern of presence/absence (Figure 3.5A).  IRF4, C1orf38,
DTX1 Ets1, PTP4A3 and P2Y11 showed different levels of up regulation (Figure
3.5A). The intensities of the band were read using the software GeneTools and were
compatible with the values obtained by microarray analysis (Figure 3.5B). A sample
of each PCR product was sub-cloned into TOPO-TA vector and sequenced to confirm
the specificity of the PCR reaction.  All PCR reactions amplified the correct products.
3.2.6 Agilent G4122A 44K  microarray analysis
Performing experiments using Hver2.1.1 cDNA spotted arrays from the
Sanger Institute had several drawbacks: it was quite time consuming, the array
covered only part of the whole genome and it was subject to several variables linked
to the nature of the labelling agent and the quality of the batch of slides used.
Moreover, the sequences spotted on the slides derived from long amplifications of
cellular mRNA. This  created  a  background  from  non-specific  binding  and  it  was
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Inefficient in identifying different members of a family of genes. All these drawbacks
were reduced using Agilent G4122A 44K high technology microarrays. These
microarrays consist of 44k features representing the whole human genome. Every
feature is a synthetic 60-mer oligonucleotide, printed using non-contact inkjet
technology. Microarray experiments were carried out using total RNA from EREB2.5
cells treated under the same conditions as for cDNA spotted microarrays. Total RNA
preparations from cell cultures were reverse transcribed into cDNA and subsequently
re-transcribed into Cy3- or Cy5-labelled cRNA, fragmented and hybridized onto the
A
B
Figure 3.5. RT-PCR on selected targets. 3.5A. Results of a 24 cycles GAPDH PCR amplification
from cDNA from two experiments of estrogen induction. This normalized material was used as
template in the PCRs of the present figure. 28 cycles amplifications using primer specific for
DNASE1L3, IRF4, C1orf38, DTX1, PTP4A3, ETS1, PY211. C-: Amplification from mix without
template. Figure 3.5B: The table reports levels of up-regulation of the target genes predicted by
microarray analysis and those measured by the GeneTools software on agarose gel. In column 2 are
reported the standard deviations calculated for each target gene.
Target gene Standard
deviation
Over-expression
(microarrays)
Over-expression
(GeneTools)
IRF4 0.55 2.6 2.8
DNASE1L3 0.87 2.2 presence/absence
PY211 1.24 2.91 1.9
C1orf34 0.85 2.31 2.6
ETS1 0.97 2.38 2.2
PTP4A3 2.5 4.5 2.5
DTX1 1.31 2.6 2.8
DNASE1L3                        IRF4      C1orf38                         DTX1
C-        -       +          C-   -       +        C-      -      +              C-      -         +
PTP4A3            ETS1    PY211 GAPDH
     C-     -       +            C-       -        +  C-     -       +                     -        +
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microarray slide. Three independent experiments were carried out and compared.
Arrays were scanned on an Affymetrix 428 instrument and data were extracted by
using Imagene 5.0 (Spender et al., 2006). This array hybridization was performed at
the Microarray Array Facility at Hannover Medical School. The new array data was
analyzed on Genespring, supported by statistical analysis provided by Dr Rainer Russ
at Genedata AG, Basel. Six RNA preparations derived from three independent
estrogen inductions of EREB2.5 cells and their controls were used in this experiment.
A list of selected genes consistently induced by EBNA2 at the RNA level in
these experiments is reported in table 2. It is notable that out of 44,000 sequences,
representing the whole human genome, less then 50 genes were induced more then
three fold. This is obviously a small percentage of the whole array, which reinforces
the value of this pool of novel identified genes. Less then ten genes showed an
induction higher then 10 fold (+est/-est). Amongst these, c-MYC and PI3KR1 were
already known and published (Kaiser et al., 1999, Spender et al., 2006) and
DNASE1L3 had been already identified in this thesis using the Hver2.1.1 cDNA
spotted arrays. HES1 is a novel potential target of EBNA2, which shows very high
induction and it is a member of the NOTCH pathway (Jarriault et al., 1995). CXCR7
is a newly identified gene, which has been studied recently by Infantino et al and it is
thought to share similarities to CXCR4, sharing also the same ligand, CXCL12, in T
cells. However the relationship to CXCL12 was not confirmed in B cells (Balabanian
et al., 2005, Infantino et al., 2006). All genes previously identified by cDNA spotted
microarray experiments were confirmed.
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GeneSymbol Gene name  +est/-est Std Dev
CXCR7 Chemokin (CXC) receptor 7 17.09 5.6
MYC Myelocytomatosis viral oncogene homolog 16.57 3.51
DNASE1L3 DNASE 1 like 3 15.88 7.33
HES1 Hairy and enhancer of split 1 14.24 1.38
PIK3R1 Phosphoinositide-3-kinase, regolatory subunit 1 11.03 2.54
ABHD6 Abhydrolase domain containing 6 10.77 2.45
PPEF1 Protein phosphatase with EF hand calcium binding 10.08 2.87
CHI3L2 Chitinase 3-like 2 isoform a 7.53 1.46
HEY1 Hairy/enhancer-of-split related with YRPW motif 7.01 3.53
EDG1 Endothelial differentiation, sphingolipid G-protein-coupled receptor 1 6.61 2.66
DNMBP Dynamin binding protein 6.17 0.92
CR2 Complement receptor 2 5.69 1.19
ICOS Inducible T cell co-stimulator 5.39 0.43
GCET2 Germinal centre expressed transcript 2 5.21 0.69
RS1 X-linked juvenile retinoschisis protein 4.47 0.6
ICB-1 Induced by contact to basement membrane 1 4.35 0.71
IL1R2 Interleukin 1 receptor, type II precursor 4.16 2.14
ETS1 v-ets erythroblastosis virus E26 oncogene 4.14 1.77
CCL3L3 Chemokine (C-C motif) ligand 3-like 1 precursor 4.07 0.77
CCL3 Chemokine (C-C motif) ligand 3 4.06 0.76
DTX1 Deltex Homolog 1 4.03 0.75
GNGT2 Guanine nucleotide binding protein-gamma 3.94 0.68
CDKL5 Cyclin-dependent kinase-like 5 3.90 0.16
GADD45B Growth arrest and DNA-damage-inducible, beta 3.88 0.26
BCAP B cell receptor associated protein 3.60 0.3
CD84 CD84 antigen 3.55 0.15
PRICKLE1 Prickle like 1 3.45 0.23
FRMD4A Ferm domain containing 4A 3.41 0.11
IRF4 Interferon regulatory factor 4 3.20 0.4
GMNN Geminina 3.19 1.15
EHD1 EH domain containing 1 3.17 0.78
FNBP1 Formin binding protein 1 3.16 0.23
EBI2 EBV induced G protein-coupled receptor 2 3.16 0.24
GIMAP1 GTPase family member 1 3.13 1.3
NEDD9 Neural precursor developmental down-regulated 9 3.13 0.41
CDH1 Cadherin 1 type preprotein 2.95 0.36
CCR7 Chemokine (C-C) receptor 7 2.90 0.32
CCL4 Chemokine C-C motif ligand 4 isoform 1 2.82 0.53
SLC1A4 Solute carrier family 1, member 4 2.79 0.14
IFIT3 Interferon-induced protein with tetratricopeptide repeats 3 2.76 0.49
PTP4A3 Protein tyrosine phosphatase type IVA, member 3 2.76 0.8
IFIT2 Interferon-induced protein with tetratricopeptide repeats 2 2.75 0.74
ASCL1 Achaete-scute complex homolog-like 1 2.74 0.26
TRPV2 Transient receptor potential cation channel 2.73 0.85
HECW2 HECT, C2 and WW domain containing E3 ubiquitin 2.71 0.35
ABI3 NESH protein 2.65 0.68
TMEM51 Transmembrane protein 51 2.64 0.69
CD300A Leukocyte membrane antigen 2.63 0.57
TMEM2 Transmembrane protein 2 2.61 0.45
P2RX5 Purinergic receptor P2X, ligand-gated ion channel, 5 2.60 0.32
TSC Tuberous sclerosis 1 protein isoform 1 2.59 0.53
EDN1 Endothelin 1 2.50 1.25
RUNX3 Runt-related transcription factor 3 isoform 2 2.50 0.19
SPTBN1 Spectrin, beta, non-erythrocytic 1 isoform 1 2.38 0.1
EHD1 EH-domain containing 1 2.37 0.47
BLR1 Burkitt lymhpoma receptor 1 2.37 0.23
ARHGAP10 Rho GTPase activating protein 10 2.37 0.37
FCRL3 Fc receptor-like 3 precursor 2.35 0.63
CD69 CD69 antigen 2.33 0.24
CXXC5 CXXC finger 5 2.33 0.15
Table 2: Selected direct targets of EBNA2 in EREB2.5 cells
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3.2.7 Western blot of IRF4
Interferon Regulatory Factor, 4, (IRF4), was induced consistently in all
microarray experiments and confirmed by RT-PCR. Its role in B cell development is
well established (Fillatreau & Radbruch, 2006) but IRF4 protein expression in
EREB2.5 cells and its relation to EBNA2 were unknown. IRF4 induction at the
protein level was confirmed in EREB2.5 cells in western blot analysis. EREB2.5 cells
treated with estrogen in the absence of protein synthesis inhibitors were harvested
after 0, 4, 6, 8, 24 hours. Cell pellets were extracted with RIPA buffer and protein
concentration was measured using a BioRad colorimetric protein assay, measuring the
absorbance at 750nm. 40 µg of protein extract for each sample was analysed by SDS-
PAGE and hybridized with the rabbit anti-IRF4. A steady increase in protein level
was noticed for IRF4 after 4, 6 and 8 hours. The level appeared to rise dramatically
after 8 hours and this could suggest that the protein is subjected to additional
secondary regulation (Figure 3.6).
3.2.8 IRF4 is linked to EBNA2 expression in different B cell lines
 IRF4 is known to be expressed at high levels in memory B cells and in Plasma
cells (Teng et al., 2007). Its expression is usually reciprocal to the expression of Bcl6
that is a marker of germinal centre B cells (Cattoretti et al., 2006). A panel of
Figure 3.6. Western blot analysis  of expression of IRF4.  50 µg of protein extract from EREB2.5
cell line was loaded per lane. EREB2.5 cells were treated with 1µM estrogen, in the absence of protein
syntesis inhibitors, for different time periods (0 to 24 hours). (+): estrogen treated. (-): not estrogen
treated. Actin: (43Kda) is a loading control. IRF4 recognizes a band of 51KDa.The nearest size marker
band of the protein ladder is reported for each detected protein.
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lymphoma cell lines was used to test for a correlation between EBNA2, IRF4 and
BCL6 expression (Table 3). The panel contained Group I, II and III Burkitt cell lines
since only group III will express EBNA2 and might be expected to express IRF4.
LCLs and EBV negative Burkitt line infected with P3HR1 (EBNA2 negative) or B95-
8 (EBNA2 positve), were also included. As expected, IRF4 expression was high in
Karpas-620, a plasma cell cancer line, and was also expressed strongly in extracts
from EBNA2 positive cell lines (Jijoye, IB4), (Figure 3.7). P3HR1 cells, (that have a
deletion of the EBNA2 locus), were negative for IRF4. Extracts from EBV negative
BL41 cells infected with P3HR1, gave a negative signal but a positive signal when
infected with B95-8 EBV. Group I and II EBV positive BL cell lines, did not show
any expression of IRF4. There were also some unexpected findings. Elijah is
normally a group I BL cell line but expressed a high level of IRF4. The cell line
turned out to have drifted in culture expressing both IRF4 and high levels of EBNA2.
Raji is an EBNA2 positive group II BL cell line but did not show any IRF4
expression, perhaps because EBNA2 expression is very low in this line. BCL6 protein
expression correlated negatively with the expression of EBNA2 and IRF4, indicating
a probable interplay among these genes. Since this experiment was performed, a
recent paper from Boccellato et al has shown that BCL6 is directly negatively
regulated by EBNA2 (Boccellato et al., 2007).
3.2.9 Knock down of IRF4 in EREB2.5 cells
IRF4 is a direct target of EBNA2 that has been identified in the present work.
64-nt oligonucleotides specific for puro-oriP-SUPER vector mediated shRNAi were
designed using the OligoEngine3.0 software, in order to assess its role in B cell
proliferation. Oligonucleotides  were cloned  into puro-oriP-SUPER under the control
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of the H1 promoter. EREB2.5 cells were transfected with vectors against IRF4, p53
and a control vector. The Amaxa nucleofector kit using buffer T1 was used to
increase efficiency. Puromycin was added 24 hours after transfection and cells were
grown in the presence of estrogen as usual. At days 6, 9, 12 and 15 cells were counted
Table 3. The table reports cell lines used in the following western blot . Correlation between IRF4
and EBNA2 is reported. Burkitt lymphoma (BL) groups are indicated. HGL: High grade lymphoma.
Figure 3.7. Western blot analysis of IRF4/BCL6 correlation of expression. 50 µg of protein extract
from each cell line was loaded in every lane, and blotted with antibodies against IRF4 (51KDa), BCL6
(60KDa) and EBNA2 (78-84 KDa). In red are reported cell lines which express EBNA2 and IRF4,
and result negative for BCL6. Actin is a loading control. The nearest size marker band of the protein
ladder is reported for each detected protein.
                       Bjab       DG75    MutuI    Rael     Wewak Jijoye   P3HR1   BL41/P3HR1
                            Karpas    Mak1    Akata    Elijah    Raji      BL37     IB4       BL41/B95-8
IRF4
EBNA2
ß Actin
*
BCL6
BCL6: expressed by centroblasts and centrocytes
IRF4: expressed by late centrocytes and post-germinal center
 [GC] B cells
BCL6/IRF4 EXPRESSION
Cell line Description IRF4 EBNA2 EBV
Bjab HGL Negative Negative -
Karpas Plasma cell Positive Negative -
DG75 BL Negative Negative +
Mak1 BL I Negative Negative +
MutuI BL I Negative Negative +
Akata 2000 BL I Negative Negative +
Rael BL I Positive Negative +
Elijah BL I(Drifted) Positive Positive +
Wewak BL I Negative Negative +
Raji BLII Negative Positive +
Jijoye BLIII Positive Positve +
BL41 BL Negative Negative +
P3HR1 BLII Negative Negative +
IB4 LCL Positve Positive +
BL41/P3HR1 BL(II) Negative Negative +
BL41/B95-8 BL(III) Positive Positive +
50KD
60KD
80KD
40KD
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using trypan blue exclusion (Figure 3.8A). No difference in the number of cells
between the transfected samples was noticed over the time. At days 9, 12 and 15
aliquots were harvested for western blot analysis of IRF4 expression and FACS cell
cycle analysis by staining with Propidium Iodide, PI (Figure 3.8B). The data shown in
the figure comes from the only one of three shRNA sequences tested that gave a
successful down-regulation of IRF4. It therefore appears that knockdown of IRF4 to
the extent achieved in this experiment does not impair LCL proliferation or survival.
Unexpectedly, IRF4 protein expression decreased also in EREB2.5 cells
transfected with p53 RNAi vector perhaps suggesting that p53 regulates IRF4 but this
was not explored further. No major alteration of the cell cycle was noticed; just a
slight accumulation in G1 in all samples at day 15 due to slight over growth of the
cells in the wells also noticed in the cell count.
3.2.10 DTX1 is a target of EBNA2 in EREB2.5 cells
In order to study DTX1 protein expression in EREB2.5 cells, mouse
monoclonal antibodies were raised against the C-terminal part of DTX1. Full details
of the MoAB production are given in the material and methods chapter, section 2.5.8.
Here the final western blot showing DTX1 expression in a typical time course of
estrogen activation of EBNA2 is illustrated in figure 3.9. DTX1 expression clearly
increased following EBNA2 induction, confirming that DTX1 is a target of EBNA2
in B cells. The same approach was used for detection of DNASE1L3 but, although the
antibody worked correctly on the in vitro translated protein, it failed to detect
DNASE1L3 consistently in EREB2.5 cells.
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Figure 3.8 IRF is not involved in proliferation of LCLs. 3.11A: Western blotting for IRF4. EREB2.5
cells transfected with shRNA vectors against IRF4, p53 and control were harvested at days 9, 12 and 15
after transfection. Protein extracts were obtained by RIPA buffer extraction. 30 µg of each sample were
run on SDS-PAGE and transferred on nitrocelluose. The three lanes, at each time point, represent
protein extracts from IRF4 (51KDa), p53 and CTRL RNAi transfections. Actin is a loading control.
3.11B:  PI staining: EREB2.5 cells were harvested at the same time, dehydrated over night and stained
with PI at dark for 30 minutes after re-hydration in PBS. Samples were analysed at the FacsCalibur
using the FL2-A channel.
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DTX1
ACTIN
  T0          6h              8h              24h
            -        +      -         +        -       +            Est
Figure 3.9. DTX1 is a target of EBNA2 in EREB2.5 cells. EREB2.5 cells (1X105/ml) were treated
or untreated of 1µM estrogen, at different times, in the absence of protein synthesis inhibitors.
Protein extracts were obtained by RIPA buffer extraction and 30 µg per sample were run on SDS-
PAGE. The monoclonal antibody against DTX1 (60 KDa)obtained from ascites of immunized mice
was used at a dilution of 1/200 in 10% milk/PBS. The nearest size marker band of the protein ladder
is reported for each detected protein.
60KD
40KD
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3.3 Discussion
In the present work two different microarray systems were used to identify
direct targets of EBNA2 in EREB2.5 cells: the Hver2.1.1 cDNA spotted microarrays
carrying features for 7,000 human genes (Wellcome Trust Sanger Institute) and the
Human 44k 60-mers printed array (AgilentTechnology) representing the whole
human genome. These studies, allowed the identification of about 50 genes whose
expression varies directly as a result of EBNA2 induction. Amongst these, are
included established direct targets of EBNA2 in B cells like, c-MYC (Kaiser et al.,
1999), CCR7 (Birkenbach et al., 1993), CR2 (Cordier et al., 1990), RUNX3 (Spender
et al., 2002) and BATF (Johansen et al., 2003). From the analysis of cDNA spotted
arrays, additional novel target genes were identified and some of these (IRF4, DTX1
and DNASE1L3) were studied in more detail.
From the Agilent microarray data, CXCR7 was the gene with the highest level
of induction in response to EBNA2 activation. Further studies on this gene will be
presented in the final chapter. The gene list is quite heterogeneous, showing that
EBNA2 plays a critical role in different pathways of the B cell metabolism but the
genes can be grouped in members of the NOTCH pathway, cytokines and cytokine
receptors, proteins involved in endocytosis and recycling, and transcription factors
specific to post germinal centres, germinal centre or B cell differentiation (Table 4).
IRF4 induction was confirmed for the first time at the protein level in
EREB2.5 cells, and in Burkitt lymphoma cells it tightly follows EBNA2 expression,
whereas BCL6 is negatively regulated in the same lines. After these data had been
obtained, another group also showed that BCL6 is directly down regulated by
EBNA2, mediated by RBP-Jk interaction (Boccellato et al., 2007). In this thesis, IRF4
protein  expression was  knocked down by  RNA interference assay.   EREB2.5  cells
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showed no change in the proliferation in the absence of the IRF4 protein. This result
is not surprising since knock out of IRF4 in mouse system does not interfere with B
cell growth but rather with critical differentiation steps (Mittrucker et al., 1997, Lu et
al., 2003, Klein et al., 2006). Mittrucker et al, in fact showed that B cells in the bone
marrow of IRF4 double mutant mice proliferated normally until week 5. From week
10, the differentiation stalled at the pre-B cell stage, presenting an abnormally
enlarged IgM+ /IgD- population compared to the IgM-/IgD+ and the absence of
Gene Description Function Bibliography
Notch Pathway
   HES1 Hairy and enhancer of split 1 Notch effector, differentiation
of hematopoietic stem cells
Zeidler-McKay et al, 2005
   DTX1 Deltex homolog 1 Expressed in germinal centre B cells Storck et al, 2005
   HEY1 hairy/enhancer-of-split related
 with YRPW motif
Trascriptional repressor,
Inhibits lytic cycle entry in KSHV
Oswald et al, 2005;
Yada et al, 2006
   ASCL1 achaete-scute complex homolog 1 Repressed by NOTCH1 Kunnimalaiyaan et al 2006
Cytokines, receptors,
signal transduction
   CD21/CR2 Complement component receptor 2 EBV receptor Nemerow et al, 1987
   ICOS Inducible T cell co-stimulator Critical role in CD40-mediated class
switching of immunoglobin isotypes
McAdam et al, 2001
   CXCR7 Chemokine (CXC) receptor 7 G protein coupled receptor Infantino et al, 2006
   CCR7 Chemokine (C-C) receptor 7 G protein coupled receptor, cell migration Cahir-McFarland et al, 2004
   CCL3 Chemokine (C-C) ligand 3 Monocyte inflammatory protein,
induced by RUNX1
Choi et al, 2003
   CCL3L3 Chemokine (C-C) ligand 3-like 3 Similar to CCL3
   GCET2 Germinal centre expressed transcript 2 Membrane adaptor protein,
Expressed in normal and malignant
GC lymphocytes
Pan et al, 2007
   EDG1 endothelial differentiation,
sphingolipid G-protein-coupled receptor 1
G protein coupled receptor,
required lymphoid organ egress
Matloubian et al, 2004
   NEDD9 Neural Precurson
Developmentally Down-regulated 9
Adaptor protein, target of TGF-beta Zheng et al, 2003
PI3K pathway
   PI3KR1 phosphoinositide-3-kinase,
regulatory subunit 3 (p55, gamma)
Subunit 55-alpha involved in B cell survival Spender et al, 2006
   BCAP phosphoinositide-3-kinase,
adaptor protein 1
Couples B-cell receptor
to PI3K activation
Endocytosis,
recycling
   EHD1 EH domain containing 1 clathrin-coated pit-mediated endocytosis Caplan et al, 2002
   FNBP1 formin binding protein 1 Required to coordinate reorganization
of cytoskeleton during endocytosis
Tsujita et al, 2006
   DNMBP Dynamin Binding Protein Membrane trafficking between
the cell surface and the Golgi
Salazar et al, 2003
Transcription factors
   RUNX3 Runt related transcription facto 3 Context dependent
tumor suppressor or oncogene
Spender et al, 2002;
Spender et al, 2005
   IRF4 Interferone Regulatory Factor 4 Critical for B cell class switch
and somatic hypermutation
Fillatreau et al, 2006
   ETS1 v-ets erythroblastosis virus E26
oncogene homolog 1
Regulator of peripheral
 B cell differentiation
Wang et al, 2005
   CXXC5 CXXC finger 5 Suggested to be involved I
n Wnt and NFKB pathways
Katoh and Katoh, 2004
Table 4. Selected EBNA2 target genes grouped by function
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germinal centres. Purified B cells did not show a proliferative response to anti-IgM
and LPS administration, but they proliferated normally in response to anti-CD40
stimulation (Mittrucker et al., 1997). Studies by Klein et al using conditional knock
down of IRF4 at the germinal centre stage showed that IRF4 is crucial not only for the
early development of B cells but also for the development post germinal centre,
particularly for the maintenance of memory B cells and for the differentiation into
plasma cells (Klein et al., 2006, Sciammas et al., 2006). On the other hand it is
important to point out two caveats in the experiment: first the knock down of IRF4 at
the protein level is only partial, leaving the question of whether the absence of growth
inhibition on EREB2.5 cells is due to a real lack of IRF4 involvement in B cell
proliferation or whether the remaining cellular protein is still able to exert its function.
Second, IRF4 RNAi induced a negative effect on p53 that was used as a control in the
experiment. This effect shows that p53 is not the ideal control for this particular
experiment and should be replaced with a different control. However, the parallel
down regulation of BCL6 raises interesting questions on the function of EBNA2 in
infection in vivo. BCL6 is a crucial gene expressed in germinal centre and is essential
for proliferation of GC blasts (Schaffer et al., 2000). The down regulation of a critical
germinal centre gene in favour of a memory B cell/plasma cell gene seems to indicate
that the virus has evolved to avoid the stage of proliferation, but rather is trying to
gain access to the memory compartment. IRF4 in fact is not expressed in the passage
of B cells through germinal centre, and its down regulation coincides with BCL6
induction that allows somatic hyper-mutation and proliferation (Klein et al., 2003). In
the EBV context, initial proliferation would be promoted by other viral and cell genes
induced by EBNA2 (c-MYC, CD23, RUNX3, LMPs).  The infection of a naïve B cell
could produce a differentiation toward a memory cell in the absence of somatic hyper-
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mutation due to the lack of BCL6, whereas the direct infection of a memory B cell
could lead to terminal differentiation into plasma cells with shedding of the virus by
lytic cycle activation. Recent work by Kurth et al, has shown that EBV positive B
lymphocytes of IM patients do not participate in the somatic hyper-mutation reaction
(Kurth et al., 2003). The general picture is indeed very complex and it cannot be
separated from the context of immune reaction from the host, which adds positive
(cytokine signalling) and negative (CD8 T cells) regulation mechanisms to EBV
infection.
 EBNA2 binds to DNA promoters using cell co-transcription factors like RBP-
Jk (Henkel et al., 1994), PU.1 and the AP-2 complex (Jansson et al., 2007). RBP-Jk is
involved also in the binding of NOTCH-IC to gene promoters (Fortini & Artavanis-
Tsakonas, 1994). The NOTCH pathway is involved in critical steps of the
development and differentiation of both B and T cells (reviewed in Dallman et al.,
2005). It is useful to investigate which genes that are induced by EBNA2 belong to
the NOTCH pathway. Huang et al, performed extensive studies on gene expression
regulated by NOTCH-IC in T cell differentiation (Huang et al., 2004), identifying
CCR7 and CyclinD2 as common targets. By comparing the Huang et al data with the
present work several common genes are easily identified, particularly HES1, DTX1,
HEY1 and IRF4. Others show an opposite behaviour. ASCL1, is induced by EBNA2,
but is inhibited by NOTCH1 in thyroid cancer cells (Kunnimalaiyaan et al., 2006).
CD69, which appeared to be induced in the present work, seems to be down regulated
by NOTCH in T cells. BCL6, is induced by NOTCH in T cells but in this work and in
Boccellato et al, BCL6 is actually down regulated by EBNA2 (Boccellato et al.,
2007). These data are a reflection at the molecular level of the fact that EBNA2
replacement by NOTCH only partially rescues the proliferation in B cells (Gordadze
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et al., 2001). HES1 is a NOTCH effector involved in T cell differentiation, but ectopic
expression in the absence of NOTCH only produces a block in B cell development
rather then promoting T cell differentiation (Hoebeke et al., 2006). Interestingly,
when over-expressed in B cell malignancies, IRF4 also induces growth arrest (Teng et
al., 2007, Zweidler-McKay et al., 2005).  These results are quite unexpected when
associated to a gene that is involved in B cell proliferation. In the context of viral
infection, these effects could be masked by viral LMP1 and LMP2A, which also
activates the NOTCH pathway (Anderson & Longnecker, 2008), and cell genes like c-
MYC, CCL3, CCR7, all induced by EBNA2 and having strong positive effects either
on cell proliferation or survival. Moreover, CD24, one of the most down regulated
genes in this work and in Maier et al, is known to be a strong pro-apoptotic gene in B
cells (Maier et al., 2006), and also to inhibit B cell differentiation towards antibody
secreting cells (Suzuki et al., 2001, Taguchi et al., 2003). In this context, other
pathways induced by HES1 and IRF4 could be usurped by EBV to establish long term
infection and promote cell differentiation. It is important to remember that NOTCH1,
when expressed in hematopoietic stem cells, directs the differentiation of T cell at the
expense of B cells and knock down of NOTCH hijacks T cell to B cell differentiation
(Wilson et al., 2001), but nevertheless, NOTCH1 is involved in later events of
terminal differentiation of B cells (Santos et al., 2007).  In addition, NOTCH2 is
crucial for memory cell development (Saito et al., 2003).
DTX1 whose protein induction by EBNA2 was confirmed in EREB2.5 cells is
a negative regulator of NOTCH1 in T cell development but is induced by NOTCH2
that is positively involved in post germinal centre B cell development (Saito et al.,
2003). All these data confirm that the EBNA2 relationship to NOTCH has to be
analyzed in the context of the stage of differentiation at which EBV infection occurs,
136
which may be more then one. Although this list represents a very appealing source for
the development of future projects, it should be stressed that most of these genes have
been confirmed and measured using non-quantitative PCR. The switch to real time
PCR would give a clearer picture of what is the real extent of differential expression
in EREB2.5 cells in response to EBNA2 activation.
Monoclonal antibodies raised against DNASE1L3 failed to prove an induction
in B cells probably due to the very low expression. DNASE1L3 has been linked
recently to the formation of DNA breaks during germinal centre reaction, and the
expression is controlled via CD40 activation (Okamoto et al., 2005).
The induction of genes involved in the endocytosis pathway and
trafficking/recycling through the Golgi is another interesting point. These processes
are involved in maintenance of the EBV infection, for example the up-take and
recycling of the LMP proteins. LMP1 has a very short half life and must be recycled
frequently (Aviel et al., 2000) since over expression of LMP1 results in toxicity (Lee
& Sudgen, 2007). The induction of endocytosis and endosome to Golgi recycling
could be a mechanism that EBV adopts to potentiate the effects of LMP1, which
shows some self-regulation (Lee & Sudgen, 2007).
In summary, EBNA2 activates in B cells many genes affecting different
aspects of the B cell metabolism, suggesting a prominent role for EBNA2 in a more
concerted scenario and not only restricted to B cell proliferation, as often described.
137
4. Assay for the study of EBNA2 type 1 and type 2 effects on cell
proliferation
The aim of this chapter and the following one is to investigate the molecular
basis of EBNA2 type 1 and type 2 differential effects on cell gene regulation and B
cell proliferation, using the EREB2.5 cell line as system.
4.1 Introduction
Studies by Rickinson et al, in 1987, using different strains of the two virus
types, showed clearly that EBV type 1 is much more effective at immortalizing B
cells (Rickinson et al., 1987). Cohen et al demonstrated that this phenotype is linked
to the EBNA2 polymorphism (Cohen et al., 1989). Although much is known about
the in vitro physiology of EBV type 1, relatively few publications are devoted to
EBNA2 type 2.
The previous experiments by Rickinson et al did not study EBNA2 function in
isolation from other variables. EBV polymorphism involves several genes in addition
to EBNA2 and all these genes might influence immortalization and proliferation
efficiency. In fact, although B cell immortalization and B cell proliferation was shown
to be very different between type 1 and type 2 EBV, some remarkable variation was
present among different strains of the same type. Also in the experiments of Cohen et
al, EBNA2 function is addressed in the context of EBV infection. That study used
recombinant EBV strains in which the EBNA2 deleted strain P3HR1 had been
converted to a “wild type” structure, by inserting EBNA2 type 1 or type 2 sequences.
The resultant recombinant strains were then used to infect and immortalize resting B
cells. It has been shown that EBV infection itself leads to the activation of the cell
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cycle and to induction of B cell activation markers. All these mechanisms could
partially complement EBNA2 type 2 effects.
The EREB2.5 cell line offers an opportunity to test EBNA2 effects on B cell
proliferation in isolation from other variables related to B cell metabolism or variation
in EBV strain or the process of infection. The aim was to transfect plasmids
expressing constitutive EBNA2 type 1 or type 2 into estrogen starved EREB2.5 cells
and to monitor the effects on gene regulation and cell growth. Both p554 and pAG1
vectors express the EBNA2 protein from the Wp promoter. Comparing it to the
Rickinson and Cohen experiments, this system is less close to the wild type condition,
but it depends exclusively on EBNA2 function.
Regulation of the LMP1 gene by EBNA2 is crucial in relation to EBV
infection of B cells in vivo since LMP1 is essential for conferring survival ability to
the cell (Zimber-Strobl et al., 1996) and also co-operates with EBNA2 in B cell
regulation, as for example in the control of the expression of CD23 (Wang et al.,
1987, Wang et al., 1990a). Wang et al showed that EBNA2 type 1 and type 2, when
expressed acutely in Daudi cells, activated LMP1 at the same level (Wang et al.,
1990b) and the same result was confirmed by Jansson et al in a very recent paper
devoted to the study of the LMP1 promoter regulation (Jansson et al., 2007).
Knowledge of LMP1 regulation comes from studies where either EBNA2 is acutely
expressed from an expression vector or is based on techniques like transfection or B
cell immortalization. These assays are unsuitable for the investigation of the kinetics
of induction in response to EBNA2 type 1 and type 2. For this purpose, a system was
created based on a Daudi Burkitt lymphoma cell line, expressing conditional EBNA2
type 1 or type 2. Daudi cells carry an EBV strain with a deletion in the EBNA2 locus.
As a consequence of the lack of EBNA2, LMP1 is not expressed whereas the P3HR1
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cell line that has a similar deletion usually expresses a low level of LMP1 even in the
absence of EBNA2 (Cohen et al., 1989). Introducing an EBNA2 type 1 or type 2
fused with the estrogen receptor into Daudi cells, allows the fine control of EBNA2
and consequently that of LMP1. The ER-EBNA2T1/T2 proteins are expressed from
the wild type Wp promoter as described in section 2.2.15.
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4.2 Results
4.2.1 PE2 antibody reacts equally with EBNA2 type 1 and type 2
Since the experiments performed in the present and in the next chapter involve
comparison of the effects of EBNA2 type 1 and type 2 in B cells, it was important to
understand whether the PE-2 antibody used to detect expression of EBNA2 reacts
equally with both types. To this end, EBNA2 type 1 and type 2 coding regions were
cloned into the pSP64 expression vector as described in section 2.5.6.  EBNA2 type 1
has 10 methionine residues whereas type 2 has 9. Each vector was used for in vitro
transcription and translation to produce protein that was labeled with 35S-Met in rabbit
reticulocyte extract (TnT lysate system, Promega). Different dilutions of the resulting
proteins were run on SDS-PAGE and blotted on nitrocellulose (Figure 4.1A). The
filters were hybridized with the PE2 antibody and the intensity was detected by ECL
and the radioactive incorporation by exposure to a phosphorscreen. Images obtained
with the two methods were analyzed using ImageQuant5.0 software (Figure 4.1B).
The ratio of intensities read by western blot were similar to those read by
phorphorscreen confirming that the antibody reacts equally with the two EBNA2
types in this western blotting assay.
EBNA2T1
EBNA2T2
      35S PI                                 WB
Figure 4.1. Comparison of detection of EBNA2 type 1 and type 2 by western blot using the PE-2
antibody. 4.1A. SDS-PAGE of serial dilution of in vitro translated, 35S-methionine labelled, EBNA2T1
and T2 detected at the phosphorimager (PI) and by ECL revelation of the PE-2 antibody (WB). 4.1B.
Normalization of  the values from different dilutions of EBNA2 type 1 and 2, in figure section A,
detected by ECL revelation or phosphorimager. The value for the intensity of the strongest band of
EBNA2 T2 detected by PI was set as 100%; all other values were normalized against that. 20µCi of 35S-
metionine were used in each 50µl TnT reaction.
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4.2.2 EBNA2 type 1 and type 2 expression vectors
The ability of the newly constructed pERT2 vector to express EBNA2 type 2
was tested using CaPO4 transient transfections into 293 cells. 5µg of p554, pAG1 and
an empty vector were transfected into 293 cells. Circular maps of p554 and pAG1
vectors are shown in figure 4.2.
Cells were incubated for 48 hours after which cells were scraped off the plate and
washed in PBS before lysis in RIPA buffer. A western blot for EBNA2 on protein
extracts derived from two transfections using p554 (type 1) and pAG1 (type 2)
showed that both EBNA2 type 1 and type 2 were expressed correctly. 40µg of protein
extract from transfected 293 cells was loaded per lane on SDS-PAGE, and the same
amount of protein extract, from type 1 LCL, B95-8 and type 2 cell line, AG876, was
loaded as control. Both vectors expressed a protein of the expected size and were
recognized by the PE-2 mouse monoclonal antibody against EBNA2 (Figure 4.3).
Figure 4.2. Circular maps of p554 (EBNA2 type 1) and pAG1 (EBNA2 type 2) vectors.
Constitutive EBNA2 type 1 and type 2 are expressed from the EBV wild type Wp promoter. The oriP
allows the maintenaince of the vectors during cell division, when EBNA1 is expressed.
oriP
Wp
EBNA2T1
  p554
oriP
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EBNA2T2
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4.2.3 Proliferation assay: EBNA2 type 1 but not type 2 sustains cell
growth
EREB2.5 cells in exponential growth were transfected with p554 or pAG1
vectors. An empty vector was transfected as control. After transfection, cells were re-
suspended in estrogen free medium to select cells whose growth is independent of
estrogen, having replaced the use of the conditional EBNA2 with the constitutive
EBNA2 type 1 or type 2 expressed from p554 and pAG1 vectors. 3H-thymidine
incorporation was measured to compare cell DNA synthesis sustained by either
EBNA2 type 1 or type 2 in the absence of estrogen. Figure 4.4 shows that 2 days after
transfection, the incorporation of radiolabelled thymidine is higher in EBNA2 type 1
transfected cells then with type 2, even though EBNA2 type 2 seems able to promote
some DNA incorporation compared to the control. EREB2.5 cells transfected with
EBNA2 type 1 continued to grow indefinitely whereas EBNA2 type 2 transfected
cells could not sustain the initial level of DNA synthesis and after 3 days
Figure 4.3.  Western blot of EBNA2 in transient transfection of p554 (T1) and pAG1 (T2)
vectors into 293 cells. 2X106 293 cells were transiently transfected with calcium phosphate using
5µg of p554 and pAG1 vectors. Cells were lised in RIPA buffer 24 hours post transfection. 40µg of
protein extract were loaded per lane on SDS-PAGE. B95-8 is the prototype EBV type 1. AG876 is
the prototype EBV type 2 and were used as positive controls. PE2 antibody is used to detect EBNA2
type 1 (84KDa) and type 2 (78KDa) in all lanes. The nearest size marker band of the protein ladder is
reported for each detected protein.
B95-8 AG876                    293s
                            T1      T1      T2     T2
80KD
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progressively decreased to basal levels.
Cells were harvested at days 3, 4 and 5, since this period encompasses the key
point of difference in 3H-thymidine incorporation. Protein extracts were generated by
RIPA buffer extraction. Western blotting for EBNA2 type 1 and type 2 confirmed the
trend already described by measurement of DNA synthesis. In fact, EBNA2 type 1
was found to increase in expression across the time period whereas EBNA2 type 2
slowly decreased at day 5 (Figure 4.5A). LMP1 induction by EBNA2 type 1 and type
2 was almost identical up to day 4, but decreased in extracts from the EBNA2 type 2
transfection, at day 5.  RUNX3, a well established target of EBNA2 type 1, appeared
to be induced in all transfections until day 3 but then was maintained only by EBNA2
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Figure 4.4. Trans –complementation in EREB2.5 cells. 5X105  EREB2.5 cells were washed to
remove estrogen and transfected in the absence of estrogen, with 5µg of p554 (T1) and pAG1 (T2)
vectors, expressing constitutive EBNA1 type 1 and type 2. At day 3, 4 and 5 post transfection, cell
growth was measured by 2 hours pulse labelling with 3H-thymidine and cell harvesting using the
Skatron cell harvester
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type 1. The novel target IRF4 was instead present only in EBNA2 type 1 transfections
at day 3, 4 and 5. The kinetics of these two genes was different but the result was
identical: only type 1 was able to maintain the expression in the absence of estrogen.
Several weeks after transfection only EREB2.5 cells transfected with constitutive
EBNA2 type 1 gave rise to clones that grow indefinitely in the absence of estrogen
(Figure 4.5B).
4.2.4 Attempt to stably transfect EBNA2 type 2 into EREB2.5 cells
The trans-complementation system demonstrated that only EBNA2 type 1 supported
proliferation in the long term, suggesting that in the context of viral infection other
factors can play an important role which complement for EBNA2 type 2 deficiencies.
To try to investigate EBNA2 type 2 effects more directly, a further development was
devised expressing constitutive EBNA2 type 2 in EREB2.5 cells. In the presence of
estrogen the cell would grow sustained by EBNA2 type 1 expression but upon
removal of the estrogen, ER-EBNA2 would cease its effects and the cells would rely
only on EBNA2 type 2. Since the population would be homogeneous it should be
possible to monitor very precisely the pattern of EBNA2 target genes after switching
from EBNA2 type 1 to type 2. Because the endogenous ER-EBNA2 plasmid in
EREB2.5 cells already carries G418 resistance, it was necessary to clone the EBNA2
type 2 sequence into a p294 expression plasmid carrying hygromycin resistance.
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Vectors expressing EBNA2 type 1 and type 2 were created by cloning the
EBNA2 type 1 and type 2 coding regions from p554 and pAG1, together with their
wild type Wp promoters, into p294 vector. The final vectors were transfected into 293
cells, protein extracts were obtained by RIPA buffer extraction and 40µg per sample
was run on an SDS-PAGE gel. As a control an empty p294 vector and a p294
expressing EBNA1 were transfected, RIPA extracted and run together on SDS-PAGE
(Figure 4.6).
Figure 4.5A. Molecuar events following EBNA2 transcomplementation. Western blot of extracts
from previous transfections at day 3, 4 and 5 were assayed for the expression of EBNA2 type 1 and 2,
LMP1 (71KDa), RUNX3 (46KDa), IRF4 (51KDa) and Actin (43KDa) as a loading control. 5x105
cells from each transfection were lysed in RIPA buffer and loaded on SDS-PAGE 5B. Phase contrast
images of cells 14 days after tranfection. Only EREB2.5 cells transfected with p554 show cluster
typical of proliferating LCLs. PE2 antibody has been used to detect both the conjugated ER-EBNA2
and the wild type EBNA2 (84KDa). 1, 2 and 3 are clones of LCLs growing in the absence of estrogen.
E2.5: EREB2.5 expressing ER-EBNA2 (120KDa). The nearest size marker band of the protein ladder
is reported for each detected protein.
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The PE2 antibody against EBNA2 detected protein of the expected size. EREB2.5
cells were transfected with the novel p294-EBT1/EBT2 vectors and selected 24 hours
after transfection by adding various concentrations of hygromycin. Unfortunately,
none of these conditions allowed the selection of an EREB2.5 cell line stably
expressing the transfected vectors.
4.2.5 Production of DAUDI cells expressing conditional EBNA2 type
1 and EBNA2 type 2
Past experiments by Wang et al, and Johansson et al, reporting similar levels
of LMP1 activation induced by EBNA2 type 1 and type 2 detected LMP1 induction 3
to 4 days after transfection with EBNA2 expressing vector or infection with EBV.
There are no data available on the early effects of EBNA2 type 1 and type 2 on LMP1
induction. Daudi cells are EBV positive Burkitt lymphoma cells that carry a defective
EBV strain that lacks the EBNA2 locus.
To create Daudi cell lines that express conditional EBNA2 type 1 or type 2
fused with the estrogen promoter, p554-4 vector and pERT2 expressing ER-EBNA2
type 1 and type 2 respectively, were transfected into Daudi cells and G418 selection
was started 24 hours after transfection. After three weeks of selection, with re-feeding
Figure 4.6  Calcium phosphate transient transfections of 2 dilutions of p294-T1 (T1) and p294-T2
(T2) vectors into 293 cells. 5X105 293 cells were transfected with 4 and 8 µg of p294-T1 and p294-T2
expressing EBNA2 type 1 (84KDa) and type 2 (78KDa). 24 hours post transfection 40µg of protein
extract was loaded on each lane of the SDS-PAGE and revealed with the PE-2 antibody. C: empty
vector. WT: Untransfected 293s. The nearest size marker band of the protein ladder is reported for each
detected protein.
T1       T1       T2      T2       C        T1       T1       T2        T2      C        WT
 4µg                                              8µg
80KD
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every 2 days, cells started growing out in both populations. Positive wells were
selected and estrogen was administered to test the function of the fusion proteins.
Both type 1 and type 2 EBNA2 proteins appeared at the expected position on SDS-
PAGE according to their molecular weight. Estrogen stabilized their expression and
affected their mobility on SDS-PAGE as observed also in EREB2.5 cells (Figure 4.7).
EBNA2 type 2 was always expressed at higher levels than EBNA2 type 1.
4.2.6 Kinetics of the early induction of LMP1
Daudi cells expressing conditional ER-EBNA2 type 1 and type 2, were treated
with estrogen or with the same amount of solvent (ethanol), as a control. Samples
were collected at various times after induction and protein extracts were analyzed by
western blotting (figure 4.8). Detection with PE2 antibody against EBNA2 showed
the stabilization of both EBNA2 proteins, with more type 2 EBNA2 expressed. LMP1
was induced at similar levels after 48 hours of estrogen administration but the kinetics
during the first 24 hours were different. EBNA2 type 1 induced LMP1 acutely with a
peak after 16 hours, decreasing by 48 hours, EBNA2 type 2 induced LMP1
expression gradually, reaching approximately the same level after 48 hours.
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Figure 4.7.  Complementation of EBNA2 deletion in DAUDI Bukitt lymphoma cells.  Western blot
of protein extracts from DAUDI cells expressing conditional ER-EBNA2 type 1 (120KDa) and ER-
EBNA2 type 2 (114KDa) treated and not treated with estrogen during 4 hours. Actin is a loading
control. To produce stable lines of DAUDI cells, 5X106 cells were electroporated with p554-4 and
pERT2 vectors expressing EBNA2 type 1 and type 2 fused with the estrogen receptor. 400µg/ml G418
was added 24 hours post transaction until stable clones arised from the culture. The nearest size marker
band of the protein ladder is reported for each detected protein.
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148
4.2.7 EBNA2 induction in Daudi cells up-regulates IRF4 and down-
regulates BCL6
Daudi cells expressing ER-EBNA2 type 1 or type 2 offered a good
opportunity to monitor the effects of EBNA2 on both IRF4 and BCL6 and to
understand whether the mutually exclusive expression of either is directed by
EBNA2. Daudi cells are EBNA2 negative and express BCL6 at high levels. Estrogen
was added to EREB2.5 cells and samples were harvested after 0, 8 and 24 hours.
Western blotting showed that EBNA2 induction causes BCL6 to be down regulated
and IRF4 to be induced (Figure 4.9).
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Figure 4.8.  LMP1 regulation by EBNA2 type 1 and type 2. Daudi cells expressing ER-EBNA2
type 1 (120KDa) and type 2 (114KDa) were treated with estrogen in time course of 48 hours. RIPA
buffer protein extracts were generated every 4 hours after the addition of 1  µM estrogen. 40 µg of
each extracts was run on SDS-PAGE. Protein extracts were assayed for EBNA2, LMP1 (71KDa) and
Actin (43KDa) as a loading control.
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Figure 4.9 IRF4 and BCL6 are antagonists expressed in BL cells. Daudi cells expressing ER-
EBNA2 type 1 and type 2 from p554-4 and pERT2 vectors, were treated in the presence of 1µM
estrogen at different time and 40 µg of protein extracts were run on SDS-PAGE and assayed for the
expression of EBNA2 type 1 (120KDa) and type 2 (114KDa), IRF4(51KDa), BCL6 (60KDa) and
Actin (43KDa) as a loading control. The nearest size marker band of the protein ladder is reported for
each detected protein.
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4.3 Discussion
In this chapter, EBNA2 type 1 and EBNA2 type 2 effects on B cell
proliferation were compared using the ERE2.5 cell line as an experimental system.
Transfection of constitutive EBNA2 type 1 or type 2 into estrogen starved EREB2.5
cells showed that only EBNA2 type 1 is able to maintain cell proliferation, measured
as incorporation of 3H- thymidine and production of LCL clones able to grow in the
absence of estrogen. Shortly after transfection, at day 3, 4 and 5, EBNA2 type 2 also
elicited some growth but its effects rapidly decreased to basal level. This is in line
with a previous publication (Rickinson et al., 1987) showing that recombinant EBV
strains expressing EBNA2 type 2, generally induced less growth then EBNA2 type 1
when infecting resting B cells. The major difference is that in those experiments type
2 strains were able to immortalize B cells and to produce long term growth, although
much less efficiently. In the ERBE2.5 system developed in this thesis, EBNA2 type 2
never sustained the growth of EREB2.5 cells in the absence of estrogen. This
difference might depend on additional factors linked to B cell/virus interaction during
infection, or the detailed cell culture conditions, for example the serum used.
Experiments performed by Rickinson et al and Cohen et al, have shown that cell
dilution is a critical factor for EBNA2 type 2 transformants but in the present study
the dilution, did not appear to influence the final outcome. The induction of LMP1 by
EBNA2 type 1 and type 2 was similar 3 days post transfection as expected from
previous studies already published, but the expression of selected cell genes was quite
different. In the literature, EBNA2 type 1 and type 2 have been compared for their
ability to induce cell gene promoters only in relation to the CD23 target gene (Wang
et al., 1987, Wang et al., 1990a). CD23 CAT constructs were induced better by type 1
then by type 2. My results reinforce these data at the protein level since two EBNA2
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targets in B cells, RUNX3 and IRF4 were induced at higher levels by EBNA2 type 1.
Stable expression of ER-EBNA2 type 2 in EREB2.5 cells might allow a broader study
of differentially regulated cell targets after estrogen withdrawal but that system failed
to give stable selectable clones. Either EBNA2 type 2 was titrated in the cytoplasm by
dimerisation with the ER-EBNA2T1, consequentially being unable to shift to the
nucleus properly, or the presence in the cell of three ori-P plasmids is difficult to
maintain. The failure to establish this stable system leaves some questions. p554 and
pAG1 are both large vectors and there is the possibility that their transfection in
EREB2.5 cells could produce different effects. Both vectors were transfected in the
absence of a selectable plasmid like for example, pEGFP, leaving the possibility that
the transient effect of the pAG1 plasmid on EREB2.5 cell growth might be due
simply to transient presence of the vector, which could be selected against by toxic
effects. As EREB2.5 cells growth decreases, EBNA2 expression also decreased so the
loss of EBNA2 type 2 could arise by such an effect. It should be noted that pEGFP or
similar reporter vector are not sizewise comparable to these large vectors and
therefore might not represent a good control for transfection efficiency. Detection of
the short EBNA-LP expressed from these vectors by Western blotting could be in fact
a good independent control, since is produced by both p554 and pAG1 vectors.
In Daudi cells EBNA2 type 1 and EBNA2 type 2 both induced IRF4 and
down regulated BCL6. IRF4 induction was more evident in EBNA2 type 1
transfected cells as expected from previous results, whereas BCL6 down regulation
seemed to be more effective in response to EBNA2 type 2.
The differential regulation of LMP1 by EBNA2 type 1 and type 2 observed in
this thesis is likely to be relevant to early events after EBV infection. The kinetics of
the regulation of the LMP1 gene during the first 24 hours is quite drastically different
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when compared to the effects after 48 hours. In Daudi cells, the induction of LMP1 by
EBNA2 type 1 was acute and characterized by a peak of activation at 16 hours, after
which it dropped slowly to steady state levels after 48 hours. LMP1 induction caused
by EBNA2 type 2, instead, increased continuously and slowly, until it reached similar
levels at 48. As described in the introduction, the LMP1 promoter is characterized by
a complex regulation and the LMP1 regulatory sequence (LRS) plays a crucial role
involving several transcription factors. Unfortunately almost all data on LMP1
promoter regulation depends on transient transfection assays and used reporter assays.
The Daudi system developed here provides an interesting model for studying
promoter regulation with wild type levels of EBNA2 expression, expressed from the
Wp promoter and properly chromatinized regulatory sequences. The difference in the
early regulation of LMP1 by EBNA2 type 1 and type 2 shown in this thesis, could be
the basis of the different transformation efficiency of EBV type 1 and type 2. The
process of infection happens in a period of few days during which the immune system
of the host and the infected cell establish a response to counteract the virus. A delay in
the activation of LMP1 that regulates critical events of latent infection could be a
great disadvantage for the establishment of latency by EBV type 2. It would be very
interesting at this point to determine whether these delayed effects are restricted to the
LMP1 promoter or are generalized to the activation of all cell targets. It would also
been interesting to repeat the experiment in a different EBV background to
consolidate the result and to avoid effects which are restricted to DAUDI cells. The
DAUDI cell line contains an EBV derived from a type 2 EBV strain (as does P3HR1).
p554 and pAG1 both express a short EBNA-LP type 1, whereas DAUDI cells express
a truncated EBNA-LP that lacks the C terminus. The combination of these factors
might interact differentially with type 1 and type 2 EBNA2 and cause differential
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activation of the LMP1 promoter (although there is no direct evidence for this). To
resolve this issue, new cell lines could be generated using vectors that express
conditional EBNA2 type 1 and type 2 alone.
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5. Genes induced by EBNA 2 type 1 and type 2
5.1 Introduction
The aim of this chapter is to expand the results from chapter 2 by performing
microarray analysis to identify those genes that are differentially regulated by EBNA2
type 1 and 2, particularly those that might be responsible for B cell proliferation. All
the studies aiming at establishing the molecular basis of EBNA2 driven B cell
immortalization focused on the EBNA2 type 1 targets and were conducted in B
lymphoblastoid cells or Burkitt lymphoma cells (Maier et al., 2006, Spender et al.,
2001, Spender et al., 2006, Zaho et al., 2006). Being less efficient at B cell
immortalization, EBNA2 type 2 has mostly been overlooked.
Hypothetically, gene regulation by EBNA2 type 1 and type 2 could differ only
in a discrete subset of genes, or be spread to the whole pool of targets. If it is
restricted to a small number of genes, then this pool could contain some of those
genes that are extremely important for B cell proliferation and possibly
immortalization. No pre-existing data pointed towards either direction: the CD23
promoter, the only cell gene investigated, seems to be induced more efficiently by
EBNA2 type 1 (Wang et al., 1987). For this purpose, a system would be required
whose only variable is represented by the EBNA2 type. The system used in chapter 2,
based on EREB2.5 cell estrogen starvation and transfection of constitutive EBNA2
type 1 or type 2 was very useful for comparing cell proliferation induced by the two
isoforms but it was not possible to perform a large scale experiment on gene
expression because of the very small amount of material available after transfection
and the background produced by untransfected cells. Due to the poor efficiency of
EBNA2 type 2 in maintaining B cell growth, it was necessary to choose a system
growing autonomously. The EBV negative Akata 31 BL line was chosen and stable
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expression of conditional ER-EBNA2 type 1 and type 2 was achieved transfecting
p554-4 and pERT2 vectors (section 2.2.16). Maier et al have also used Burkitt
lymphoma cells to study EBNA2 type 1 regulation of expression, and their results
were broadly similar to those obtained in LCLs in this study, supporting the use of
Burkitt lymphoma cells as a model for EBV infection in lymphoblastoid cells.
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5.2 Results
5.2.1 Creation of a system for the expression and comparison of
conditional ER-EBNA2 type 1 and type 2
Since Akata 31 cells are EBV negative and lack the EBNA1 protein that is
required for maintenance of the p554-4 and pERT2 plasmids, the puro-oriP-EBNA1
vector (Amon et al., 2004) was stably transfected into Akata31 cells. After two weeks
of selection with puromycin, cells were checked for EBNA1 expression (Figure
5.1A). Cells were then grown for a month before being re-transfected with p554-4 or
pERT2 vectors, expressing respectively, conditional ER-EBNA2 type 1 and ER-
EBNA2 type 2. Selection was applied 24 hours after transfection by administering
G418 and puromycin. Selected cells were then assayed for ER-EBNA2 type 1 or type
2 and EBNA1 expression by running RIPA protein extracts from estrogen treated and
not treated Akata31 cells on SDS-PAGE and western blotting. Proteins of the
expected size were revealed with PE2 antibody (Figure 5.1B). As in Daudi cells,
EBNA2 type 2 was expressed at a higher level and migration of both proteins altered
after stabilization by estrogen administration. In order to check EBNA2 type 1 and 2
correct activity, a western blot against c-MYC was performed to verify the down
regulation effect on the µ-immunoglobulin enhancer to which the c-MYC locus is
translocated. Both type 1 and 2 EBNA2 efficiently suppressed c-MYC expression
(Figure 5.1C).
5.2.2 Comparison of cell targets induced by EBNA2 type 1 and
EBNA2 type 2
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To compare gene regulation by EBNA2 type 1 and type 2, microarray experiments
were performed. Agilent G4122A 44K HD arrays were used and all conditions of
estrogen administration, RNA extraction and hybridization were identical to those
explained in chapter 1 for the analysis of EBNA2 type 1 targets in EREB2.5 cells.
The result is reported on figure 5.2.
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Figure 5.1. Set up of Akata 31 expressing conditional EBNA2 type 1 and type 2. 5.1A. Western
blot on protein extracts from EBV negative Akata 31 cells transfected with vector expressing a
constitutive EBNA1. EREB2.5 (E2.5) and untransfected Akata 31 are used as a positive and negative
control for detection of EBNA1 using the CS1-4 polyclonal antibody. 5X105  Akata 31 cells were
transfected with 5 µg of EBNA1 expressing vector and selected with 1 µg/ml of puromicin 5.1B.
p554-4 and pERT2 vecotrs expressing conditional ER-EBNA2T1/T2 were transfected into Akata31-
EBNA1 and selected with 1µg/ml og G418. Akata31-EBNA1-EBNA2T1/T2 were treated and not
treated with estrogen and assayed with the PE2 antibody against EBNA2. Actin is used as loading
control. Stabilization of both EBNA2 types is evident after estrogen induction. 5.1C. c-MYC
repression. Western blot for c-MYC after a time course of estrogen in Akata 31 cells stably expressing
ER-EBNA2 type1 and type 2, showing that both EBNA2 types are equally able to repress MYC
expression. The nearest size marker band of the protein ladder is reported for each detected protein.
(Brady, G. From Lucchesi et al., 2008, in
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Most of the genes did not show any variation and a large group, comprising 100
genes, was induced by both EBNA2 types at the same level. A small number of genes
were strongly induced only by EBNA2 type 1 in Akata 31 cells. These were: CXCR7,
IL1-ß, ADAMDEC1, and MARCKS. CXCR7 has already been described as being the
most strongly induced gene in EREB2.5 cells in Chapter 3 in EREB2.5 cells.
MARCKS was already been shown to be expressed following EBV infection
(Birkenbach et al., 1993), but did not appear in the list of genes induced in EREB2.5
by EBNA2 type 1.
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Figure 5.2. Comparison of direct target genes of EBNA2 type 1 and type 2 in Akata 31 Burkitt
lymphoma cells. Akata 31 cells stably expressing ER-EBNA2T1 and T2 were diluted at 5X105 cells/ml
and 1µM estrogen was administered for 4 hours in the presence of protein synthesis inhibitors. Total
RNA was extracted and used for expression profiling on Agilent 44K gene chips. Each column
represents the ratio of the mean of values plus estrogen over the mean of values minus estrogen for
selected genes whose expression was altered by the activation of EBNA2 type 1 and type 2.
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5.2.3 Confirmation of targets: CXCR7
CXCR7 expression at the RNA level in Akata 31 cells stably transfected with
ER-EBNA2T1/T2 was detected by semi-quantitative RT-PCR. Two splice variants
are known (Figure 5.3A), which will be called splice 1 and 2. The gene is composed
of 4 non coding exons at the 5'-UTR and a fifth exon which carries the coding region
plus the 3'-UTR. Splice 1 is generated by junction of the first three exons with the
fifth one, whereas splice 2 is generated by junction of the fourth exon with the fifth.
Primers were designed to amplify both splice variants. A common reverse primer was
located on the fifth exon in the coding region but forward primers were specific for
each splice variant (Figure 5.3C), Splice 1 forward primer was on exon 2 and splice 2
forward primer on exon 4. RT-PCR was run on cDNA generated using random
primers on RNA extracted from Akata31 ER-EBNA2T1/T2 cells and EREB2.5 cells
treated or not treated with estrogen with or without PSI. RT-PCR confirmed that in
response to estrogen administration, CXCR7 expression increases more in Akata31
EBNA2T1 then in Akata31 EBNA2T2 transfected cells (Figure 5.3C). The amplified
products were all of the expected size but the amplification of splice 1 variant resulted
in a doublet. The band of larger size appeared also in amplification from EREB2.5
cells but was stronger in Akata 31/EBNA2 cells. The result was consistent in different
amplifications. The individual fragments were isolated from the gel, cloned into
Topo-TA vector and sequenced. The additional fragment comes from a variation of
the first splice variant where exon three is omitted and exons 1 and 2 are joint directly
to exon 5 (Figure 5.3C). This is a novel splice variant. The same amplification in
EREB2.5 cells in the absence of PSI confirmed the result. CXCR7 expression is not
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restricted to EREB2.5 cells. RT-PCR on cDNA derived from a panel of LCLs showed
that CXCR7 is broadly expressed, although at different levels (Figure 5.3B).
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Figure 5.3 5.3A Detection of CXCR7 expression by RT-PCR. Akata 31 cells were treated for 1
hour with PSI and 4 and 24 hours with estrogen. RNA was extracted and retro-transcribed into
cDNA. Primers were designed on different exons. EREB2.5 cells in the big quadrant were starved for
5 days and treated with PSI and estrogen for the same time. The small quadrants on the left show RT-
PCR on cDNA derived from EREB2.5 treated and not treated with estrogen but in the absence of PSI.
5.3B RT-PCR for CXCR7 on a cDNA generated from RNA extracts from a panel of LCLs. 5.3C
CXCR7 splice variants reported in literature.
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5.2.4 Intracellular expression of IL1ß  in Akata 31 ER-EBNA2-T1/T2
but not in EREB2.5 cells.
The expression of IL1ß was confirmed by western blotting and ELISA. Akata
31 EBNA2T1/T2 cells were treated with estrogen for 24 hours, protein was extracted
using RIPA buffer and analysed by western blotting. The signal was weak but IL1ß
was detected only in Akata 31 ER-EBNA2T1 cells after 24 hours of estrogen
administration (Figure 5.4A). The size of 30KD indicates that this IL1ß was not
cleaved by the interleukin converting enzyme, ICE. An even weaker signal appeared
at 17KD which is the size of the cleaved IL1ß. The antibody was tested on synthetic
IL1ß to check sensitivity of the antibody (Figure 5.4B). Detection was lost between
100 pg and 10 pg of pure protein. The ELISA kit from R&D systems detects IL1ß
down to a minimal concentration of 1 pg/ml. EREB2.5 and Akata31 EBNA2T1/T2
cells were estrogen or ethanol treated for 24 hours, protein was extracted with the
CAT-ELISA lysis buffer and tested in the ELISA assay. The result was similar to that
obtained by western blot (Figure 5.4C). The signal was present only in Akata31 cells
expressing EBNA2 type 1 and negative in all other extracts and supernatants
including the supernatant of Akata31 cells expressing EBNA2 type 1.
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Figure 5.4 Detection of IL1ß. 5.A. Western blot for IL1ß on protein extracts from Akata 31
expressing ER-EBNA2T1 and EBNA2T2 treated (+) or not treated (-) for 24h with estrogen. 40 µg of
RIPA protein extracts were loaded on SDS-PAGE and hybridized with the PE-2 antibody. 5.4B.
Western blotting on serial dilution of synthetic IL1ß. 5.4C. ELISA for IL1ß. Akata 31 cells
expressing ER-EBNA2T1/T2 and EREB2.5 cells were treated or not treated with estrogen for 24
hours. Lysate from 5X105 cells and and 200 µl of supernatant (SN) were used in an enzyme linked
immuno-sorbent assay. Plates were read at the luminometer and here the values are reported as
columns. The nearest size marker band of the protein ladder is reported for each detected protein.
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5.2.5 ADAMDEC1
ADAMDEC1 is a recently discovered metalloprotease that is expressed in
lymphocytes, dendritic cells and macrophages (Bates et al, 2002). Its induction was
confirmed by RT-PCR following the same procedure described for the other induced
genes. ADAMDEC1 relative levels expected from microarray analysis, comparing
induction in response to EBNA2 type 1 or type 2, were also confirmed (Figure 5.5).
5.2.6 Knock down of CXCR7 at mRNA level impairs proliferation of
EREB2.5 cells
The main aim of this work is to identify genes that are differentially induced
by EBNA2 type 1 and type 2 so as to explain in part the higher efficiency of EBV
type 1 in producing proliferating cell lines from resting B cells.  CXCR7 is the only
gene that is highly expressed in both EREB2.5 and Burkitt cell lines in response to
Ak31      T1                T2
Est      -        +         -         +
Ak31      T1                T2
Est      -        +         -         +
Adamdec1
Gapdh
Figure 5.5. Detection of ADAMDEC1 expression. RT-PCR for ADAMDEC1 on cDNA generated
from RNA extracts from Akata 31 cells expressing ER-EBNA2 type 1 and type 2 in the presence (+)
or in the absence (-) of estrogen. GAPDH was amplified as internal control.
ADAMDEC1
GAPDH
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EBNA2 activation. In Burkitt lymphoma cells, EBNA2 type 1 induces CXCR7 RNA
at a substantially higher level then type 2. shRNAi based on the pSUPER expression
vector was previously used to study the function of the p55-alpha subunit of  PI3K in
EREB2.5 cells (Spender et al, 2006). pPuroOriPSUPER is a vector containing an oriP
sequence, H1 promoter and puromycin resistance. The H1 promoter directs
transcription of shRNA sequences which are composed of a 23 nt homolog to the
target sequence separated from its complementary strand by a harpin sequence.  The
double stranded RNA is processed by the cell RNAi machinery. Sequences for
shRNA were chosen using the OligoEngine3.0 software and three sequences located
in different part of the mRNA were produced. EREB2.5 cells were transfected with
each shRNA vector, a control against p53 and or empty vector control. Puromycin
was added 24 hours after transfection and the medium with selection was replenished
every two days. Because the antibody against CXCR7 did not work in western blot
assay, the levels of expression were checked directly by RT-PCR on cDNA generated
from RNA extracted from cells 5, 7, 9 and 11 days after transfection (Figure 5.6). One
of the RNAi sequences (sequence 1) proved to be very efficient in knocking down
proliferation to a level that few cells were left after 9 days. RT-PCR confirmed that
CXCR7 RNA levels decreased after transfection with sequence 1. No variation was
detected in cDNA from cells transfected with sequence 2, 3, anti-p53, and scrambled.
Although a CXCR7 antibody was available, there is no evidence that it works
correctly in a western blot. The level of “CXCR7” was assayed at the protein level on
protein extracts from the same EREB2.5 transfected cells at the same time points. A
protein was detected which showed no variation among CXCR7 (R1), p53 and control
(Figure 5.7A). The same antibody was therefore assayed on protein extracts from
EREB2.5 cells and Akata31-EBNA2T1 treated and untreated with estrogen as well as
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MCF-7 and 293 cell lines respectively positive and negative for CXCR7 expression
(Figure 5.7B). Again western blotting resulted in a strong signal that showed in every
lane confirming that the antibody does not recognize CXCR7 correctly in western
blotting assays.
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Figure 5.6 Knock down of CXCR7. 5.6A  5µg of plasmids expressing shRNA for CXCR7 (R1, R2,
R3), p53 protein and a scrambled  control, CTRL were transfected in 5X106 EREB2.5 cells in the
presence of estrogen and selected with 1µg/ml of puromycin. Cells were counted by trypan blue
exclusion at days 5, 7, 9, 11 after selection. 5.6B RT-PCR on CXCR7 was performed on a cDNA
generated from RNA extracts from the same transfected EREB2.5 cells at days 5.
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5.2.7 CXCR7 role on proliferation can be extended to other LCLs
and it is specific.
To assess whether the role in the proliferation described in EREB2.5 cells can
be generalized, CXCR7 RNA was knocked down in LCL3 following the same
procedure explained already for RNAi in EREB2.5 cells. The only difference was the
absence of estrogen, which these cells do not require. After 6 days of puromycin
selection, a strong reduction in the cell number was noticed only in the cell population
transfected with the CXCR7 RNAi vector. This effect was very similar to the one
described for EREB2.5 cells (Figure 5.8). HEK 293 cells are CXCR7 negative and
were used as a control to show that the effect observed in the RNAi experiment is
specific and restricted to CXCR7 positive cells. 293 cells at 50% of confluence were
transfected with the same RNAi vectors already described (CXCR7, p53, empty and
puromycin resistance negative). Puromycin selection was started 24 hours after
            5 days                      7 days
R1        p53      C        R1      p53       C  
CXCR7
p53
Actin
CXCR7
p53
Actin
Figure 5.7 Western blot on CXCR7. 5.7A: To test the quality of the antibody against CXCR7 for
western blot, CXCR7 positive and negative cells were tested. Protein extracts were obtained with the
same methods as above and western blotting performed in the same way. MCF-7: positive for
CXCR7 (60KDa). 293: negative for CXCR7. Actin (43KDa): loading control 5.7B: EREB2.5 cells
transfected with shRNA vectors against CXCR7, p53 and control were harvested at days 5 and 7 post
transfection. Protein extracts were obtained by lysis in RIPA buffer at room temperature over night
and never boiled to avoid clustering of transmembrane domains. 40µg of each sample were run on
SDS-PAGE. Western blot was performed on different membranes and different hybridization
conditions.
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   E2.5        AK31   MCF-7 293
 -        +      -       +
A    B
60KD
50KD
40KD
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transfection and refreshed every second day. When cells reached confluence they
were passaged and split 1 to 3 to allow continuous proliferation. By day 4, cells
transfected without puromycin resistance had died and cells were counted on day 6 of
selection (Figure 5.9). No variation in cell number was observed between CXCR7
already described in EREB2.5 and LCL3 and excluded the possibility that the CXCR7
shRNA might have prevented expression of the puromycin resistance gene.
CXCR7
GAPDH
Figure 5.8. CXCR7 shRNA in LCL3. The shRNA plasmid for CXCR7 (R1) used in the previous
experiment in EREB2.5 cells, the shRNA plasmid for the p53 protein and a scrambled control, (C)
were transfected in LCL3 cells and selected with puromycin. Cells were counted at days 6, 9 and
12 after selection. The RT-PCR was performed on cDNA generated from RNA extracted at day 6
post selection.
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Figure 5.9. shRNAi of CXCR7 in HEK-293 cells. 293 cells were transfected using lipofectamine
with shRNAi vector for CXCR7 (R1), p53, scrambled control and puromicin negative. Cell count 6
days after puromicin selection shows that there is no variation in cell number comparing CXCR7.
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5.4 Discussion
This study is the first attempt to comprehensively study and compare EBNA2
type 1 and 2 target genes. Microarray analysis of EBV negative Burkitt lymphoma
Akata 31 cells, stably transfected with conditional ER-EBNA2 type 1 and ER-
EBNA2 type 2 identified a very similar gene expression profile for the two isoforms,
except for a few genes: CXCR7, IL1ß, ADAMDEC1 and MARCKS. CXCR7 and
ADAMDEC1 are novel targets of EBNA2 whereas MARCKS and IL1ß have been
already associated to EBV or EBNA2 type 1 (Brichenbach et al., 1993, Krauer et al.,
1998). IL1ß was confirmed at the protein level but there was no detectable expression
in LCLs. CXCR7 had already been identified as an EBNA2 type 1 target in chapter 3
of the present study (Chapter 3, table 1). Out of 42,000 probes represented on the
array, only one hundred were consistently induced at least two fold by both isoforms.
Several target genes already described in the literature as targets of EBNA2 type 1
were included in this group. From the analysis of the data we could infer that the
difference between type 1 and type 2 could be subtle in terms of number of genes, and
may indicate some genes that are particularly important in the process of B cell
proliferation and immortalization. CXCR7, which is the most consistently induced
target, in both LCLs and Burkitt lymphomas has been shown in this thesis to be
important for B cell proliferation. In fact, knock down of CXCR7 in lymphoblastoid
cell lines (EREB2.5 and LCL3 cells) severely impaired cell proliferation. This effect
was obtained from an RNAi sequence designed on the 3’UTR of the transcript,
perhaps suggesting that the knock down of several forms could be required to observe
the effect or simply could be due to the fact that 3’UTR targeting is often much more
efficient. In CXCR7 negative HEK-293 cells the same construct did not produce any
effect. A similar effect on proliferation has been observed in a system closely related
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to EBV. CXCR7 was shown to be highly induced in response to KSHV infection and
to be critical for endothelial cell transformation (Raggo et al., 2005). Moreover,
ectopic expression of CXCR7 increased the rate of proliferation. Supporting the role
of CXCR7 as a proliferating factor in wide range of cells, Miao et al have shown that
CXCR7 is closely correlated to increase in the growth rate of breast and cancer cells
when over expressed and negatively correlated to the same phenotype when knocked
down in the same cellular context (Miao et al., 2007). We have identified a novel
splice variant that, although apparently it does not affect any coding region, could be
significant in terms of gene expression and regulation. When expression of CXCR7 in
EREB2.5 cells was analyzed by western blotting, FACS (data not shown) or immuno
fluorescence microscopy (data not shown) no variation in signal was observed at all.
Attempts to investigate CXCR7 expression by western blot analysis did not produce
any useful results, even using different conditions and denaturing solutions; the same
band appeared even in CXCR7 negative cells. It is important to remember that the
functional demonstration of the significance of a product of the CXCR7 gene in LCL
proliferation has only been shown in this thesis at the RNA level and there might be a
different protein product or a post translational modification of CXCR7 in LCLs.
CXCR7 has been discovered very recently and it was described as the Chemokine
orphan receptor 1. Infantino et al and Balabanian et al have discovered that CXCL12
is the ligand for the receptor in T cells even thought it was not confirmed to be the
same in B cells (Balabanian et al., 2005, Infantino et al., 2006). The fact that the
binding ability was not confirmed in B cells by previous studies suggests that the
receptor could undergo some modification specifically in B cells, or that other splice
variants could be present.
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The picture that we extrapolate from this experiment is that EBNA2 type 1
and type 2 are probably very similar at inducing gene expression in the cell but they
may differ in a small number of important genes. Some of improvement in this system
might be achieved by stably transfecting p554-4 and pERT2 vectors, expressing
EBNA2 type 1 and type 2 fused with the estrogen receptor, into the EBV negative
BJAB. This cell line is a high grade non -Burkitt lymphoma, and therefore lacks the c-
MYC translocation. Microarray analysis could be repeated and confirmed in this
background. This might be interesting since the current data have been obtained in a
background where c-MYC is over-expressed. Of course BJAB cells also contain their
own (unknown) oncogene and tumour suppressor gene changes that resulted in the
lymphoma so that would affect the interpretation of BJAB data. Moreover in order to
confirm that EBNA2 type 1 and type 2 indeed induce CXCR7 gene at different level
even in a more physiological context, primary B cells could be infected with type 1
and type 2 EBV and the expression of CXCR7 could be followed over a time course.
The analysis of the promoters of these genes will be very interesting to understand
whether the function is related to specific transcription factors that co-activate gene
expression at different levels.
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6. Final Discussion
The results obtained in this thesis suggest that EBNA2 type 1 and type 2 differential
gene regulation involves a restricted group of genes. Future experiments should be
performed in order to confirm and expand these data, preferably based on systems that
involve the use of wild type EBV type 1 and 2, or in vivo studies. Work by Spender et
al, Zaho et al, and Maier el al, cited in section 3.1 have extensively studied the gene
expression profile controlled by EBNA2 type 1. These three studies report similar
results but the population of genes identified is quite large. It is consequently difficult
to single out those genes that are responsible for efficient B cell transformation, if
there are just a few. In the past, as reported on section 4.1, Wang et al, Cohen et al and
Johanson et al, have studied and compared EBNA2 type 1 and type 2 in relation to
gene regulation but their studies were restricted to the viral gene LMP1 and the cell
gene CD23. The comparison between the two types should allow identification of
those genes whose expression is differentially regulated and that might be involved in
enhancing the transformation efficiency. The data obtained in this thesis draw
attention to a particular cell gene: CXCR7. Although interesting, the studies need
further clarification, possibly in a system which is closer to the wild type.
The use of wild type viruses will be instrumental, since it is possible to infect
primary B cells with EBV type 1 and type 2 and to follow the induction of this group
of genes. Particularly interesting is the analysis of the induction of CXCR7. CXCR7
has been shown to be critical for B cell growth of EREB2.5 cells. The infection of
wild type primary B cells with type 1 and type 2 EBV should recapitulate the same
result, with CXCR7 expressed at higher levels in EBV type 1 infection. If that holds
true it would be desirable to over-express CXCR7 cDNA in EBV type 2 infected cells
to determine whether this would improve cell transformation. It is important to
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mention that antibodies against CXCR7 failed to work in B cells. This could imply
that the receptor undergoes some post translational modification but also that some
alternative transcripts, that alter the coding region, could exist. Before over-
expressing the CXCR7 cDNA into infected B cells, it would be critical to investigate
further this last hypothesis. To this aim, either a RACE of the 5’UTR of the CXCR7
transcript or northern blot analysis of RNA from B cell would be required.
The fact that only a small group of genes seems to be differentially regulated
by the two proteins suggests that this effect could depend on a specific module rather
than on a general differential conformation between type 1 and type 2 EBNA2. Most
of the modules that have been shown to be important for gene regulation or B cell
transformation are conserved, but a careful look shows some interesting variations.
For instance, the R-G domain of EBNA2 type 2 that is required for chromatin
interaction and modification, has three important amino acidic substitutions, a G to W
and two R to Q and also a two amino acids insertion, P-D, just in front of the domain
(Figure 1-6). The R-G domain is located at the C terminal part of the protein that is
involved in trans-activation and DNA binding. In order to resolve this issue it would
be useful to generate a collection of EBNA2 mutants by swapping protein regions
between the two EBNA 2 types. The chimeric proteins would then be used in the
EREB2.5 cells transcomplementation assay as explained in chapter 4. When a region
that is essential for transformation is swapped between type 1 and type 2, the former
should lose the ability to maintain long term growth of EREB2.5 cells in the absence
of estrogen whereas the latter should acquire it. Once this region has been identified it
would be easier to refine the search by swapping smaller fragments of directly
mutating the site on the EBNA2 type 2.
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It would also be interesting to consider some in vivo experiments. Moreover
most of the western population carries a type 1 EBV and it is possible that the
immune system of a healthy individual renders type 2 infection much less effective.
As discussed earlier, HIV patients carry an unusually high rate of EBV type 2
infections. These patients analysed during the asymptomatic infections would not give
any additional information, but it would be interesting to follow the progression of the
disease and to monitor EBV type 1 and type 2 infection once the AIDS starts. In this
period the EBV types would not be subjected to the host’s immune system and it
might be possible to analyse periodically the blood and lymph nodes of these patients.
As mentioned previously, EBV type 1 and type 2 epidemiology is remarkably
different and one hypothesis explains his difference on the basis of the impaired
ability of EBV type 2 to cope with the host’s immune system. This hypothesis argues
that EBV type 2 strains are common in regions of the world where malaria is endemic
because the immune system of these patients is already challenged by co-infection of
the Plasmodium falciparum. AIDS patients develop EBV positive lymphomas much
more frequently than healthy people. If the above hypothesis is true, lymphomas from
AIDS patients should equally carry type 1 and type 2 strains since the immune system
does not constrain the type 2 EBV persistence. A very recent experiment by Mendes
et al, was based on a very similar approach (Mendes et al., 2008). 44 EBV positve
lymphomas associated with different immune-compromising conditions in children
and adolescents were analysed by PCR on the EBNA2 locus. 23% of these samples
were type 2 positive, which corresponds to the distribution of EBV type 2 in healthy
population, if not slightly higher. This indicates that in an immune-compromised
system, the presence of EBV type 2 must be considerate a risk as it is EBV type 1.
Although conceptually similar, this experiment lacks of a complete picture of the
174
EBV infection in the patients before the immune-compromisation.  This could be
resolved only by studying the history of HIV patients.
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